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ABSTRACT

This dissertation describes the development of new tailored methods for the
discriminative detection of amphiphilic lipopolysaccharide (LPS) antigens, so as to
improve screening methodologies for food-safety applications, and detection of
amphiphiles in general. LPS is associated with the outer membrane of Gramnegative bacteria, and is a primary virulence biomarker of several pathogens. Direct
detection of amphiphilic LPS in the aqueous matrices of the host/sample requires an
appreciation of the complex biochemistry of the molecule, and forms the basis for
this research. The unique structure of this molecule can be used for identification of
both the serogroup and strain of pathogen. However, current detection methods lack
sensitivity, and are also not serogroup specific. To achieve discriminative detection,
we have first created a unique repertoire of associated reagents by isolating
amphiphilic LPS from seven strains of Shiga toxin-producing Escherichia coli, and
developing highly specific monoclonal antibodies against the O antigen regions of
the same. We demonstrate the use of a targeted detection technique, called
membrane insertion, which facilitates the physiological presentation of LPS by
inserting the hydrophobic lipid A portion of the molecule into a lipid bilayer, leaving
the O antigen exposed. This method is advantageous because it minimizes
exposure of the highly conserved lipid A epitopes, and maximizes exposure of the
serogroup specific O antigens. In addition, we present the first comprehensive
biophysical analysis of the interaction of LPS with supported lipid bilayer
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architectures, and identify several novel and interesting effects of the same. Further
characterization of these effects reveals the role or impact of membrane proteins
and complexity on the interactions between host and pathogen biomarkers and
significantly questions the design and execution of cell studies and in vitro platforms
for amphiphilic targets like LPS. Cell studies clearly reveal that presentation of LPS
either in buffer or in serum dramatically alters associated cytokine profiles. Our
conclusions indicate that the biochemistry of amphiphilic molecules, like LPS, and
their presentation, should always be considered when interfacing with physiological
systems.
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Chapter 1.
Introduction
1.1 Considerations for universal bacterial detection systems
The increasing occurrence of infectious diseases is a global issue. Newly
emergent diseases and re-emerging pathogens with increasing levels of drug
resistance are a continuing danger to both public health and agriculture. Accurate
and rapid detection of pathogens is critical for our ability to implement preventative
measures and treatment procedures to mitigate this problem. Despite the need for
rapid analytical detection measures, conventional methods for bacterial detection
require the use of cell culture and serology, which can take up to several weeks for a
confirmed result. As new pathogens emerge, it is ever more important that our
detection technologies evolve to keep pace with the need to discriminate pathogen
from host flora in a variety of complex sample backgrounds. To achieve
discriminative detection, it is necessary to understand the biology of pathogens, the
types of samples they occur in, and how pathogens interact with their hosts upon
infection. Effective detection strategies involve a critical characterization of the
bacteria and their biological signatures that interact with the host, attach or enter
cells, and trigger (or evade) immune response1.
There are many methods for detection of pathogens. However, each
technique has problems associated with it. For many pathogens, culturing for
positive identification is the gold standard, but this can take up to a week, or even
longer depending on the bacteria.2,3 In most cases, waiting a week or more is not a
viable option, especially if patient treatment is delayed. Other techniques for
detection of bacteria and viruses, screen for the presence of pathogen virulence
factors or other biomarkers present in clinical samples,1,3 but not all methods are
capable of discriminating pathogen from non-pathogenic near neighbors. These
techniques include traditional methods like bacterial plating, culturing and
biochemical testing,4,5 immunological assays, as well as newer methods which use
polymerase chain reaction (PCR), DNA microarrays, mass spectrometry, flow
cytometry, and different biosensors.3,4,6 Some methods such as polymerase chain
reaction (PCR) are highly sensitive, but target isolated pathogen DNA, and therefore
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are not capable of determining viable from non-viable pathogens without utilizing
special enzymes.3 Immunological methods, like the well-established enzyme-linked
immunosorbent assay (ELISAs) or immunomagnetic separation methods take
advantage of antibody-antigen interactions to measure antibody titers or identify
pathogens. These methods rely heavily on antibodies, which can be highly crossreactive and can denature on hydrophobic surfaces. One reason for poor antibody
performance is due to the conformational differences in antigen presentation
between the antibody-selection process, and the detection assay platforms. In many
cases, reliable antibodies have not even been developed due to the large diversity of
antigens.7-10 ELISAs also suffer sensitivity issues due to inconsistent sample
processing and variation in protocols.11 In fact, many of these techniques suffer from
limitations. They are either time consuming, expensive, yield false positives, have
low throughput, or do not selectively detect viable bacteria.
The human innate immune system is able to discriminate pathogens from
non-pathogenic strains, and rapidly sense pathogen biomarkers in the complex
milieu of the host. Exploiting this recognition via the measurement of pathogenic
molecular signatures produced by bacteria can provide a universal strategy for
biodetection, and help discriminate pathogens from near neighbors. Molecules
associated with the presence of pathogens in the host are called pathogenassociated molecular patterns (PAMPs).12 PAMPs are evolutionarily conserved
molecular signatures that bind pattern-recognition receptors in the mammalian host,
and activate the innate immune response.13,14 Due to their role in innate immune
recognition, targeted detection methods for PAMPs could provide a means to
facilitate both early and specific detection of pathogens. Also, the short half-life15 of
these signatures in the infected host ensures that detection results in positive
identification of viable bacteria for diagnostic applications. There are a diverse array
of proteins, lipopeptides, lipoglycans, peptidoglycans, teichoic acids, and nucleic
acids associated with different species of pathogens that present as PAMPs upon
infection.16
Aside from proteins and nucleic acid PAMPs, there are many other virulence
markers associated with early onset disease14,17,18 that have until recently been
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ignored in detection methods as their small size, unique biochemistry, and low
concentration in samples makes them difficult to detect in gold standard screening
methods, such as immunoassays.19,20 One of these classes of virulence biomarkers
are lipoglycans, which are small molecules that have an amphiphilic biochemistry.21
A classic example of this is the molecule lipopolysaccharide (LPS), which is
associated with Gram-negative pathogens. As detection platforms advance, so do
our capabilities to detect LPS as an early indicator of infection.22 With an
understanding of host-pathogen biology, biomimetic capture surfaces can be
optimized to bind these amphiphilic molecules in conformations that are
physiologically relevant, which not only optimizes the capability to detect low
concentrations, but also maximizes the specificity with which antibodies can bind
conformationally viable epitopes.23 Developing systems with incorporated biomimicry has given rise to a large array of biosensors, with multiple detection
capabilities. However, current strategies for the detection of amphiphiles, like LPS,
are not optimized and do not consider the biochemistry of this category of virulence
signatures. LPS is also much more stable than its protein counterparts, which is
clear advantage for food safety applications. Coupling sensitive detection platforms
with surfaces designed to maximize the binding of amphiphilic PAMPs is a potential
solution to facilitate the early and specific detection of pathogens.

1.2 Sources of lipopolysaccharides
Bacteria are historically classified into two categories, Gram-negative, and
Gram-positive24 (Figure 1.1). All bacteria are single-cell organisms with a cell
membrane, and an exterior peptidoglycan layer on the outside of the membrane.
However, Gram-negative bacteria have an additional cell membrane outside of the
peptidoglycan layer, creating a periplasmic space sandwiched between25 the two cell
walls. Gram-negative bacteria are characteristically named due to the inability of the
cell to retain a crystal violet dye during the Gram staining procedure.25 This inability
is a result of the peptidoglycan layer being ‘too thin’ to retain enough dye. In Grampositive bacteria, the peptidoglycan layer is much thicker, and readily absorbs and
retains the crystal violet after a subsequent alcohol wash. Both Gram-positive and
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Gram-negative bacteria secrete amphiphilic virulence factors such as LPS,
lipoarabinomannan (LAM), and lipoteichoic acid (LTA) that are associated with the
bacterial outer membrane (Figure 1.1).

Figure 1.1. Physiology of bacteria. Gram-positive bacteria are single cell organisms with
one cell membrane and a thick, heavily cross-linked peptidoglycan layer on the outside of that
membrane. Gram-negative bacteria share the same structure with Gram-positive, but have an
additional cell wall surrounding the peptidoglycan layer. Due to this additional cell wall, Gramnegative bacteria do not retain the crystal violet “Gram-stain” after washing. Both LTA and LPS are
considered amphiphilic biomarkers associated with each type of bacteria.

Species of pathogenic Gram-negative bacteria of concern to human health,
include, but are not limited to Acinetobacter,26 Burkholderia,27 Bordetella,28
Campylobacter,2,3,29 Chlamydia,30,31 Escherichia coli (E. coli),3,32 Helicobacter,33,34
Hemophilius,35 Klebsiella,36 Legionella,3,37 Moraxella,38 Neisseria,39 Pseudomonas,40
Proteus,41 Salmonella,3,42 Shigella,43 Yersinia,44 and others, grouped into the
Enterobacteriaceae family. These pathogens can be found as contaminants in food,
water, and soil; used as agents of bioterrorism, or be the cause of nosocomial
infections.4 Detection and differentiation of these organisms is an important aspect
not only for epidemiology, but also for disease control and treatment.
Detection of these bacteria by measuring associated protein and nucleic
biomarkers is well reviewed in the literature.6,45-49 However, a largely ignored
category of detection techniques uses PAMPs, and more specifically lipoglycans, as
diagnostics for detection and identification of bacterial infections. This discussion
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specifically addresses current methods and challenges for detection of LPS, as LPS
is a strain-specific antigen50-52 and an ideal target for differential diagnostics. Briefly
mentioned are some of the methods to detect other PAMPs with similar molecular
structures,20 such as LAM and LTA from Gram-positive bacteria. Since E. coli is an
intensely studied Gram-negative organism, it often serves as the basis for this
discussion surrounding LPS. While many detection methods for LPS can be
extremely sensitive, only a few of these are capable of identifying strain specific LPS
antigens, and are therefore useful as a true diagnostics of infections.

1.3 Lipopolysaccharide structures and conformations
One of the primary challenges for developing detection assays for LPS is the
unique amphiphilic structure of the molecule. Lipopolysaccharides have been the
subject of intense study for over half a century.53-55 LPS is the prototypical
lipoglycan16 and the primary component of the outer membrane of nearly all Gramnegative bacteria.50 It is a key bacterial PAMP that stimulates the mammalian innate
immune system through activation of Toll-like receptor 4 (TLR4).56 The bacterial
membrane of each E. coli cell is comprised of approximately 106 lipid A moieties and
107 glycerophospholipid molecules, comprising approximately three-quarters of the
outer membrane.57-59 This implies that there is approximately 62 picograms of LPS
per cell (for E. coli in log phase growth).60
In general, LPS is a complex molecule with an overall net negative charge.6163

It has an amphipathic tripartite structure (Figure 1.2). Lipid A is the most

conserved portion of the LPS molecule, and consists of 6, sometimes 7, fatty acid
tails (E. coli and Salmonella respectively), which gives the molecule its hydrophobic
properties. Lipid A is often referred to as ‘endotoxin’,58 as it is the part of the LPS
molecule responsible for the biological effects in the host.59,64,65 Structurally, lipid A
is covalently bound to the core polysaccharide, which is further divided into the inner
and outer core polysaccharides, with the outer core being less conserved in both
sugar moeity composition and location of glycosidic linkages compared to the inner
core.66-68
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There are two main forms of LPS, designated smooth (S-form) and rough (Rform).63,69 In S-form LPS, the distal end of the molecule extends to an Opolysaccharide antigen (O-ag(s)). Smooth form LPS is considered an indicator of
virulence of bacteria,70,71 while R-form LPS is devoid of the O-ag,72 but can still
induce an immunogenic response.73 The O-ag is hyper-variable, and made up of
repeating subunits, each composed of 1-7 glycosyl residues.74,75 As many as 40 size
variations in subunit repeats of the O-ag have been reported just for E. coli
O111:B4,76 and 180 O-ag have been identified for E. coli species.64,77 The sugars
that help make the O-ag unique are seldom found elsewhere. These include
moieties such as colitose, paratose, tyvelose, and abequose.78 Other variations to
the polysaccharide chain are implemented through the addition of non-carbohydrate
entities such as acetyl or methyl groups.78 This variability in sugar repeats and
degree of branching of the glycosyl residues in the O-ag makes distinction between
serotypes within strains a possibility.74 However, this variability of LPS structure also
poses a challenge for its characterization. Due to the heterogenous presentation of
LPS, often in micelle conformation in aqueous solutions, it is impossible to determine
the exact molecular weight of S-form LPS. As such, LPS concentrations are reported
in weight per volume, or in Endotoxin Units (EU), a measure of activity rather than
concentration. As degree of endotoxicity can vary according to bacterial origin, a
rough estimate of 100 pg = 1 EU is used in many cases to facilitate unit
conversion.79,80 Due to the abundance on Gram-negative bacteria, the highly
conserved nature of the lipid A molecule, and the variability of the O-ag, LPS is an
ideal target for the early detection and identification of Gram-negative pathogens.
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Figure 1.2. Representative structure of the components of lipopolysaccharide. LPS is divided
into three distinct molecular components. The highly conserved, hydrophobic lipid A group, the
moderately conserved core polysaccharide (inner and outer core), and the hypervariable O
polysaccharide antigen which is made up of repeating sugar subunits.

The physiological conformation of an amphiphilic molecule should be
considered for the design and execution of both synthetic and in vivo detection
schemes. In aqueous solutions, amphiphiles like LPS can present in a micellar
conformation,65,76,81,82 as the hydrophobic lipid A region is sequestered away from
the hydrophilic medium.83 This occurs at a concentration specific to the amphiphile in
question,76 and is known as the critical micelle concentration (CMC). When the CMC
is reached, it does not imply that all amphiphiles present in solution exist as
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micelles.76 Instead, at or above the CMC, there is an equilibrium state between
monomers, micelles or supramolecular aggregates,62,65,81,84-89 depending on the
environmental conditions.
The structure and orientation of the hydrophobic lipid A moiety is the primary
driving factor for shaping the LPS micelle90-92 (Figure 1.3). Although fairly conserved
amongst species, lipid A can vary between species both in the number of fatty acid
chains, as well as the degree of saturation59,91 within those chains.30,64,93 Many
structures of lipid A have been identified to date64 (Figures 1.3A and A1.1). These
structural variations influence the shape of micelles formed in aqueous media. 94
Aggregate shapes that have been recorded for LPS micelles include cubic, lamellar,
and hexagonal inverted structures.95-98

Figure 1.3. Factors that influence micelle conformation. Micelle conformations of LPS are
governed by the orientation and structure of the lipid A group. A. Multiple structures of lipid A
associated with various bacteria have been documented and studied. Common substitutions are
indicated by grey lines (S. minnesota) . Endotoxic activities are indicated by ‘+++’ for strongest activity
and ‘-‘ for no activity. Scale is intended as a qualitative guide only. (Adapted from Erridge et al. 2002
and reprinted with permission from Elsevier). B. The angle of orientation of the lipid A group affects
the hydrophobic interface and therefore the shape of the lipid A molecule and the aggregate micelle.
C. The aggregate shapes that have been recorded for LPS include lamellar, cubic, and hexagonal
inverted structures. (B-C were reprinted from Seydel et al. 2000, with permission from Karger
Publishers.)
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While some sources point to LPS aggregates as being the form required for
activation of innate immunity,98,99 others indicate that it is a monomer.100 Both states
may induce immune response, however, since LPS-mediated toxicity and immune
activation occur in aqueous blood, it is unlikely that the molecule is presented as a
monomer, until it becomes associated with serum binding proteins. In any case,
since samples like blood and serum are aqueous, detection strategies should take
into account the variability due to micelle conformations of LPS. This is
predominantly driven by the shape of the lipid A molecule,69,89,98,101,102 but other
factors can also influence the shape and size of aggregates. R-form LPS is
composed of lipid A and core polysaccharide,103 and is therefore primarily
hydrophobic.72,104 However, the large oligosaccharide region on S-form LPS makes
the molecule amphipathic in nature,78 which influences the overall shape of micelles
in solution. This variation in the shape of LPS micelles76 in solution can modify the
presentation of O-ag specific epitopes for detection, making quantitative immunebased detection of LPS challenging.105,106 This is specifically true when the
heterogenous presentation of linear107 and conformational epitopes67,108 present on
LPS are considered.
Additional driving forces regulate the shape of LPS micelles.88 In addition to
structural variance in the lipid A and O-ag regions, the primary structure of the LPS
molecule also varies within the core polysaccharide, both within and between
species.64,76 Core polysaccharides are primarily made up of common sugars such as
heptose and 2-deoxy-D-mannooctulosonic acid (a.k.a. KDO), which can be
functionalized with components such as phosphate or ethanolamine groups.66,68,109 It
has been demonstrated that a KDO molecule bound to a lipid A group is the
minimum requirement for growth in Gram-negative bacteria.58,59,64,72 This additional
degree of variability can contribute to varying charge distributions. It can also vary
the size ratio of the cross-sectional area of the hydrophobic to hydrophilic regions;
influencing the assembly of micelles.83,90,103,110 Other factors that contribute to LPS
micelle assembly90,103 are pH,85 ion concentration,111-116 and temperature.86 When
developing detection strategies for LPS, all of the variability issues related to
structure and micelle conformation are especially important to consider.
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1.4 Detection methods for lipopolysaccharides and similar amphiphiles
Due to the endotoxic nature of the LPS, there have been many efforts to
establish rapid and reliable detection methods for the molecule.117,118 The detection
of endotoxin is critical not only for bacterial detection, but also important for testing
pharmacological products such as infusion fluids, sterile injectables, medical device
implants, and other biological supplies.119 In 1980, McCabe120 reported that as many
as 20 different methods for the detection of endotoxin were currently in existence,
and that number has only grown higher with passing time.118 Analysis of the
methods reveals that they can be broadly divided into six overlapping categories: in
vivo and in vitro tests, immunoassays and their derivatives, biosensors, chemical
sensors, and cell-based sensors. These assays have a broad range of sensitivity for
endotoxin, but most of them lack the ability to differentiate LPS O-ag.

1.4.1 Limulus amoebocyte lysate assay and the rabbit pyrogen test
There is surprisingly very little information available on the first type of
endotoxin test. The first method approved by the US Food and Drug Administration
for LPS detection was called the rabbit pyrogen test.121-123 Since endotoxin is a
pyrogen (a fever inducing compound), a rabbit was inoculated with the material in
question and its body temperature recorded over time. Any pyrogenic activity was
attributed to contamination of the material with endotoxin.122-124 The test, clearly, is
activity based, and non-specific. However in the case of some types of vaccine
manufacturing, the rabbit pyrogen test is still the standard method for determining
contamination with endotoxin.124 As an in vivo assay, the rabbit pyrogen test is cost
prohibitive and is minimally utilized in present day, except for detecting endotoxin in
some parenteral devices.118
In 1956, Frederick Bang discovered that amoebocytes from Limulus
polyphemus (a.k.a. horseshoe crab) agglutinate upon addition of endotoxin,125 as a
result of a protease cascade118 (Figure 1.4). Realizing the medical relevance of this
discovery, Bang and Levin126,127 subsequently developed an assay for the detection
of endotoxin in clinical samples. Since the lysates of amoebocytes were required, it
was called the limulus amoebocyte lysate (LAL) assay, and has since been the gold
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standard for detection of lipid A (endotoxin). The LAL assay is prone to variability
and can be inhibited through several mechanisms. The United States Pharmacopeia
and the Code of Federal Regulations have consequently published guidances for
both the manufacturing and testing required when using these assays for testing of
human products.128,129 However, despite challenges, the LAL assay is reportedly 300
times more sensitive,117 and much more cost effective as rapid compared to the
rabbit pyrogen test, so it has largely displaced the in vivo test.130

Figure 1.4. Summary mechanism of the Limulus amoebocyte lysate pathway. Blood is drawn
from the horseshoe crab and the amoebocytes are isolated via centrifugation and then lysed and the
clotting enzymes are purified to use in the assay. Factor C is a protease zymogen, which is activated
through interaction with endotoxin. Factor C activates Factor B, which activates the pro-clotting
enzyme, which can activate creates clotting or converts the substrate. False positives result when the
pro-clotting enzyme is alternatively activated by Factor G, which is activated by glucans. Results can
be determined by visual evaluation of the clot, measuring the optical density of the solution, or by
adding a colorimetric p-nitroaniline substrate, which is cleaved by the activated clotting enzyme.

Several variants of the LAL assay use turbidimetric,131 chromogenic,132 or
viscosity133 readings to determine results.117,118 A turbidimetric gel clot has more
coagulen and evaluates the change in turbidity over time, but does not form a solid
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clot.117,131 The viscosity assay works in much the same way, but by measuring the
degree of clotting via the change in viscosity. The chromogenic assay can be an
endpoint or kinetic readout and varies from the former in that a p-nitroaniline
substrate, which is cleaved by an LAL proenzyme, is added and results in increasing
color intensity over time.134 The sensitivity of LAL assays are largely dependent on
the sample type, processing method and time, as well as the dilution factor.117
Additionally, the source of the LAL reagent plays a factor, as is apparent when
comparing the different limits of detection (LoD) that are reported for endotoxin
standards. A survey of the relative sensitivities of the LAL assay as compared to
other LPS detection methods is reported in Table 1.1.
As research progressed, more knowledge about the LAL assay came to light.
In 1970, Levin did multiple studies on the LAL assay in the blood of patients. Initially,
he discovered that samples tested in whole blood would not render a positive
result,135 but if the plasma was extracted in chloroform and diluted 1-10%, then the
endotoxin reactivity could be detected in the 0.5-5 ng•mL-1 range.127,135 Levin
correctly assumed that components of whole blood were bound to endotoxin,
therefore inhibiting the reaction with the LAL reagent,135-137 or changing the kinetics
of the reaction.138 This is immediately apparent when the amphiphilic nature of LPS
and the aqueous media of blood are considered. Therefore, by implementing
different processing methods to degrade serum proteins and release the LPS, one
could improve the sensitivity of endotoxin measurement.
In addition to blood or plasma of septic patients,127,135,139,140 the LAL assay
has also been used in other clinical samples such as: urine,132,141 cerebral spinal
fluid,140,142,143 synovial fluid,143 ascites fluid,144 vaginal and cervical fluids,145 bronchoalveolar lavage samples,146 seawater,60 and even agricultural samples like bovine
milk147 and beef tissue148,149. Virtually all of these have reported ng•mL-1 LoDs, for
endotoxin, but none are serotype specific to facilitate bacterial detection. Many
researchers have used different methods such as heat,150,151 chemical treatment
with chloroform,152 acids,153,154 alakali,155,156 or ether157 to improve the sensitivity of
the LAL test, with some successes in improving sensitivity when using heat or
chemical extraction of endotoxin prior to running an assay.158,159 However, when
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comparing samples of purified endotoxin standards, different researchers achieved
highly varied results even when using similar preparation methods (Table 1.1). Yin
and Galanos155 reported a sensitivity of 10-11 ng•mL-1 for Salmonella spp. while
Cooper and Levin122 reported a sensitivity of 1.0 ng•mL-1 for E. coli endotoxin. While
some variation is expected between species, this disparity leaves a lot of questions,
especially when considering that the structure of E. coli endotoxin is considered to
be the most biologically active type of LPS.89,90,92,98,103,160 Thus, in an activity-based
assay, the E. coli endotoxin should theoretically demonstrate the better sensitivity.
However, as seen in Table 1.1, this is not always the case and the source organism,
reagents, and processing methods play a heavy role in determining assay
sensitivity. Even small changes in preparation methods, such as heat or chemical
treatments, the usage of plastics instead of silanized glass, or the addition of
surfactants can result in altered sensitivity of assays. This variation in sensitivity
could also be explained by the variable structure of the Salmonella lipid A molecule
as a result of biosynthesis,161 as discussed by Erridge et al.64 (Figure A1.1). There
are also cross reactivity issues as the LAL can show false positives upon reacting
with other polysaccharides or β-(1,3)-glucans.162,163 However, the main reason for
variability is the source bacteria of the endotoxin. LPS/endotoxin varies in toxicity
levels,89,90,92,103 especially in regards to stimulation of the immune system.62,160,164 It
is therefore a safe assumption that an assay such as the LAL assay or the rabbit
pyrogen test, which are both based on the native immune responses of the
horseshoe crab or rabbit, would therefore vary accordingly in the reported
sensitivities with respect to the toxicity level of the LPS being detected.
Despite these variabilities, there are many instances when a rapid test such
as LAL is useful for quickly determining whether contamination exists. For example,
in 1981, Jay149 used the LAL test to determine both microbial counts and endotoxin
load in 153 samples of store bought ground beef. He reported a mean sensitivity of
7.9 µg•mL-1 (endotoxin/beef sample), and a processing time of 1 hour. In 1985,
Nachum and Shanbrom132 reported using a chromogenic LAL system to detect
between 2-175 ng•mL-1 of endotoxin in 324 patient urine samples, with an assay
taking between 2-4 hours. Obviously timely detection in these scenarios is valuable
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to both patient care and product viability. Despite being an ideal test for the
presence of endotoxin, determining identity of the pathogens in the sample still
requires culture identification. While the LAL assay is extremely sensitive for
detection of nanogram quantities of endotoxin contamination in parenteral injections,
or on medical devices, the assay lacks specificity and therefore is not a good
diagnostic method for determining bacterial species or serogroup.

1.4.2 Immunoassays for LPS detection and antibody screening
Many researchers have made attempts to develop specific and sensitive
ELISAs that target LPS O-ag. Developed in 1971,165-167 the ELISA is an established
method for the detection of antigens or antibodies in many sample types.
Schematics of standard types of ELISAs are seen in Figure 1.5. Since ELISAs are
based on an immune reaction between an antigen-antibody pair, each assay must
be specifically developed for the unique antigen being tested. This can lead to a
highly specific result if appropriate reagents are available. ELISAs were specifically
designed and optimized for the detection of proteins, but the importance of LPS as a
biomolecule of wide significance is further illustrated by the fact that some of the
earliest research using ELISAs was investigating targeted antibody binding to
Salmonella O-ags.168 However, ELISAs for lipoglycans such as LPS and LAM, suffer
from low sensitivity and reproducibility.169-171 One of the primary reasons for this is
the structure of said molecules, which in addition to being amphipathic, are
heterogenous and micellar, leading to inconsistent binding on ELISA plates,172 and
variable conformations of epitope binding sites.51,173
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Figure 1.5. Schematics of ELISA types. A. Direct ELISA where antigen is coated directly to the
plate and then detected with an enzyme-linked primary antibody. The enzyme is often horseradish
peroxidase (HRP). An indirect ELISA adds an additional enzyme-linked secondary antibody to a
direct ELISA. A direct sandwich and an indirect sandwich are based on the same detection methods,
but a capture antibody against the antigen is used to pull down the target from the medium.

Despite challenges with lipoglycan binding, there exist two primary types of
LPS-ELISAs, each with many experimental variations. The first is designed to
directly detect the LPS antigen (Figure 1.5), and the other uses serology to measure
LPS antibody titers. For direct detection, the surface of the plate is typically coated
with a primary capture antibody specific to LPS. Alternatively, the plate can be
directly coated with the sample being tested for LPS.172 After antigen capture, an
epitope-specific antibody is used to detect LPS. The detection antibody can be
directly labeled with an enzyme to facilitate colorimetric detection.167 Alternatively, a
secondary antibody can be used.174,175 In 1998, Mackenzie et al.176 reported on the
effectiveness of a commercial assay to screen stool samples for E. coli O157
antigens, and found that re-testing samples provided inconsistent results in some
cases. It was speculated that this was due to inefficient washing of the micro-wells
between assay steps, but the inconsistency in amphiphilic antigen preparation and
its presentation to antibodies was not discussed. In clinical samples, the association
of amphiphilic LPS with host carrier molecules may affect its ability to
adhere/associate with capture surfaces. It was also not considered that LPS is
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notorious for causing non-specific and inconsistent binding on microplates.170,172,177
Some groups have also reported cross reactivity or false positives when developing
sandwich ELISAs for LPS antigens. 178,179 Choi et al. 179 developed a sensitive
capture ELISA, but it was found to cross react with 24 species of Salmonella. To
mitigate cross reactivity and non-specific interactions, attempts have been made to
substitute antibodies with other ligands more apt to physiologically bind LPS. Grallert
et al.180,181 coated microplates with proteins from bacteriophages, which are specific
to core polysaccharides, in order to capture LPS, and then perform detection with
Factor C (a component from the LAL assay, see Figure 1.4). This resulted in the
development of the sandwich ENDOLisa®, a microplate assay for direct detection of
endotoxin which was tested in various buffers and detergents, and reports
sensitivities between 0.05-500 endotoxin units (EU) per millilter. At present,
ENDOLisa® technology is sold as the Endotoxin Sample Preparation (ESP™) Kit,
and is one of the few kits available for the direct detection of endotoxin in blood or
serum.182 Even though the ENDOLisa is sensitive, it is not serogroup specific due to
the semi-conserved nature of the core polysaccharide between different subtypes.
For determining exposure in clinical samples, a modified immunoassay is
used to screen for LPS antibody titers. This is one of the most common methods for
determining exposure to specific Gram-negative pathogens. To perform the assay,
the surface of the plate is functionalized with the antigen in order to pull down the
antibodies from serum (Figure 1.5). Since this method is based on adaptive
immunity there is a lag between initial exposure to a pathogen, and increased
antibody titers,183 which makes early detection difficult. In contrast, directly targeting
LPS antigen (as in the first type of ELISA discussed) facilitates early and specific
detection. Because this is an indirect method to assess for LPS-induced immune
activation, and cannot be correlated with active infection, it is of limited use.
Furthermore, many LPS antigens have not been isolated from their respective
bacterial strains10 and are not available for development of screening assays.
Screening for LPS antibody titers (Immunglobulins A, G, and M (IgG, IgA,
IgM)) has been used in many studies to monitor population health and track
epidemiology of infectious diseases. For example, it has been used to detect
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exposure of military personnel to Shigella,184 obstetric patients to Chlamydia spp.,185
and Salmonella patients from Vietnam,186 as well as many other species of
pathogens.168,187-191 Suthienkul et al.188 used an indirect ELISA (Figure 1.5) to
passively adsorb LPS to the surface of polystyrene plates, and screen patient serum
samples for IgG and IgM titers against the LPS of Vibrio cholera. However, the
results indicated some possible discrepancies between the titers of IgG and IgM in
young versus older patients. This could either be due to the inconsistency of LPS
coating on the surface of the microplate, or the issues with cross reactivity of
IgMs.192 Suthienkul also acknowledged that antibody levels in the infants screened
could be inherited from the mother’s exposure, since said antibodies are known to
cross the placental barrier.188,193
Functionalizing ELISA plates with the amphiphilic LPS antigens is a technical
challenge,51 since the surfaces are optimized for protein binding. Researchers have
examined methods for increasing adherence of LPS to the surfaces of microtiter
plates. In the late 1970’s, it was discovered that polymyxin B (an antibiotic, PmB)
interacted with LPS monomers in a 1-to-1 ratio,116,194 and can be used to
functionalize surfaces for Gram-negative detection schemes.173 However, PmB
recognizes the lipid A group of LPS in much the same manner as other LPS
recognition proteins, and does not allow for discriminative detection. Takahashi et
al.172 studied methods for increasing the adsorption of LPS from samples directly to
microtiter plates. By pre-coating the plate with high molecular weight poly-L-lysine,
they determined that LPS from Klebsiella O3 could be selectively detected at 1
µg•mL-1, with no cross reactivity with other O-groups. Others have studied the
effects of ions such as calcium and magnesium,195 trichloroacetic acid,196 mixing the
antigen in chloroform/ethanol and drying on the plate surface,187 or complexing LPS
with a protein such as bovine serum albumin.197 Functionalization of ELISA plates
with other proteins known to bind LPS, such as high- or low- density lipoproteins
(HDL, LDL), chylomicrons, and LPS Binding Protein (LBP), have been performed, to
study the preferred binding associations of LPS with these proteins.198,199 However,
using molecules known to bind LPS, like PmB, HDL, LDL, LBP200, chylomicrons,
peptides, and lectins, are potential ways to optimize detection assays, and present
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LPS in physiologically relevant conformations, to enable binding of antibodies to
their preferred epitopes.
There are other drawbacks to using classical schemes for detection of LPS.
In some cases, antigens are not readily available, and thus antibodies with high
affinity for the target cannot be developed.10,201 Additionally, ELISAs can suffer from
high background noise due to non-specific interactions with both the sample matrix
to the polystyrene plate or the antibodies sticking to non-specific targets.176,177,187,202
There is also a concern that endogenous endotoxin present in reagents, on
glassware, or plastics203 can add to the problem.
To mitigate this, researchers have worked to develop better antibodies
against both the O-ag of LPS, as well as the conserved epitopes within the
molecule.9,204-208 However, the main problem with developing antibodies against Oag lies in the technique used. While there are variations of the procedure,177 ELISA
plates are typically functionalized with whole dead bacteria to screen monoclonal
antibody cultures,9,204,208 giving rise to potentially cross reactive antibody clones.10,177
To minimize undesired cross reactivity, potential clones are screened against a
multitude of bacterial strains.204,205,207 However, it is impossible to screen clones
against all epitopes of LPS. In 2000, Jauho et al.51 addressed this issue by
covalently linking purified LPS O-ags to polystyrene ELISA plates using
anthraquinone and UV irradiation. This technique could prove immensely useful in
developing serogroup specific antibodies against LPS, as conserved antigens like
lipid A and core polysaccharide, are absent. Alternative methods for antibody
screening and epitope affinity have utilized immunoblotting techniques 10,205,209-211
and flow cytometry.212-215 These techniques allow for careful analysis of epitopes
being bound by antibodies, and can help minimize cross reactivity.

1.4.3 Biological and chemical-based LPS sensing
As biotechnology advances, the development of many sensing capabilities
such as electrochemical impedance spectroscopy (EIS)216-218, antimicrobials,106,219
aptamers,220 synthetic polymers,221 optical immunoassays,176,178,222 waveguide
technology,106,223,224 lipid bilayers,20,105,225 and in vitro226-228 assays have all been
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used to study LPS interactions and develop sensitive and/or specific detection
methods. These technologies, similar to older ones, use a common strategy of
functionalizing biosensors with proteins or molecules to pull down LPS from a
sample matrix. The researchers typically utilize one of many specialized proteins
and ligands that interact with LPS, as discussed above, for this purpose.
A primary protein that binds LPS is the LPS Binding Protein (LBP),229 a
relatively small protein (~60 kDa) that transports LPS in the bloodstream. LBP
passes LPS off to the cluster of differentiation 14 (CD14) protein, located in the
extracellular matrix, or on the membrane of immune cells, such as macrophages.229
After LPS binds CD14, it is passed to the hydrophobic binding pocket of myeloid
differentiation factor 2 (MD-2),18,104 which is a necessary cofactor for activation of the
innate immune receptor, TLR4. In addition to these, LPS has been demonstrated to
bind aptamers,216,217 various peptides,119,219,230-232 and metal/cation
complexes.114,116,218,233-235 All of these molecules, along with the serum carriers (HDL
and LDL) of LPS, are potential receptors for capturing LPS on surfaces, and have
been evaluated in that context.
Electrochemical and fluorescence-based sensors for detection of LPS have
been developed. Existing methods are based on the idea that LPS must be pulled
down from the sample matrix to a receptor molecule on the sensing surface.
Electrochemical sensing of LPS requires a recognition ligand (similar to ELISA) and
a transducer to measure the variation in signal.218 For fluorescence-based sensing,
a receptor is required to capture LPS while another molecule emits a fluorescent
signal when bound to the antigen. Burkhardt et al.236 used solubilized LBP to transfer
LPS to a CD14 functionalized surface, and detected it at a LoD of 10 ng•mL-1 using
an electro-chemiluminescent assay. This method enforces the role of LBP as a lipid
transfer protein, as previously demonstrated by Wurfel et al.237,238 and that CD14 can
bind monomeric LPS in the absence of TLR4.239 Highly sensitive (LoD = 0.0005 EU)
electrochemical sensors have also been developed using a recombinant innate
immune (TLR4 + MD-2) receptor complex for recognition of LPS.240 However, such
an assay has no capability for O-ag specificity, unless a recognition molecule could
be used to bind the exposed O-ag.
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Priano et al.230,231 functionalized an electrochemical sensor with a
recombinant endotoxin neutralizing protein on a dextran matrix to perform a
competitive LPS assay, and achieved a detection range of 1-100 ng•mL-1. Endotoxin
neutralizing protein has also been used in a capacitive biosensor with an extremely
low LoD (1.0 x 10-13 M).241 As mentioned in Section 1.4.1, small changes in the
preparation of LPS can lead to large changes in sensitivity of assays. The disparity
in detection signals between these two assays can perhaps be explained by the
method of surface functionalization. Priano et al.230,231 used the dextran matrix, and
Limbut et al.241 used self assembled monolayers (SAMs), which are known to have
particularly low background interference.242-244 Inoue and Takano245,246 used a
recombinant factor C (a protein from the LAL enzyme pathway)247 to make an
electrochemical-based hybrid LAL-biosensor chip with a reported sensitivity range of
5 x 10-4 – 1.0 EU/mL. This strategy would work well for detection in ground beef and
patient urine. However, the inability to detect bacterial species leaves health care
providers with little information on treatment strategies.
An interesting adaptation of LPS pull down with PmB was performed by
Kato119 and Iijima.248 PmB was labeled with ferrocene-bound LPS in solution, and
then captured on a nanocarbon-film electrode to measure bound LPS. This
electrochemical sensor reported a detection range of 2-50 ng•mL-1 in as little as 5
minutes.248 However, previously, Ding et al.219 functionalized an electrode with PmB
and performed EIS with a detection range of 0.2-0.8 ng•mL-1 which is sufficiently
more sensitive, but has a much smaller range. A broader detection range was
demonstrated by Rahman et al.,232 who were able to functionalize interdigital
sensors with PmB and tested 0.1-1000 µg/mL of LPS O111:B4 in various food
samples, using impedance spectroscopy.
A special category of protein functionalization is the usage of lectins (sugar
binding proteins) to pull down and bind LPS. Lectins have been covalently linked to
the surface of a luminescent biosensor, resulting in a sensitivity of ~200 ng•mL-1
LPS,249 and also to polyaniline coated electrodes to detect both LPS and a similar
amphiphilic PAMP, LTA.250 This method indicates the importance of being able to
detect both Gram-positive and Gram-negative pathogens, however the ability to
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differentiate between the two amphiphiles was not a capability of this particular
platform. Similar methodology was used to functionalize the surface of an EIS
sensor with the lectin, CramoLL, to develop a proof of concept assay with a
detection range of 25-200 µg/mL.251
Other biosensor platforms have used gold electrodes or surfaces
functionalized with LPS-binding materials to develop assays capable of detecting
LPS O-ag. Su et al.217,252,253 used aptamers attached to gold nanoparticles to detect
LPS using EIS, and achieved an impressive detection limit of 0.1 pg/mL.253
Aptamers have also been used in a magnetic aptasensor, where two different
aptamers were used in a sandwich format to detect LPS in complex medias
containing BSA, sucrose, glucose, or RNA.220 The range of detection for the
aptasensor was determined to be 0.01 – 1.0 x 106 ng•mL-1 (LPS O55:B5) using a
flow cytometer within 1 minute. Bai et al.254 developed an electrochemical sensor
where aptamers that bind LPS were hybridized with capture probes, and then the
capture probes were hybridized to complementary DNA sequences on gold
nanoparticles. This method reported a very sensitive detection range of 10 fg•mL-1
up to 50 ng•mL-1, and is arguably the most sensitive endotoxin assay. Such a
sensitive method could also have high potential as a discriminative assay, especially
because multiplexing with LPS aptamer probes is feasible. However, multiple
aptamer libraries against O-ag would be essential before this method could be
implemented on a broader scale.
Some researchers have used more specialized surfaces for detection. In
some cases, SAMs have been used to functionalize sensors with peptides,255
PmB,219 antibodies,256 and aptamers,216 to develop pull down assays for LPS
detection. A schematic of SAMs for detection can be seen in Figure 1.6A. Nieradka
et al.256 used strain specific antibodies attached to SAMs on the surface of
microcantilevers for detection of LPS from Hafnia strains, but the LoD was in the
µg•mL-1 range. Kim et al.216 performed sensitive detection of LPS O55:B5 (0.01 – 1.0
ng•mL-1) using SAMs functionalized with aptamers, but the decreased detection
range could prove a limiting factor. Both antibodies and aptamers are advantageous
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methods for specific detection, however they can both be cost prohibitive given the
sero-diversity of LPS.

Figure 1.6 – Functionalized surfaces for detection of biomarkers. A. Self-assembled monolayers
(SAMs) can be put on the surface of detection platforms to minimize the background noise associated
with detection in complex bilayers. SAMs can be functionalized with a multitude of moieties, including
aptamers, antibodies, or polymyxin B. B. Membrane insertion uses a substrate functionalized with
supported lipid bilayers and the target amphiphile diffuses into the bilayer due to hydrophobic
associations. C. Detection with membrane insertion in which the waveguide is functionalized with a
lipid bilayer, the amphiphile diffuses into the bilayer and is detectable with a fluorescently labeled
antibody. (Figure B (LAM structure) was adapted from Mukundan et al. 2012 and reprinted with
permission from Elsevier.)

Other research groups have exploited the chemical nature of LPS by
demonstrating interactions with other synthetic systems such as copolythiophene
copolymers221 and polydiacetylene liposomes,257,258 both of which generate a
fluorescent signal in solution when associated with LPS. Johnson et al. 259
demonstrated an endotoxin capture technique by functionalizing a bead matrix with
proanthocyanidins and binding with fluorescein isothiocyanate-labeled LPS. While
the technique was developed as a purification system, it could potentially be applied
to detection of endotoxin as proanthocyanidins have a high affinity for lipid A. 259
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Pyrenyl-derived quaternary ammonium probes, developed by Zeng et al.,260
exhibited fluorescence when bound to LPS and were able to detect nanomolar
concentrations, and fluorescently labeled CD14 synthetic peptides demonstrated an
increase in Förster resonance energy transfer when bound to LPS, but were only
able to detect µM concentrations of the antigen.261 Lim et al.262 functionalized a
graphene oxide surface with a fluorescently labeled LPS binding peptide, which
when bound to the graphene oxide was quenched. Upon binding of 130 pM LPS,
fluorescence recovery occurred due to release of the peptide from the surface. While
this method was tested with many types of LPS, it is a method specific to the
biological activity of lipid A, and not the O-ag. Thompson et al.263 designed a tandem
system to both detect (LoD = 1.0 ng•mL-1) and filter LPS from blood using piezo
electric quartz discs funtionalized with PmB. These separation and concentration
approaches have accounted for the biochemistry of LPS, and such lessons should
be transitioned into detection schemes for effective assay design.
Other methods for detection of LPS have taken advantage of its unique
amphipathic nature. Harmon et al.264 demonstrated that disrupting the hydrophobic
association of LPS with lipid liposomes increases the sensitivity of the LAL assay. In
contrast to lipid disruption, Sakamuri et al.19 was able to detect 0.8 pM of amphiphilic
LAM in patient serum on a waveguide biosensor using a technique called membrane
insertion. In this technique, the amphiphile partitions into a lipid bilayer, and
fluorescence detection with a labeled antibody is performed within an evanescent
field,225,265 resulting in very sensitive detection. A schematic of membrane insertion
of amphiphilic biomarkers can be seen in Figure 1.6 B and 1.6 C. Membrane
insertion uses the natural association of amphiphiles with a lipid bilayer to facilitate
detection, and is particularly applicable to LPS since the native form of the molecule
is associated with the outer membrane of Gram-negative bacteria. An additional
advantage of membrane insertion is that it is not exclusive to pathogen biomarkers,
but universally adaptable to many types of amphiphiles, such as carcinoembryonic
antigen from tumor cells.266 Most sensor platforms report exquisite sensitivity, even
down to the picogram221 and femtomolar20,225,265 range, but very few are capable of
physiological presentation of amphiphiles to facilitate discriminative detection of O-
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ag groups. The detection of LPS associated with a membrane takes advantage of
physiological presentation to minimize cross reactivity with the conserved lipid A
epitopes, and maximize binding of O-ag specific antibodies.

1.4.4 Cell-based LPS detection platforms
More specialized systems for detection of LPS look at the in vitro effects of
the molecule on cell systems. While cells are the systems best built to recognize
endotoxin, interpreting the signal response can be challenging in some instances,
making for a more qualitative strategy rather than a quantitative one. Bouafsoun et
al.226 functionalized the surface of an impedance biosensor with endothelial cells and
measured the decrease in impedance with endotoxin binding. This system could
detect 500 ng•mL-1 of endotoxin by measuring the decrease in resistivity of the
monolayer, which was attributed to the LPS-induced formation of pores in the
endothelial layer. Veiseh et al.267 patterned macrophage cells onto gold electrodes
(silicon oxide substrates) to detect LPS concentrations of 0.1-10 µg•mL-1. However,
cells were concurrently stained with necrosis and apoptosis markers in parallel
studies, and no staining effect could be seen in cells using concentrations less that
10 µg•mL-1. This is an interesting effect as many in vitro studies on innate immune
response use much lower concentrations of LPS and still document increased levels
of pro-inflammatory cytokines.137,268,269 However, while not specified, it can be
deduced that Veiseh used serum supplemented media in the experiments, and the
lipoproteins and LBP in serum could have a protective effect on cells.136,269,270 The
most sensitive cell-based detection system was developed by Inoue et al.,227 and
could detect LPS between 0.1-1.0 ng•mL-1. In this system, cells were engineered to
secrete alkaline phosphatase in the presence of endotoxin, and then patterned on
the surface of an amperometric biosensor. Cells were incubated in the presence of
LPS and p-aminophenyl phosphate (substrate). When the expressed alkaline
phosphatase oxidized the substrate, a concentration dependent increase in voltage
was recorded. Despite sensitivity and physiological relevance, cell-based in vitro
assays are notoriously prone to errors and contamination, so developing a robust
and fieldable assay based on this technology is not plausible. However, by studying
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LPS in cell-based systems, a lot of knowledge about interactions with receptors and
cell membranes can be gained, which can facilitate detection. It becomes obvious as
one looks at the advancing research that the ability to detect low concentrations of
endotoxin increases over time as new LPS binding molecules are discovered, and
used to functionalize the surfaces of biosensors. However, while the detection of
endotoxin is of critical importance, the new focus needs to look at the early
discriminative detection of the pathogen to facilitate early response, preventing
further infection and transmission in both epidemics and food safety scenarios.

1.5 Present studies
Shiga-toxin producing E. coli (STEC) is a virulent Gram-negative pathogen
that commonly presents as a contaminant in the food chain, especially in beef. Upon
infection, STEC can cause severe symptoms in humans, such as gastroenteritis and
hemolytic uremic syndrome. The increasing occurrence of non-O157 STEC in both
cattle271 and humans272 has caused the United States Department of Agriculture
Food Safety Inspection Service to require that all non-intact cattle products be
screened for the presence of seven serotypes of STEC. The detection and
differentiation of STEC strains from one another and from non-pathogenic near
neighbors is essential to ensuring the safety of the food supply. However,
developing strain specific detection methods for STEC predominantly relies on the
identification of the LPS O-ag biomarker. For most strains of STEC, these antigens
were not available for assay development. As such, in the work presented here, we
show the isolation and antigen characterization of a set of LPS antigens and
commercial antibodies to use for development of discriminative LPS O-ag assays.
This involved bacterial culturing, antigen extraction, purification, and testing of LPS
subgroups including the whole antigen molecule as well as O-ag, and lipid A
components from multiple strains of STEC. We demonstrate techniques for
assessing cross reactivity between O-ags using available antibodies, and then use
these methods in turn to develop monoclonal antibodies with higher specificity. To
develop discriminative detection methods for LPS, we applied the previously
established waveguide biosensor technology using SLBs and performed detection of
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LPS antigens inserted into the membrane using fluorescently labeled antibodies. An
advantage of this system is the physiological presentation of LPS in a mimetic
membrane system, which leaves the O-ag exposed in the aqueous matrix for
detection. While this approach exploited the current knowledge that LPS passively
diffuses into DOPC bilayers, we were also able to shed new light on the dynamic
effects of LPS in bilayer systems. To ensure the validity of our detection platform, we
extensively characterized the effects of various subtypes of LPS under multiple
conditions. Understanding the physical ramifications of LPS-SLBs interactions not
only aids in the development of better biosensors for detection of amphiphilic
biomarkers, but also gives deeper understanding of the bioactivity of endotoxins in
vivo. Finally we explore the ramifications that this knowledge has on our current
understanding of endotoxin activity in biomimetic complex lipid systems, as well as
the optimal presentation methods of LPS used in in vitro studies.
Table 1.1 Survey of Methods and Reported Sensitivities of Assays Against Bacterial
Endotoxins and Similar Amphiphiles
Description

Rabbit Pyrogen

Sample

Detection
Method

Species

Purified
endotoxin

Febrile
Response

Specific* Reference

CFU/mL

Sensitivity

−−−−

−−−−

−−−−

No

122

LAL

Plasma

Gelation

multiple
species

−−−−

0.5-5.0
ng•mL-1

No

273

LAL

Spiked Blood/
Serum Plasma

Gelation

E. coli

−−−−

0.5-5.0
ng•mL-1

No

135

LAL

Serum/Plasma

Optical Density

E. coli

−−−−

0.025-0.5
ng•mL-1

No

139

LAL

Spiked Urine

Gelation

E. coli
(standard)

>10 5

0.5
ng•mL-1

No

141

LAL

Urine

Optical Density

multiple
species

≥10 5

2.0
ng•mL-1

No

132

LAL

Cerebral
Spinal Fluid

Gelation

Haemophilus
influenzae B

−−−−

0.03
ng•mL-1

No

142

LAL

Cerebral
Spinal
Fluid/Plasma

Optical Density

Haemophilus
influenzae B,
E. coli
(standard)

10 7

0.01 (CSF)
0.1
(plasma)
ng•mL-1

No

140

LAL

Bronchoalveolar lavage

Chromogenic

Pseudomonas
Haemophilus
influenzae B

≤10 2

0.005
ng•mL-1

No

146
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Description

Sample

Detection
Method

Species

Chromogenic

Specific* Reference

CFU/mL

Sensitivity

−−−−

−−−−

0.07
(cervix)
0.14
(vagina)
ng•mL-1

No

145

Gelation

E. coli
(standard)

−−−−

0.5
ng•mL-1

No

144

LAL

Cervical and
urethral
exudates

LAL

Ascites

LAL

Cerebral
/Synovial

−−−−

E. coli
(standard)

−−−−

1.0
ng•mL-1

No

143

LAL

Seawater

Optical Density

E. coli
(standard)

4.23

2.3
ng•mL-1

No

60

LAL

Purified
endotoxin

Gelation

E. coli

−−−−

1.0
ng•mL-1

No

122

LAL

Purified
endotoxin

Gelation

Klebsiella

−−−−

0.1
ng•mL-1

No

122

LAL

Purified
endotoxin

Gelation

Salmonella
minnesota

−−−−

10-11
ng•mL-1

No

155

LAL

Ground Beef

Gelation

Enterobacter
aerogenes

3.5 5

−−−−

No

274

LAL

Ground Beef

Gelation

multiple
species

5.24 5

51.0
ng•g-1

No

148

LAL

Milk

Chromogenic

Pseudomonas
putida

1.4*102

0.01
ng•mL-1

No

147

LAL

Purified
endotoxin

Gelation

E. coli O114

−−−−

100
ng•mL-1

No

275

changes in
resonant
frequency of the
sensor

E. coli O111:B4

−−−−

0.0105
EU•mL-1

No

276

Fluorescence

E. coli spp.
Salmonella
spp. and others

−−−−

0.05-500
EU•mL-1

No

277

Yes

171

LALMagnetoelastic
sensor

Purified LPS

ENDOLisa®
(LAL)

Purified
endotoxin

ELISA - LAM

Urine

Abs @ 450 nm

Mycobacterium
tuberculosis

−−−−

−−−−

Milk

Abs @ 405 nm

E. coli

−−−−

100-200
ng•mL-1

222

LPS pull down Sandwich ELISA

Pure cultures

Abs at 450nm

E. coli O157

10 5

−−−−

178

LPS pull down Sandwich ELISA

Purified LPS
and
pure cultures

Abs at 450 nm

Salmonella
spp. (31 total)

1120

1.0
ng•mL-1

Yes

179

ELISA

Purified LPS
in PBS buffer

Abs at 492nm

Klebsiella O3

−−−−

1000
ng•mL-1

Yes

172

ELISA
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Description

Sample

Detection
Method

Species

Spectrophotometric

Specific* Reference

CFU/mL

Sensitivity

E. coli O157

−−−−

−−−−

Yes

176

Premier EIA E.
coli O157

human stool
extract

LPS pull down

Purified
endotoxin

RIA

E. coli O114

−−−−

300
ng•mL-1

No

275

LPS pull down ion capture
(NTA-Cu)

Purified LPS

EIS

E. coli O55:B5

−−−−

0.0001–0.1
ng•mL-1

No

218

Electrochemical diaphorase
functionalized
surface

Purified LPS

chemically
amplified current

E. coli O127:B8

−−−−

50
ng•mL-1

Maybe

119

Electrochemical
competitive

Purified LPS

amperometric

E. coli O26:B6
Salmonella
minnesota

−−−−

1.0-100
ng•mL-1

No

231

LPS pull down SAMs with
synthetic peptide
capture

Purified LPS

Electrochem.

E. coli ATCC
35218

−−−−

21.8
pg•mL-1

No

255

LPS pull down SAMs with
aptamer capture

Purified LPS

EIS

E. coli O55:B5

−−−−

0.1-1.0
ng•mL-1

Maybe

216

LPS pull down gold electrode
with aptamer
capture

Purified LPS

EIS & cyclic
voltammetry

E. coli O55:B5

−−−−

0.001-1.0
ng•mL-1

No

217

LPS aptamer
sandwich

Purified LPS
in BSA,
glucose or
RNA

Electrochem.

−−−−

−−−−

10
fg•mL-1

Maybe

254

LPS pull down gold electrodes
w/ PmB capture

Purified LPS

EIS

E. coli O111:B4

−−−−

0.2
ng•mL-1

No

219

Polydiacetylene
Liposomes

Purified LPS
(5 groups)

Change in Abs electronic
tongue

E. coli spp and
Salmonella spp

−−−−

2.22
mg•mL-1

Yes

258,278

Impedance
enthothelial
biosensor

Purified LPS
in culture
medium+

Electrical
resistivity of
endothelial
monolayer

−−−−

−−−−

500
ng•mL-1

No

226

Macrophage
microarrays on
gold electrodes

Purified LPS
in culture
medium+

FTIR

E. coli O111:B4

−−−−

0.1
µg•mL-1

No

267

Primary culture
HDME cells

Purified LPS

Fluorescent
labeleing of Eselectin with
antibodiy

E. coli O111:B4

−−−−

1.0
µg•mL-1

No

228
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Description

Sample

Detection
Method

Species

CFU/mL

Sensitivity

Specific* Reference

Engineered cells
secrete alkaline
phosphatase in
the presence of
LPS

Purified LPS
in culture
medium+

Electrochem.
Oxidation of
substrate

−−−−

−−−−

0.1
ng•mL-1

No

227

LPS pull down PmB capture

Purified
labeled &
unlabled LPS

Evanescent
sensing competitive
replacement by
LPS

E. coli
O128:B12

−−−−

25
ng•mL-1

No

106

LPS pull down TLR4/MD2
complex on gold
electrodes

Purified LPS

Electrochem.

E. coli O55:B5

−−−−

0.0005
EU•mL-1

No

240

LAM pull down membrane
insertion

Infected
patient serum
(LAM)

Evanescent
sensing fluorescence

Mycobacterium
tuberculosis

−−−−

0.8 pM

Yes

19

PGL pull down membrane
insertion

Purified
phenolic
glycolipid

Evanescent
sensing fluorescence

Mycobacterium
leprae

−−−−

500 nM

Yes

20

LAM pull down membrane
insertion

Purified LAM

Evanescent
sensing fluorescence

Mycobacterium
tuberculosis

−−−−

10 fM

Yes

225

LPS pull down membrane
insertion

Purified LPS
(3 groups)

Evanescent
sensing fluorescence

E. coli

−−−−

4.20
µg•mL-1

Yes

105

LPS pull down antibody capture

Pure cultures
in ground beef

Evanescent
sensing fluorescence

E. coli O157

520/g

−−−−

Yes

223

LPS pull down proanthocyanidin
on beads

FITC-labeled
LPS

Fluorescence

E. coli O55:B5

−−−−

−−−−

No

259

Copolythiophene
interacts with
LPS

Purified LPS

Fluorometric conformational
change in
copolythiophene
backbone

E. coli O55:B5

2.5E-5 – 2.0
µM#

No

221

Polydiacetylene
liposomes

−−−−

Fluorometric Binding of LPS
to PDA
liposomes turns
on fluorescence

−−−−

−−−−

0.1 µM#

No

257

Peptide-based
fluorescence

Purified LPS

FRET - increase

E. coli O111:B4

−−−−

0.15-2.0
µM#

No

261

Pyrenyl-derived
long-chain
quaternary
ammonium
probe

Purified LPS

Fluorescence probe binds to
LPS

E. coli O55:B5

100 nM#

No

260
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Description

Sample

Detection
Method

Species

Specific* Reference

CFU/mL

Sensitivity

−−−−

130 pM#

No

262

1.0
ng•mL-1

No

263

−−−−

10.0
ng•mL-1

No

236

4.0*106

0.2
µg•mL-1

No

249

−−−−

50.0
µg•mL-1

No

250

LPS pull down –
peptide
functionalized
Graphene Oxide

Purified LPS
(4 groups)

Fluorescence
turn on

Several species

LPS pull down
PmB capture

Purified LPS
spiked in
blood

High frequency
acoustic sensing

E. coli O55:B5

LPS pull down
CD14 capture

Biotinylated
LPS

Luminescence

−−−−

LPS pull down
Concanavalin-A

Purified LPS
in buffer and
pure cultures

Changes in
luminescence

Hafnia alvei

LPS pull down
Polyaniline +
Concanavalin-A

Purified LPS
and LTA

EIS

E. coli
aureus

LPS pull down
specific
antibodies on
SAMs

Purified LPS
(2 strains)

Change in
resonant
frequency of
microcantilever

Hafnia alvei

−−−−

50
µg•mL-1

Yes

256

Aptamer
sandwich on
beads

Purified LPS

Flow cytometry,
fluorescence

E. coli O55:B5

−−−−

0.01
ng•mL-1

Maybe

220

LPS pull down
Endotoxin
neutralizing
protein capture

Purified LPS

Change in
capacitance

E. coli

−−−−

1.0•10-13
M#

No

241

LPS pull down
CramoLL lectin

Purified LPS
(4 types)

EIS

E. coli
Salmonella
Klebsiella
Serratia

−−−−

25.0
µg•mL-1

No

251

S.

* Where specificity refers to ability to detect specific O-antigens of LPS, or differentiate between species, Maybe = indicates
that specificity could be achieved, but was not tested with multiple LPS types; # Authors assumed a homogenous molecular
weight (10 kDa) for LPS; +Indicates that based on methods description, culture medium was positive for serum
−−−− Indicates a values not specified by the author or not applicable to a given situation
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Chapter 2.
Goals and Overview of this Work
Shiga toxin-producing Escherichia coli (STEC) are food-borne pathogens that
present as contaminants in beef, produce, and water. These bacteria are capable of
causing serious infections in humans, often resulting in severe symptoms such as
gastroenteritis and hemolytic uremic syndrome. Due to the severity of disease and
increasing prevalence of STEC in the food chain, the United States Department of
Agriculture currently mandates screening for several serotypes of STEC in raw beef
products. Discriminative detection of STEC serotypes is critical for prevention and
management of outbreaks, as well as for epidemiological modeling. However, the
discrimination between types of bacteria is challenging due to similarities between
strains and serotypes. LPS is a critical component for determining the serotype of a
bacterial species. Therefore, the goal of this work is to develop, characterize, and
optimize both assays and functional surfaces for detection of serogroup-specific
STEC LPS in beef homogenates by using a signal transduction scheme specifically
designed for amphiphiles, termed membrane insertion.
Historically, detection of LPS has relied on the presence of non-specific
endotoxin contaminants. In this work, we propose the development of targeted
methods for differential detection of LPS O-ag to facilitate serotyping of bacterial
pathogens. This effort required special consideration of the amphiphilic biochemistry
of LPS. Developing and implementing methods where LPS is presented in
physiologically relevant conformations is critical, not only for the development of a
universal amphiphile sensor, but also for understanding the conditions necessary for
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in vitro immune studies. We established guidelines for the serogroup specific
detection of LPS and for extension of these methods to other amphiphilic
biomarkers.
To achieve these goals, several aspects of the problem had to be
simultaneously considered. Development of these individual aspects, and their
integration into a well-characterized discriminative assay for amphiphilic LPS from
the seven major serotypes of STEC is the focus of this work. This comprehensive
effort involved the purification and characterization of LPS from seven serotypes of
STEC, as they are not commercially available, and evaluation of the efficiency of
available antibodies for discriminative detection, as outlined in Chapter 3. This effort
demonstrated the poor efficacy and extensive cross-reactivity of available
antibodies, highlighting the need to generate specific antibodies, as is described in
Chapter 4.
Once the antigens were prepared, we proceeded to develop membrane
insertion assays for amphiphilic LPS, as outlined in Chapter 6. To optimize the
assay, we characterized the LPS interactions with sLBAs using fluorescence and
atomic force microscopy. These experiments revealed an effect of LPS interacting
with supported lipid bilayers – hole formation and other deformities which is detailed
in Chapter 5. These interactions with bilayers resulted in a driving question as to
whether LPS-induced hole formation occurred under the same conditions as
membrane insertion assays or even when incubated with cell membranes. To
answer the former, we developed a flow-cell mimetic system as outlined in Chapter
6, and evaluated LPS-induced hole formation under the conditions of the membrane
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insertion assays. With respect to the latter, we realized that two different factors may
contribute to, or impede, hole formation in cells. The first factor being complexity of
the membrane and the second being association of LPS with carrier molecules in
host blood. We used complex sLBAs enriched with cholesterol and sphingomyelin to
investigate the effect of membrane complexity on LPS-induced hole formation as
shown in Chapter 7. To examine the latter question, we used murine cell lines, and
explored the effect of LPS-induced cytokine induction when the antigen was
presented with serum versus buffer, as outlined in Chapter 7.
While the details of work performed in each chapter are outlined below, taken
together, the work provides a comprehensive insight into the different factors that
should be considered while working with amphiphilic biomarkers. Biochemistry is
significant, and has a purpose in biological systems. It should not be ignored in our
design and execution of laboratory studies if true corroboration with the physiological
systems is the ultimate goal. Our studies show that time, temperature, serogroup,
membrane complexity, and association with carrier molecules, all affect the
presentation and subsequent interaction of LPS with physiological systems. This
plethora of dependencies may, in fact, explain some of the glaring discrepancies in
LPS-research in the literature.
The work detailed in Chapter 3, was published as a research article in the
Journal of Microbiological Methods. As the primary author of this article, the majority
of this research was performed by me at several institutions (University of NebraskaLincoln (UNL), University of New Mexcio (UNM), and Los Alamos National
Laboratory (LANL)). Zachary Stromberg assisted with final steps in the purification of

50

LPS from bacteria, and Afsheen Banisadr assisted with protocol development for
SDS-PAGE and western blotting. Investigators on this project, Steven Graves,
Rodney Moxley, and Harshini Mukundan, provided experimental guidance and
assistance with data interpretation. In this chapter, we describe the sourcing and
characterization of LPS from various serotypes of STEC used in our research.
Developing highly sensitive and discriminatory detection assays requires the use of
equivalent grade reagents, and in many cases both the antigens and antibodies
required were not commercially available when this work began, and thus, had to be
created. Isolation of the whole LPS and its respective sub-component antigens
allowed for characterization of specificity associated with commercial antibodies.
Additionally, the antigens resulting from this work were used for development and
screening of new monoclonal antibodies with higher specificity to the O-ags of six
strains of STEC. These antigens can also be made available as a resource for other
investigators interested in these serotypes of STEC. The format of this chapter is as
appears in the original publication: abstract, introduction, materials and methods,
results and discussion, acknowledgements, and references. Supporting information
for each body of work is available in the corresponding appendix, where figure
numbers are preceded by a letter ‘A’ followed by the appendix number (e.g. Figure
A2.1 indicates Figure 1, located in Appendix 2). Subsequent chapters are formatted
in a similar manner to maintain consistency for the reader.
Chapter 4 details ongoing efforts to develop monoclonal antibodies against
O-ag of LPS from six serogroups of STEC. This research is a collaborative effort
between UNM, UNL, LANL, and The Dana Farber Cancer Institute-Monoclonal
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Antibody Core Facility (DFCI-MACF). As the primary author of this work, my role
was to design assays and perform screening of all mouse serum for antibody
reactivity to LPS antigens. This effort involved using both ELISA and immunoblotting
techniques to assess cross reactivity and response. I was also responsible for
developing assays with which to test the specificity of the resulting antibodies, which
included performing waveguide assays with the LPS antigens and their
corresponding commercial antibodies. Heather Mendez, the second author, has
recently begun assisting with these screenings and will be responsible for the
continued effort. Heather has also begun development of serum lipoprotein capture
assays, as an alternate method for screening antibody specificity. Supervision,
facilities, and experimental input for this project were provided by Steven Graves,
Rodney Moxley, and Harshini Mukundan, while mouse immunizations and antibody
production were managed by collaborators at the DFCI-MACF.
The work within this Chapter 4 pursues the development of antigen-antibody
suites of superior sensitivity and specificity for use in research and diagnostic
assays. We discuss the current techniques used for screening LPS monoclonal
antibodies in an attempt to highlight the difficulties with developing antibodies
against the sugar epitopes of amphiphilic molecules. To address these challenges,
we demonstrate alternative methods of screening that will result in antibodies with
high specificity towards the O-ag and minimal cross reactivity against the conserved
epitopes of LPS. Additionally, we show the membrane insertion-based detection of
these LPS groups using commercial antibodies to explore feasibility of the method,
and to identify areas for further development when said monoclonal antibodies
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become available. Future work will implement the established antibodies into current
detection platforms for multiple serogroups of STEC.
The work in Chapter 5, published in Biophysical Journal, details the
interactions of a model LPS subtype with supported lipid bilayers (sLBA). The
primary author is Dr. Peter Adams, who performed the majority of the experiments in
this chapter. As the second author of this article, my role was to assist in
experiments and provide suggestions for experiments as well as troubleshooting and
advice for handling LPS, while learning various techniques for future projects. This
investigation was commenced to study the interactions of LPS with supported lipid
bilayer architectures, in order to optimize and enhance the performance of
membrane insertion assays. Together, Dr. Adams and myself investigated different
substrates, cleaning methods, and handling methods of LPS. I provided several
different LPS subtypes to use as controls or for additional experiments; the
preparation of these is described in Chapter 3. I participated in every weekly meeting
to specifically discuss this paper and the data. I created the cover artwork that we
submitted alongside the paper, though it was not selected. I also provided
references for citations and proofread and revised all manuscript drafts. I worked
closely on this project with Dr. Adams for 1.5 years and the results we obtained were
fundamental in establishing the goals for my research. Additional contributions to the
work were made by Kirstie Swingle, who participated by performing replicate
experiments and data analysis. Investigators Harshini Mukundan and Gabriel
Montaño provided experimental direction, data analysis, and interpretation.
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A thorough understanding of the biophysical interactions of amphiphilic
biomarkers with membrane architectures is required for optimization of our
membrane insertion assay approach. Based on previous work by our group with the
amphiphile LAM, we hypothesized that LPS would insert into sLBA, and be
detectable by fluorescence microscopy using labeled antibodies. Instead, these
studies revealed that LPS forms holes or multi-lamellar structures upon interaction
with sLBA under specific ionic conditions. This observation allowed for more precise
control and understanding of how the molecule interacts with specific hydrophobic
interfaces. It also raised the critical question of whether LPS forms holes in lipid
bilayers inside of a flow cell, and how that affects detection using membrane
insertion. Lastly, this discovery caused us to question whether LPS-induced
deformation would extend beyond the simple sLBA architecture, into complex
bilayers and cell systems. This chapter describes the biophysics of the interaction of
LPS with simple lipid bilayers, whereas its impact on our detection assays and in
cellular systems is covered in the Chapters 6 and 7 of this dissertation.
Membrane insertion assays for detection of STEC LPS are presented in
Chapter 6, which is currently being revised for publication in PLOS One. As the
primary author of this manuscript, my role was to perform the membrane insertion
assays, and biophysical studies of LPS interactions with lipid bilayers. I also
designed and built the flow cell mimetics for imaging. Nicolas Hengartner was
responsible for statistical analysis and ensuring accuracy of reporting in the
manuscript. Kirstie Swingle performed temperature dependent studies of LPS with
lipid bilayers and assisted with atomic force microscopy, both of which were
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originally included in the manuscript, but were later cut. Kirstie was also instrumental
in document proofreading. Membrane insertion assays for amphiphile detection were
developed by Harshini Mukundan and her collaborators at LANL. Additionally,
Harshini Mukundan and Gabriel Montaño served as primary investigators by
providing experimental oversight, troubleshooting, and data analysis. Other
investigators on this project were Steven Graves and Rodney Moxley.
The purpose of this research was to develop tailored methods for the direct
detection and identification of amphiphilic LPS moieties in complex samples. Using a
waveguide biosensor platform, and membrane insertion, we demonstrated the
detection of intact LPS in ground beef lysates, which has only previously been
performed by detecting endotoxin in processed samples. Membrane insertion
exploits the natural association of amphiphilic LPS into a lipid bilayer, leaving the Oag exposed to facilitate specific detection using fluorescently labeled antibodies.
This study examines the signal response, and exhaustively looks at the physical and
statistical variability associated with detection of amphiphilic molecules in aqueous
systems on sLBA. The outcome of this study has important implications for detection
of other pathogens that display similar biochemical targets. We also investigate the
implications of LPS-induced deformities under the context of the detection assays.
To determine if hole formation occurred in the bilayers under conditions synonymous
with the established detection assays, we designed an imaging compatible flow cell
modeled after the one used in the waveguide assays. We also studied the
interactions of various LPS serogroups to determine if LPS induced hole formation
was a mechanism of virulence, and could potentially interfere with the detection
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assays. This study validated membrane insertion as a reliable method for detection
of LPS, and demonstrated broad scale applicability for membrane insertion-based
detection of amphiphiles in complex matrices. It also led to critical questions about
the virulence mechanisms of subtypes of LPS in association with membrane mimetic
architectures.
The work in Chapter 7 looks at the interactions of LPS with enriched lipid
bilayer systems to interrogate the consequence of the findings from Chapters 5 and
6 in physiologically relevant systems. While this work is still in preparation for
publication, the contributions to the work made by other individuals are indicated
here. I performed the majority of the imaging studies as well as all of the work
pertaining to the in vitro experiments. Kirstie Swingle assisted by performing
temperature dependence studies of LPS interacting with lipid bilayers. Investigators,
Harshini Mukundan, Gabriel Montaño, and Steven Graves provided project
supervision, experimental oversight, and data interpretation.
Since hole formation was noted in simple bilayer systems in the presence of
physiological buffers, we wanted to investigate the consequences of LPS-induced
hole formation in bilayer/membrane systems of increasing complexity. By increasing
the complexity of lipid bilayers with relevant components such as sphingomyelin and
cholesterol, we sought to more closely resemble cell membranes, where the
mechanism of LPS-induced hole formation should be inhibited. Investigating the LPS
interaction in this model system provides information for creating a more stable
interface for membrane insertion and detection of all amphiphiles. While complex
bilayers provide a molecular insight into such interactions, they do not represent the
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entire complexity of cell membranes. Therefore, we also studied LPS interaction with
in vitro cell lines, specifically using various methods to present LPS to cells with
different serum variants. Our hypothesis was that presentation of amphiphilic LPS
with serum binding proteins would result in a differential cytokine profile when
compared to the one generated when the antigen is presented in buffer. LPS is a
known stimulator of inflammatory cytokines, however, serum lipoproteins can play a
major role in tissue protection, although their precise functions are not completely
defined. By characterizing the effects of LPS binding in the presence and absence of
serum binding proteins, we not only seek to answer key questions about the
physiological requirements for immune studies, but also those necessary to develop
universal detection sensors. Further studies will continue to explore presentation of
LPS to complex bilayer systems, and will graduate from murine to human cell lines.
While individual chapters presented herein look at highly specific interactions
of LPS molecules in small systems, taken as a whole, this dissertation represents a
comprehensive approach to developing and optimizing detection methods for
amphiphilic pathogen biomarkers. We present a careful evaluation of antigen
sourcing, antibody testing, and assay development. This work can be readily
transitioned to other bacterial pathogens that secrete amphiphilic biomarkers, as well
as to non-infectious disease biomarkers, which have similar amphipathic structures.
Continuing research and future directions for this work are presented in Chapter 8.
The need for developing rapid, accurate, specific, and sensitive pathogen sensing
systems will continue as long as new pathogens emerge, reemerge, or continue to
develop drug resistance.
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3.1 Abstract
Certain Shiga toxin-producing Escherichia coli (STEC) are virulent human
pathogens that are most often acquired through contaminated food. The United
States Department of Agriculture, Food Safety and Inspection Service has declared
several serogroups of STEC as adulterants in non-intact raw beef products. Hence,
sensitive and specific tests for the detection of these STEC are a necessity for
implementation in food safety programs. Escherichia coli serogroups are identified
by their respective O-antigen moiety on the lipopolysaccharide (LPS)
macromolecule. We propose that the development of O-antigen-specific
immunological assays can facilitate simple and rapid discriminatory detection of
STEC in beef. However, the resources (antigens and antibodies) required for such
development are not readily available. To overcome this, we extracted and
characterized LPS and O-antigen from six STEC strains. Using hot phenol
extraction, we isolated the LPS component from each strain and purified it using a
series of steps to eliminate proteins, nucleic acids, and lipid A antigens. Antigens
and crude LPS extracts were characterized using gel electrophoresis,
immunoblotting, and modified Western blotting with commercially available
antibodies, thus assessing the serogroup specificity and sensitivity of available
ligands as well. The results indicate that, while many commercially available
antibodies bind LPS, their activities and specificities are highly variable, and often
not as specific as those required for serogroup discrimination. This variability could
be minimized by the production of antibodies specific for the O-antigen. Additionally,
the antigens generated from this study provide a source of characterized LPS and
O-antigen standards for six serogroups of STEC.

3.2 Introduction
Certain STEC are virulent human foodborne pathogens that are most often
acquired through contaminated food. These organisms are the primary cause of
hemolytic-uremic syndrome in children, and a leading cause of gastroenteritis
worldwide.1 In 2012, the United States Department of Agriculture, Food Safety and
Inspection Service began testing beef manufacturing trimmings for six serogroups of
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non-O157 STEC, in addition to STEC O157:H7. All seven serogroups have been
declared adulterants in raw, non-intact beef,2 and the six non-O157 serogroups
include O26, O45, O103, O111, O121, and O145. Additionally, the newly emergent
O104:H4 strain has raised concerns about additional STEC serogroups
contaminating food.
The emergence of STEC O157:H7 in the 1980’s led to the development of a
number of commercially available reagents and detection methods for this organism
and more recently, several have become available for non-O157 STEC as well.
These include differential agar for isolation of bacteria;3,4 latex agglutination for Oantigen (O-ag) group testing of isolates;5 immunomagnetic separation for targeted
enrichment in broth culture;6-8 enzyme-linked immunosorbent assay (ELISA) for
detection of target antigens;9-11 and polymerase chain reaction (PCR) for detection
of virulence factor genes, including targeted amplification of the O-antigen gene.8,1214

In general, the reagents and detection methods for STEC O157:H7 are relatively

sensitive and specific, but in contrast, those for non-O157 STEC are not.11,15-17
Cross-reactivity, batch-to-batch variability, excessive cost, limited shelf life, and lag
time to available results are some of the immediate issues associated with such
assays. PCR assays, while very sensitive, are laboratory intensive, may detect
residual nucleic acid contaminants, and cannot discriminate whether target genes
originated from one or more bacterial cells or types. All of the above are factors that
can potentially lead to false positive results.
Historically, identification of serotype has been an important part of the
Escherichia coli (E. coli) diagnostic repertoire, and is part of the requirement for
identification of STEC as adulterants. Serotyping is performed by identifying the
unique chemical structures of O-, capsular (K), and flagellar (H) antigens, and
combinations thereof present on the bacterial cell surface.17,18 Due to the frequent
problems associated with their identification, K-antigen testing is now only
infrequently done. Current procedures primarily focus on identification of the O- and
H- antigens or their associated genes. The detection of adulterant STEC in food
products and distinguishing them from non-pathogenic species is problematic.
Further, the number of existing O-, H-, and K- antigens is estimated to be 180, 60,
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and 80 respectively, resulting in hundreds of serotypes of E. coli,19-22 more than 200
of which are known to possess Shiga toxin.23
Lipopolysaccharide (LPS) makes up approximately 70% of the outer
membrane of Gram-negative bacteria.24-26 It is a virulence factor produced by
several bacteria including E. coli27,28 and released by the bacterial cells during an
infection. The LPS molecules of various pathogens are structurally different. The
contribution of LPS to virulence, and the differences in this biomarker between
bacterial species contributes, not only to pathogenesis, but also makes LPS an ideal
target for pathogen detection29 and serogroup identification. The biochemical
differences in LPS between different bacteria are attributable to three major
components of the LPS macromolecule.26 Specifically, the molecule contains a
highly conserved lipid A group attached to a core polysaccharide and a
hypervariable O-antigen (O-ag) polysaccharide chain.25
Since many structural elements of LPS are largely conserved between strains
of E. coli, antibodies directed against the intact macromolecule exhibit crossreactivity between different serogroups of STEC. Serogroups of LPS primarily differ
in the chemical nature of the O-ag, while the other components remain relatively
conserved.26,30 Thus, to ensure serogroup discrimination, it is important that
antibodies are targeted against the variable O-ag of LPS, and not the conserved
regions of the molecule. It naturally follows that some research groups have
developed antibodies against the specific O-ag epitopes of LPS31,32 to facilitate
serogroup-specific detection of E. coli. However, in the absence of purified and wellcharacterized STEC LPS from different serogroups, the evaluation of these
antibodies is difficult. To overcome this limitation, the objective of this work was to
isolate and purify the O-ag from strains of non-O157 STEC. These antigens can also
be used to develop targeted and specific monoclonal antibodies, and consequently
discriminatory detection assays for specific serogroups of STEC LPS. Isolation and
characterization of LPS and O-ag from non-O157 STEC, including a comprehensive
evaluation of commercially available antibodies against the same is presented
herein.
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3.3 Materials and methods
3.3.1 Materials
Unless otherwise stated, all chemicals and reagents were obtained from
Thermo Fisher Scientific Inc (Rockford, IL). STEC strains DEC10B (O26:H11),
B8227-C8 (O45:H2), MT#80 (O103:H2), 0201 9611 (O111:H11), and GS G5578620
(O145:NM) were obtained from Dr. Shannon Manning (STEC Center, Michigan
State University, Lansing, MI). Serogroup was confirmed using latex agglutination
kits (Abraxis Inc, Warminster, PA) and PCR according to Bai et al.12 TY-2482
(O104:H4) was obtained from Dr. John Luchansky (USDA, Agricultural Research
Service, Eastern Regional Research Center, Wyndmoor, PA) and serogroup was
confirmed by PCR as previously described.33 MDCH-4 (O113:H21) was obtained
from the STEC Center at Michigan State University and serogroup was confirmed by
PCR according to Bai et al.12 and subsequently retyped at the E. coli Reference
Center at Pennsylvania State University (University Park, PA).12,34 Twelve separate
antibodies were used for characterization studies, and the identifying numbers used
throughout this paper, as well as supplier information are listed in Table 3.1. LPS
O111:B4 phenol extract, cetyltrimethylammonium bromide (CTAB), phenol (purified
by re-distillation), eosin B, acetic acid, and bovine serum albumin (BSA) were from
Sigma-Aldrich (St. Louis, MO). Precision Plus Dual Xtra Protein Standards, 40%
acrylamide solution (19:1), polyvinylidene difluoride (PVDF) membrane, and
nitrocellulose 0.2 µm membrane, were from Bio-Rad® Laboratories (Hercules, CA).
Regenerated cellulose dialysis tubing (molecular weight cutoff, 12-14000) was from
VWR Scientific (Radnor, PA), LPS O157:H7 was obtained from List Biological Labs
(Campbell, CA), and sheep blood agar plates were from Remel (Lenexa, KS). Nitroblue tetrazolium/5-bromo-4-chloro-3'-indolyphosphate (NBT-BCIP) came from
Pierce Thermo Fisher Scientific (Grand Island, NY), and Tryptic soy broth (TSB),
amino methylpersulfate (APS), and tetramethylethylenediamine (TEMED) were from
Thermo Fisher Scientific Inc. (Rockford, IL). FreeZone6® Freeze Dry System and
accompanying freeze drying flasks and accessories were from LabConco® (Fort
Scott, KS). Water unless specified otherwise was 18.2 MΩ-cm, filtered through a
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0.22 μm membrane from a BarnsteadNanopure system (Thermo Fisher Scientific
Inc., Rockford, IL).
Table 3.2. Commercial Antibodies.
#a

Antibody

Animal/Description

Catalog #

Source

1

Lipid A - O157

goat polyclonal

PA1-73178

Thermo Scientific Pierce (Grand Island, NY)

2

LPS - O157

goat polyclonal

LS-C71709

LSBio (Seattle, WA)

3

E. coli 'O' & 'K'

rabbit polyclonal

NB200-579

Novus Biologicals (Littleton, CO)

4

E. coli LPS

rabbit polyclonal

BS-2351R

Bioss (Boston, MA)

5

O104

rabbit polyclonal

40120

Abraxis (Warminster, PA)

6

O26

mouse monoclonal

410000

Abraxis (Warminster, PA)

7

O45

mouse monoclonal

410010

Abraxis (Warminster, PA)

8

O103

mouse monoclonal

410020

Abraxis (Warminster, PA)

9

O111

mouse monoclonal

410030

Abraxis (Warminster, PA)

10

O145

mouse monoclonal

410050

Abraxis (Warminster, PA)

11

O157

mouse monoclonal

ab75244

AbCam (Cambridge, MA)

12

O121

mouse monoclonal

410040

Abraxis (Warminster, PA)

13

Anti-Goat AP

rabbit secondary

31300

Thermo Scientific Pierce (Grand Island, NY)

14

Anti-Rabbit AP

goat secondary

31340

Thermo Scientific Pierce (Grand Island, NY)

15

Anti-Mouse AP

goat secondary

D0486

Dako (Carpinteria, CA)

a

Numbers 1-5 indicate polyclonal antibodies and numbers 6-12 indicate monoclonal antibodies.
Numbers 13-15 are secondary antibodies labeled with alkaline phosphatase (AP).

3.3.2 Growth of STEC
Pure cultures from each STEC strain were streaked for isolation onto sheep
blood agar plates. Isolated colonies were inoculated into 20 milliliters (mL) of TSB
(125 mL flasks) and incubated on a shaking incubator at 220 revolutions per minute
(rpm), 37 degrees Celsius (°C), overnight (approximately 18 hours (h)). Broth
cultures were swabbed for confluency on 150 millimeter (mm) TSB with agar plates
using sterile cotton swabs. 32,35 Plates were allowed to dry for 3 minutes (min), then
incubated for 24 h at 37° C. Bacterial paste was harvested with a sterile cell scraper,
and suspended in water at an estimated 100% weight to volume (w/v) ratio.
Theoretical bacterial yields for 150 mm plates, based on data previously collected by
our lab,31 was used to approximate an equivalent w/v ratio of wet bacterial cultures
to water.36 Bacteria were dried under vacuum with -20° C acetone using a Büchner
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funnel apparatus.35,36 Repeat washes were applied, and the bacteria were
continually stirred and crushed using a glass rod.

3.3.3 Phenol extraction
Hot phenol-water extraction, following a modified procedure for high
molecular weight polysaccharides was performed as outlined by Jann et al.31,35,37,38
Dried bacterial cultures were suspended in 68° C water (5% w/v) with stirring for 20
min. Equal volumes of 90% hot phenol, were prepared in water, heated to 68° C,
added to the bacterial suspension, and stirred for 20 min at 68° C. The mixture was
cooled on ice to 10° C, and centrifuged at 5,100 x gravity (g), 10° C for 45 min. The
resulting upper aqueous layer was collected and set aside on ice. Remaining
organic interphase and phenol layers with bacterial pellet were rewashed with water,
using equal volume to volume (v/v) ratios. Heating, cooling and centrifugation were
repeated and the aqueous layers collected and combined. Aqueous supernatant
was dialyzed, in large volumes of water for 72 h,39 with periodic water changes to
ensure removal of low molecular weight compounds and phenol. The resulting
solution was spun at 5,100 x g for 30 min to remove insoluble material. Material was
lyophilized at -40° C and 0.133 mBar, until a dry crude extract was obtained.

3.3.4 Purification of LPS
Crude extract was dissolved in 50° C water (3% w/v) with stirring. Resulting
opalescent solution was centrifuged at 109,000 x g for 4 h at 4° C. Supernatant was
collected and lyophilized. The pellet was re-dissolved in warm water and the process
repeated two more times until the supernatant was completely clear. Resulting
purified extracts were lyophilized prior to CTAB precipitation.

3.3.5 Precipitation of nucleic acids from purified extracts
To remove nucleic acids, 4% w/v CTAB was dissolved at room temperature
(RT, 25° C) into sterile 0.25 M sodium chloride (NaCl) solution as described by Jann
et al.35 Lyophilized extracts were dissolved separately in 0.25 M NaCl with stirring,
and 25 mL CTAB/NaCl solution was added to precipitate the nucleic acid-CTAB
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salt.35 The solution was stirred for 15 min, RT, and centrifuged at 7,197 x g for 1 h,
RT, to remove the precipitated pellet. Three equal volumes of water were added to
the supernatant to form the LPS precipitate. The mixture was placed on ice for 2 h,
then centrifuged at 7,197 x g, 4° C for 1 h and supernatant was removed. The white
LPS pellet was dissolved in 5 mL of 1.0 M NaCl, and purified LPS was precipitated
using 40 mL of 100% ethanol, and repeated cooling and centrifugation. 35 The NaCl
and ethanol precipitation was repeated and the ethanol supernatant was discarded.
The final pellet was dissolved in 30 mL water and dialyzed (molecular weight cutoff
12-14000) at 4° C for 24 h in 1.0 liter of water with stirring. The resulting solution was
then freeze dried to give the final purified LPS product.

3.3.6 Hydrolysis of lipid A
Lyophilized LPS was dissolved in glass vials using 1.5% acetic acid.36,40
Solution was heated to 100˚ C using an oil bath, (to adjust for the lower boiling point
of water at altitude) for 5 h to separate core polysaccharide from lipid A. Samples
were centrifuged for 20 min, 2000 x g.36,40,41 The supernatant was collected, and
lipid A precipitate was rewashed with acetic acid and centrifuged two more times. 36
Acetic acid was removed from samples by rotary evaporation under high vacuum.
Evaporated samples were brought up in water,36,41 lyophilized on a Schlenk line and
then stored at -20˚ C until further use.
3.3.7 Sodium dodecyl sulfate – polyacrylamide gel electrophoresis
Large polyacrylamide gels (16 cm x 16 cm) were prepared using a 15%
resolving gel.32,42-46 Gel was prepared by mixing a ratio of 15:15:6:4, acrylamide, gel
buffer (3.0 M Tris, 0.3% sodium dodecylsulfate (SDS), pH 8.45), water, and glycerol,
respectively.44 Polymerization was induced by adding 100 microliters (μL) of 10%
APS, then 10 μL TEMED. Two milliliters of ethanol was added to level the air-gel
interface, and the gel allowed to cure for 2 h at RT. Ethanol was removed by wicking
and a 4% stacking gel was cast 8:1:1 (water, acrylamide, gel buffer) and allowed to
cure for 1 h 44. The apparatus was assembled and filled with anode buffer (0.2 M
Tris-hydrochloride (Tris-HCl), pH 8.9) and cathode buffer (0.1 M Tris-HCl, 0.1 M

65

tricine, 0.1% SDS, pH 8.25). LPS extracts were prepared in phosphate buffered
saline (PBS) at 5 mg/mL, then diluted to 2.5 mg/mL in Laemmli buffer 47, and heated
at 96˚ C for 5 min. Ten microliters of protein standard was loaded into several lanes
to monitor potential distortion patterns across the gel. Twenty five micrograms of
each LPS sample was loaded, and the gel was run for 1.5 h to allow samples to
enter the resolving matrix.44,48 Voltage was increased to 90 V, and optimized to a
period of 15 h, after which the gel was removed from the apparatus.

3.3.8 Inverse staining with eosin B
Gels were removed and fixed with 3 rinses of 400 mL, 50% methanol for 7
min each.49 A solution of 0.4% eosin B and 50% methanol49 was prepared by first
dissolving eosin in tap water and titrating with 1.0 M sodium hydroxide until all eosin
was in solution. Gels were stained for 40 min, RT, with shaking. Four hundred
milliliters of 5% acetic acid was used to develop the gels for 2 min. Gels were
scanned at 800 dpi using an HP Scanjet 4890, and adjusted for brightness and
contrast.49

3.3.9 Antibodies and immunoblotting
Several commercially available antibodies (Table 3.1) were tested against
LPS antigens. Antibodies were evaluated for specificity to whole LPS extracts, O-ag,
and lipid A subgroups. In each case, nitrocellulose membranes were blotted two
times with 2 μL blots of 5 mg/mL LPS (20 μg), or concentrated solutions of O-ag,
and lipid A. Standard commercial preps of LPS O111:B4 and LPS O157 were used
as comparative standards for determining activity. PBS and 5% BSA blots were
used as negative controls. Antigen and control blots were allowed to dry and the
membrane was blocked with 5% BSA for 2 h, 37˚ C in a shaking incubator.
Membranes were rinsed three times each, first with PBS/0.1% Tween 20 (PBS-T),
then with PBS, for 5 min/each, RT, and shaking. Primary antibodies (1-12) were
prepared 1:2000 in PBS and incubated with the membranes for 4 h, 37˚ C.
Membranes were rinsed again as previously described. Appropriate secondary
antibodies (13-15) were diluted 1:5000 in PBS and incubated for 1 h, RT with
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shaking, and the membrane was again rinsed as described. NBT-BCIP substrate
was added, incubated for 30 min with shaking and rinsed twice with water. Blots
were photographed with a Nikon CoolPix P50 against a dark purple background to
increase contrast in the photos.

3.3.10 Western-type blotting of lipopolysaccharides
To further characterize the LPS extracts, we used a Western-type blotting
method as an alternative to SDS-polyacrylamide gel electrophoresis (PAGE).
Alternate lanes were loaded with 25 µg of LPS, and run as described above. Gels
were removed from the electrophoresis apparatus, then equilibrated in Bjerrum
Schafer-Nielson buffer (BSN) (48 mM Tris, 39 mM Glycine, pH = 9.2),48,50 for 2 h on
an orbital shaker, RT, prior to transfer. PVDF membrane was cut to width of 1.5
lanes and strips were aligned to match up with lanes on the gel. Gels were
transferred to PVDF using a Trans-Blot® SD Semi-Dry electrophoretic transfer
device (BioRad) in BSN buffer at 24 V for 30 min. PVDF was then rinsed twice in
tris-buffered saline (TBS, pH 7.5) for 5 min each on an orbital shaker at RT.
Membranes were blocked with 5% milk/TBS for 2 h at 37 ˚C,32 then overnight at 4˚
C. Membranes were subjected to a rinse cycle of 3 times with TBS + 0.05% Tween
20 for 5 min, and then 3 times with TBS, 5 min. Each strip of PVDF was individually
blotted with the respective primary antibody, diluted 1:2000 in 1% milk/TBS,

32

and

incubated with membranes for 4 h at 37˚ C with shaking, then rinsed as described.
Secondary antibodies were prepared 1:5000 in 1% milk/TBS, and incubated 1 h, RT
with shaking. Again PVDF was rinsed 3 times each with TBS-Tween and TBS, then
developed with NBT-BCIP substrate for 30 min, RT, shaking. Membranes were then
rinsed with water two times for 5 min each and photographed.

3.3.11 Image processing
Images of Western-type blots and immunoblots were processed using Adobe
Photoshop CS5, and gels (Figure A2.1) were processed using ImageJ. All images
were converted to black and white, then brightness and contrast were optimized and
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compared to the original images. All attempts were made to conserve the integrity of
the original images.

3.4 Results and Discussion
3.4.1 Bacterial growth and purification of lipopolysaccharides
The resulting yields from harvest of bacterial strains (Table A2.1) spanned a
range of 11.1 – 53.3 grams of dried bacteria. According to previous studies, LPS
crude extract should make up 8-10% of dry bacterial weight.35,51 The crude extracts
of only two strains, DEC10B and GS G55078620, fell within the expected range, but
the products of B8227-C8 and MDCH-4 exceeded theoretical yields. Calculated
yields of extracts from ultracentrifugation were obtained by using a theoretical yield
of 200-250 mg LPS per gram of dry bacteria.35,38 However, yields of extracts isolated
were significantly lower than this predicted range, as were the yields from CTAB
precipitation.35 This was attributed to the low initial low yields from the LPS crude
extracts, and also from withholding 100 mg of LPS crude extracts for assay
development and antigen characterization. Upon hydrolysis of lipid A, the resulting
low amounts of O-ag and lipid A in each vial inhibited our ability to gravimetrically
estimate the mass of isolated O-ag and lipid A subgroups.

3.4.2 Gel electrophoresis
Gel electrophoresis was performed to characterize the relative size of isolated
antigens and test for the presence of lipid A contamination in the sample preps. In
Figure A2.2, lane 3 and 4 show the resulting ladder-like banding patterns of core
polysaccharide LPS O157, indicated by black arrows 1 and 2. 39,44,45 Concentrations
of LPS below 2.50 mg/mL were not visible in lanes 5 and 6, due to poor sensitivity of
staining methods.49 Additionally, O-ag and lipid A from LPS O157 were also not
visible in lanes 7 and 8. Good visualization of the typical O-ag banding pattern45,52 of
LPS O111:B4 were visible in lanes 9-11, and very faintly in lane 12, as indicated by
arrow 3. Also seen, were strong banding patterns in the core polysaccharide region,
indicated by arrow 4. In lanes 9 and 10, there was also a faint band, as indicated by

68

arrow 5 that we identified as lipid A, as it has the lowest molecular weight of the
subgroups, and should migrate the furthest on the gel.

3.4.3 Western-type and immunoblotting
Since we were unable to detect the presence of O-ag and lipid A in our LPS
control groups with SDS-PAGE, we began investigating the specificity of antibodies
to O-ag and whole LPS to confirm binding activity. Results of the immunoblots are
summarized in Table 3.2, and original pictures of the blots, inclusive of lipid A
antigen blots, are shown in the supporting files, Figure A2.1 and Table A2.2 of
Appendix 2. As expected, polyclonal antibodies 1-4 were the most cross-reactive
due to the presence of multiple antibody paratopes in polyclonal antibody
preparations. These antibodies seemed to have the lowest affinity for antigens from
the O104 and O145 groups. As TY-2482 O104:H4 is a newly emergent strain,53
available polyclonal antibodies against conserved epitopes of LPS would be
expected to bind lipid A, or core polysaccharide present in whole LPS O104. This
raises the question of whether the molecular structures of LPS O104 are similar to
other LPS serogroup counterparts.
The results of the monoclonal antibodies were highly varied in regards to
binding response against the antigens. We note that in all these cases, surfaces
developed and optimized for protein estimation (e.g. nitrocellulose, PVDF) are being
utilized for the detection of a lipoglycan antigen, LPS. These methods are therefore,
sub-optimal due to the lack of adsorption efficiency demonstrated with LPS. 42,54
Antibody 6 had the highest degree of non-specificity amongst all of the monoclonal
antibodies tested, as it reacted with all groups of whole LPS, many groups of O-ag,
and was faintly reactive to some groups of lipid A (Table A2.2). Of note, antibodies 8
and 10 were exclusively specific to whole LPS O103 and O145, respectively, with no
cross-reactive binding to other serogroups. However, no response signal was seen
with either O-ag or lipid A, indicating poor sensitivity at the concentration of antigens
used here, or that the epitope for this antibody is only present on whole LPS.
Additionally, reduced adsorption of the antigens to nitrocellulose as well as
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conformational presentation to the antibody may negatively affect the binding of the
antibody.42
Table 3.3. Immunoblotting antibody activity against LPS antigens
Antigen Serogroup
Antigen
LPS O-ag

Whole LPS

ID #

Antibody

1

Lipid A - O157

+

2

LPS - O157

3

O111:B4 O157

O26

O45

O103

O104

O111

O113

O145

+

+++

+

+++

+

++

++

+

++

++

+++

+

++

+

+++

+++

+

E. coli 'O' & 'K'

+

+

+++

+

++

+

++

++

+

4

E. coli LPS

+

+

+++

+

+++

+

++

++

+

5

O104

−

−

++

−

++

−

+

+

−

6

O26

+

−

+

+

+

+

+

+

+

7

O45

−

−

−

++

−

−

+

−

−

8

O103

−

−

−

−

−

−

−

−

−

9

O111

−

−

−

−

−

−

+++

−

−

10

O145

−

−

−

−

−

−

−

−

+

11

O157

−

−

−

−

−

−

−

−

−

12

O121

−

−

−

−

−

−

−

−

−

1

Lipid A - O157

+++

+++

+++

++

++

+

++

−

−

2

LPS - O157

+++

+++

+++

++

+++

++

+++

++

−

3

E. coli 'O' & 'K'

+

++

+++

++

++

+

++

+

+

4

E. coli LPS

+++

+++

+++

++

++

+

+++

+

+

5

O104

−

+

++

+

+

+++

−

−

−

6

O26

+++

+

++

+++

+

+++

+++

++

++

7

O45

++

−

+

+++

−

+

+

−

−

8

O103

−

−

−

−

+

−

−

−

−

9

O111

++

−

−

−

−

−

+++

−

−

10

O145

−

−

−

−

−

−

−

−

+++

11

O157

−

++

−

−

−

−

−

−

−

12

O121

−

−

−

−

−

−

−

−

−

+++ = intensely positive, ++ = moderately positive, + = weakly positive, − = negative result.

Antibody 9 was also highly specific to both O111 serogroups, and reactivity against
the commercial O111:B4 whole LPS as well as the extracted O111 O-ag can be
seen. Interestingly enough, this antibody did not bind the O-ag or lipid A components
of commercial LPS, but did bind these targets when tested with the extracted LPS
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O111 antigens. As shown in Table 3.2, Antibody 12 did not react with any of the
serogroups, either in the immunoblots or the Western-type blots (data not shown).
Originally, the O121:H21 strain tested negative for O121 by latex agglutination, but
had an amplicon similar to that of the O121 serogroup by PCR.12 As such, the strain
was sent to be retested by the E. coli Reference Center (Pennsylvania State
University) and subsequently identified as O113:H21; a result previously seen by
Son et al.34 Since antibody 12 was not directed against the LPS antigens tested in
this study, we have used it as a negative antibody control. Overall most antibodies
exhibited some cross-reactivity indicating the need for more specific reagents for
targeting O-ag, in addition to optimized surfaces for LPS detection. To address these
issues, our team has been working on the development of targeted assays
specifically designed for the detection of amphiphilic moieties like LPS. 55,56
Due to poor results of our control antigens obtained with eosin staining, we
decided to investigate the regions that antibodies would bind to by using a method
similar to Western blotting for proteins. Since coating the LPS molecule with SDS
does not result in the same effect of charge per mass unit of protein, it does not
migrate through the gel based exclusively on size as proteins do.42 The molecule,
however, has been characterized by many to separate into size discriminate regions
when subjected to a high percentage of acrylamide and extended run times. 32,43-46
Interestingly, in contrast to SDS-PAGE, LPS O111:B4 was not well represented on
the blot (Figure 3.1) when incubated with antibody 1 (Figure 3.1, lane B), indicating
perhaps that transfer of the O-ag region of LPS to PVDF membrane was
diminished.54 However, antibody 1 did bind the antigen in the core polysaccharide
region, suggesting that lipid A attached to core polysaccharide was most likely
present. The strongest binding responses in the Western-type blot (lane C and G)
were seen with antibodies 5 and 11. This contrasted with the immunoblots where a
very poor response was recorded with antibody 11 against LPS O-ag, but it did bind
specifically to whole LPS O157. Additionally, antibody 5 reacted with whole LPS
O104, but not against LPS O-ag O104.
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Figure 3.1. Western-type blotting of LPS purified extracts. Lane A is protein ladder to ensure
even migration through the gel. (B). LPS O111:B4/antibody # 1 (C). LPS O157/# 11 (D). LPS O26/# 6
(E). LPS O45/# 7 (F). LPS O103/# 8. (G). LPS O104/# 5 (H). LPS O111/# 9 (I). LPS O145/# 10.

This discrepancy could be due to a variety of factors, the first being the choice
of membrane (nitrocellulose in immunoblotting and PVDF in Western-type blotting)
or blocking agent employed.42 Additionally, the effect of electrophoretic charge
separation on the conformation of LPS transferred to membranes should be
considered when sensitivity of antibodies is evaluated.42,54 Indeed, antibodies are
known to exhibit differential performance in different assays (e.g.
immunohistochemistry, ELISA, Western blot and others) as often indicated on their
product information sheets. This may also explain the weak binding activity exhibited
by antibody 6, (lane D) in Western-type assays, when compared to the
indiscriminate binding seen in immunoblots.
Overall, we see that most antibodies appear to target the core polysaccharide
region as demonstrated by bands in lanes, B-E, and arguably lanes G and I. We
cannot, however, overrule the occurrence of trace O-ag in these preparations. Of all
the antibodies tested, antibodies 8-10 have the most consistent results between
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immunoblotting and Western-type blotting, with the exception that antibody 8 did not
bind O-ag in the dot blots. These studies indicate that some commercial antibodies
that are designed to be serogroup specific for different serogroups of STEC
demonstrate significant cross-reactivity as evidenced with monoclonal antibodies 6
and 7, as well as polyclonals 1, 2, and 5.

3.5 Conclusions
The overall goal of this work was to develop methods to contribute to the
rapid and discriminatory detection among non-O157 STEC and non-pathogenic E.
coli in beef products. Serotyping is often performed using antibodies that are not
only expensive, but are also poorly effective as they cross-react between multiple
serotypes of bacteria. However, this does not mean that antibody detection is a poor
method for serotyping. Antibodies with high specificity and affinity for their epitopes
can produce very rapid and discriminate results if the cognate antigens are available
for screening the antibodies. Unfortunately, in the case of several non-O157 STEC,
the O-ag for screening antibodies are not commercially available and must be
prepared by extracting and purifying them from bacteria. We have extracted and
chemically purified the LPS, lipid A, and O-ags from six non-O157 STEC strains and
characterized them against 11 commercially available antibodies for cross-reactivity
and specificity. These studies demonstrate that while some antibodies are specific
and discriminatory, many of them are not, and there is still a need for improvement
in monoclonal antibodies against STEC. As such, to our knowledge, this is the first
time that these non-O157 STEC antigens have been prepared for the purposes of
developing antibodies and detection tools against STEC. Future studies will involve
screening monoclonal antibodies against O-ags, which we intend to implement into
multiple detection schemes for more rapid and accurate serotyping of STEC.
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4.1 Abstract
Shiga toxin-producing Escherichia coli (STEC) is an important human
pathogen and foodborne contaminant. In recent years, there has been an increase
in the occurrence of some serogroups of STEC, namely O26, O45, O103, O111,
O121 and O145 in food products. Identification of the O antigens of bacterial
lipopolysaccharides (LPS) is a critical part of serotype-specific detection, and an
important element in disease control. However, many of the available antibodies for
these O antigens are cross-reactive not only with other bacterial species, but also
other serogroups. The goal of this work is to create highly specific antibodies that
target STEC O-ag thereby allowing for discriminatory detection of serotypes. Using
specific LPS extracts, O antigens and lipid A components, we have developed and
characterized monoclonal antibodies. Immunized mice were used for pre-selection,
followed by subsequent selection of hydridoma cell lines. We also present a new
ELISA method for specifically screening LPS O antigens, and demonstrate
serogroup specific detection of LPS using membrane insertion assays. The
generation of a pool of highly specific antibodies against the O serogroups of nonO157 STEC is an important tool for developing detection assays for monitoring the
health of the food chain. Herein we present the outcome of these screenings and
assays for specific antibodies selected for STEC serogroups.
4.2 Introduction
Shiga toxin-producing Escherichia coli (STEC) are virulent strains of
enterohemorrhagic E. coli. STEC are a major health concern, as they are foodborne
pathogens, which upon infection can result in severe symptoms, such as diarrhea,
hemorrhagic colitis, and hemolytic uremic syndrome.1 One of the most frequent
strains of STEC that causes disease from the serogroup O157.2 However, in recent
years the increasing emergence of several other pathogenic serotypes of STEC has
been recognized as a threat to the food supply and human health.3,4 As a result, the
United States Department of Agriculture’s Food Safety and Inspection Service
(USDA-FSIS) declared mandatory screening for serogroups O26, O45, O103, O111,
O121, and O145.5
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Bacterial serotypes are determined by the chemical identity of the surface
antigens, O polysaccharide (O-ag), capsular polysaccharide, and flagella.6,7
Lipopolysaccharide (LPS) is the primary component of the outer leaflet on the outer
membrane of Gram-negative pathogens.8-10 The molecule itself is amphipathic in
nature and consists of a hydrophobic lipid A group, a core polysaccharide, and the
O-ag. The O-ag is considered hypervariable in nature, and is the component of LPS
that is used to determine the serogroup of E. coli isolates.11,12 Structurally, the O-ag
is made up of subunit repeats of glycosyl residues, which are typically 1-7
oligosaccharide units in length. The variability of the O-ag stems from both the
composition of the oligosaccharide subunits, and the degree of branching within the
polysaccharide chain. Identity of the O-ag is important, as serogroup is a key
indicator of virulence,13 and STEC have a wide range of pathogenicity and virulence.
To date, 187 unique O-ag have been identified for E. coli,14 many of which have
pathogenic phenotypes. The lipid A component of LPS is highly conserved within a
species of bacteria8 and several polyclonal antibodies have high affinity for the
epitopes on lipid A, which results in many of the cross-reactivity issues seen in
serotyping assays.15,16 The core polysaccharide is also conserved in nature, but
subject to variability due to substitutions of sugar groups and the possibility for
chemical functionalization of those moieties.17,18
The development of antibodies against LPS, and its specific epitopes has
proven a useful tool for investigating LPS structures, bacterial virulence, and in the
development of detection assays.16 Monoclonal antibodies in general have also
been shown to be highly effective tools for disease treatment and detection, 19 but
developing specific antibodies to the sugar epitopes of O-ag has unique
challenges.16 Antibodies for LPS are typically raised and screened against the whole
antigen, resulting in a variety of clones. Another problems is the assays with which
we screen resulting antibodies. Screening is performed using ELISAs, which
historically have suffered from poor and inconsistent binding of the lipoglycan
antigens to microtitre plates,20-24 because the polystyrene is not optimized for the
binding of amphiphiles and micelles. In fact, many researchers use the same
methods for LPS as those used for proteins, which disregards the amphipathic
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chemistry of LPS. For example, immunoblotting combined with sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis, is used to determine the
antigencity of antibody clones.25 While it assumed that binding of the antibodies to
the ladder pattern of the blots is indicative of specificity for the O-ag, LPS antigens
are highly stable, and large intact antigens will remain higher in the gel in the O-ag
region, which results in antibodies binding to that area. These issues can be
circumvented by using functionalized ELISAs to facilitate physiological binding of
LPS. Additionally, by implementing methods such as immunoblotting against all
parts of LPS (whole antigen, O-ag, and lipid A), the resulting antibodies will have
higher specificity towards the target antigen.
We have used a long-term immunization protocol with mice and whole heatkilled bacterial cells to develop O-ag specific monoclonal antibodies against six nonO157 STEC strains. To screen these antibodies, we have used standard sandwich
ELISAs and immunoblotting against whole LPS, O-ag, and lipid A. Resulting clones
with be tested in complex matrices to ensure assay performance. For additional
screening and implementation into detection assays, we have tested multiple LPS
antigens with membrane insertion assays and commercial antibodies. Lastly, we
have developed protocols for functionalization of ELISA plates with serum proteins
to facilitate physiological presentation of O-ag epitopes to antibodies. The
development of these highly specific antibodies is a critical tool to facilitate detection
and discrimination of non-O157 STEC pathogens in current detection platforms.
4.3 Materials and Methods
4.3.1 Bacterial strains and serum screening
Strains for antibody production, DEC10B [O26:H11], B8227-C8 [O45:H2],
MT#80 [O103:H2], TY-2482 [O104:H4], 0201 9611 [O111:H11], MDCH-4
[O113:H21], DA-37 [O121:H21], and GS G5578620 [O145:NM] were grown in
lysogeny broth (LB) for 24 h, then harvested and suspended in saline at a
concentration of 106 CFU/mL. Cultures were heat inactivated for 2 hours at 100 ˚C
on a heat block. Aliquots were centrifuged and the majority of the supernatant
removed, then stored at -80 ˚C. To ensure inactivation of the dead cells, an aliquot
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of the cells were inoculated into LB broth and fluid thiglycollate media and incubated
at 37 ˚C, cultures were checked for any growth at 24 h and 48 h. LPS O157:H7 (List
Biological Labs), and LPS O111:B4 (Sigma Aldrich) were purchased as control
groups. LPS from the same strains of bacteria were prepared by hot phenol
extraction, separated into their O-ag and lipid A portions, then tested for antigen
activity as we have previously described.15 Remaining strains not used for antibody
development were used for assessing cross-reactivity of resulting antibodies.
Mice from strains BALB/c, Swiss Webster, and C57BL/6 were housed and
inoculated at the Dana Farber Cancer Institute-Monoclonal Antibody Core Facility
(DFCI-MACF) in accordance with the Institutional Animal Care and Use
Committee guidelines. A mouse from each strain was bled prior to inoculation with
heat-killed bacterial cells26,27 and then bled again 35 days post-inoculum. Pre- and
post-inoculated serum were shipped to The University of New Mexcio, and screened
using an indirect sandwich ELISA in which polyclonal anti-E. coli O157 antibody
(pAb O157, LifeSpan Biosciences) was used as the capture antibody and goat antimouse horseradish peroxidase (HRP) labeled antibody (Pierce) was used as the
reporter. Capture antibody was diluted 1:2000 in phosphate buffered saline (PBS,
Sigma Aldrich) and incubated overnight, at 4 ˚C, in Nunc™ MaxiSorp™ 96-well
plates. Wells were subsequently blocked for 1 h at room temperature (R/T) using 1x
Tris-buffered saline (TBS, BioRad) + 0.05%Tween-20 (Sigma) + 0.5% bovine serum
albumin (BSA, Sigma). LPS was prepared first by sonicating stock solutions (5
mg/mL in PBS) for 15 min in a water bath, then diluting to 50 µg/mL in blocking
buffer, and sonicating an additional 15 min. LPS (whole antigen) solution was added
to the microwells, covered, and incubated for 2 h at R/T. Wells were washed 3 times
with 1x TBS/0.5% Tween-20. Pre- and post-inoculum mouse serum was diluted from
1:500 down to 1:64000 in blocking buffer, and then applied to the respective wells in
triplicate, covered and incubated at R/T for 1.5 h. Wells were washed 3 times and
then a 1:4000 solution of goat anti-mouse HRP diluted in 1x PBS, was applied to the
wells and incubated for 1 h at R/T. Wells were washed 4 times, and 100 µL of 1Step™ Ultra TMB-ELISA substrate (Pierce) was added to each well and incubated
for 40 min at 37 ˚C to aid in color development. Development was stopped by adding

83

100 µL of 2.0 M H2SO4, and the absorbance was measured at 450 nm on a
SpectraMax M5 microplate reader (Molecular Devices). Data were averaged and
plotted as absorbance for each value of serum dilution. The axes of the graphs are
displayed on the same scale to facilitate the visual evaluation of response over time.
In addition to the evaluation discussed above, pre- and post-inoculated
mouse serums were also screened using immunoblots to determine cross reactivity
between O-ag and lipid A groups. Whole LPS, O-ag, and lipid A from control LPS
groups O111:B4 and O157:H7 were blotted onto nitrocellulose (0.45 µm, BioRad), 1
µL at a time, allowed to dry, and an additional 1 µL was reapplied to the same area.
The target antigen for each LPS subtype was also blotted. Additional controls were
5% BSA, and 1x PBS. Membranes were blocked for 1 h at R/T using 2% BSA and
then rinsed 3 times first with 0.1% Tween-20/PBS and then another 3 times with 1x
PBS. Each rinse lasted for 5 min on an orbital shaker. Serum was diluted 1:500 in
ELISA blocking buffer, and incubated with membranes for 4 h at R/T on an orbital
shaker. Blots were rinsed again (3 times each with both buffers) and a 1:4000
dilution of goat-anti mouse alkaline phosphatase (AP, Pierce) in 1x PBS was applied
and incubated for 1 h, R/T, on an orbital shaker. Nitrocellulose was again rinsed and
1-Step™ NBT-BCIP (Pierce) was applied to develop the blots. After development,
blots were rinsed 2 times each with distilled water then laid on a paper towel and
allowed to dry. Images, for the most part, were acquired using an HP Envy 100
scanner, and brightness and contrast were optimized. Immunoblot results were
compared to ELISA results to determine if mice should be re-immunized or used to
make hybridomas. In general, mice required 2-3 rounds of immunization before
developing a strong response.

4.3.2 Hybridoma production and screening
Mice that developed a strong immune response to the LPS antigens were
selected for hybridoma development. All hybridomas were developed and cultured at
the DFCI-MACF using their previously established proprietary methods. Resulting
clone supernatants were sent to us for screening. In general, culture supernatants
were screened using the indirect ELISA method described in Section 4.5.1, with the
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exception that undiluted culture supernatants were used in the place of mouse
serum, and we also ran an additional background control of 1 mg/mL beef lysate
(prepared as previously described28,29) to assess any cross reactivity that the
resultant antibodies may have with the LPS subtypes present in beef lysates.
Hybridomas were sub-cloned until a satisfactory activity response was obtained.
4.3.3 Developing assays to test antibody specificity
To develop ELISAs capable of improved O-ag specific detection, we adapted
protocols from Heumann et al.26 and Vreugdenhil et al.30 to complex LPS with serum
lipoproteins to facilitate presentation of physiologically relevant LPS O-ag to
antibodies. The surface of microtitre plates was functionalized with 50% mouse
serum (Sigma Aldrich), in order to capture LPS with the serum lipoproteins. Mouse
serum was diluted 1:2 with PBS, and incubated overnight (4 ˚C) in Nunc™
MaxiSorp™ 96-well plates. Wells were blocked for 1 hr, R/T, using 1x TBS/0.05%
Tween/0.5% BSA. LPS O104, O26, and O45 (50 µg/mL) were prepared in blocking
buffer as described in Section 4.3.1, and added to the microwells (R/T for 2 hr).
Plates were washed (3 x) and then incubated with their respective pAb O104, mAb
O26, or mAb O45 (Abraxis, 1:2000 in 1x PBS, R/T, 1.5 hrs). The assays were then
carried out as described in Section 4.3.1. To further evaluate functionalization with
serum proteins, and facilitate the use of anti-mouse reporter antibodies, we also
repeated the experiment using donkey serum as the capture surface and goat antimouse HRP as the secondary antibody.
LPS membrane insertion assays were carried out as previously described, 29
to assess the performance of subtypes of LPS (O26, O45, O103, O111, O145) with
pAb O157 and LPS O26 with its respective mAb O26 (Abraxis). Antibodies were
labeled with Alexa Fluor® 647 labeling kits (af647, Molecular Probes) per
manufacturer’s instructions, and pre- and post-labeled antibodies were
immunoblotted to ensure reactivity to the antigens. Waveguides were cleaned and
bilayers prepared as previously described28,31-33 using 1,2-Dioleoyl-sn-glycero-3phosphocholine (DOPC, Avanti Polar Lipids) and 1,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-(cap biotinyl) (sodium salt) (cap-biotin, Avanti Polar Lipids).
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Flow cells were blocked for 1 hr with 2% (w/v) BSA, then rinsed with 0.5% BSA/PBS
prior to running an assay.
Incident light (635 nm) was coupled into the waveguide using a diffraction
grating, and the response signal was adjusted for power and peak intensity using a
spectrometer (USB2000, Ocean Optics) interfaced with the instrument and an
optical power meter (Thor Labs).28,29,32,33 The background signal of the lipid bilayer
and BSA block was recorded after which the flow cell was incubated (90 min) with
25 nM of reporter antibody (either pAb O157-af647 or mAb O26-af647) to determine
the amount of non-specific binding (NSB) between the antibody and the lipid bilayer.
The flow cell was rinsed with wash buffer (0.5% BSA/PBS) after all incubations. After
the NSB measurement, the flow cell was photobleached to the background signal
level by opening the shutter.29 This facilitates accurate measurement of the specific
binding of the antibody to LPS. 25 µg/mL of LPS was incubated for 2 hr, and the
signal recorded. Subsequently, reporter antibody was incubated for 90 min and
rinsed, and the specific binding signal of the antibody was recorded. The average of
the background spectra was subtracted from both the NSB and specific binding
signals. Data was plotted as an average of the three replicates.
4.4 Results and discussion
4.4.1 Serum screening and immunoblotting
STEC O45. Three mice, one from each strain were immunized with dead
bacterial cells. Serum was screened after each period of immunization to assess
antibody response. In general ELISA responses were often poor, with high standard
deviations, likely because of the configuration of antigen epitopes. The highest
response for the O45 serogroup mice was recorded in the C57BL/6 mouse after two
inoculations (Figure 4.1). This suggested that this mouse had developed better
immunity over time. However, a comparison of the ELISA vs. immunoblot results
between the two serum screens, (Table 4.1) showed significant discrepancy.
Initially, the immunoblots showed an antibody response to at least one of the
antigens from each of the serogroups in both the pre- and post-inoculated serum.
However, this response diminished in the immunoblots by the next serum screen,
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which was in sharp contrast to the ELISA. This is one of the main challenges in
developing antibodies to sugar epitopes. The relative binding affinity of the antigens
(whole LPS, O-ag, and lipid A) to nitrocellulose vs. polystyrene (ELISA plate) is
unclear, and can affect the outcome of the assay. Further, antibodies were
developed in an animal, wherein the presentation of LPS is in a distinctively different
conformation, further affects the results of the assay. More importantly, this casts a
question on the nature of the assay that should be used for antibody selection for
amphiphilic antigens.
Initially we used an immunoblotting protocol, which required 4 h of incubation
with the mouse serum at an elevated temperature (37 ˚C). After a few iterations of
immunoblots, we discovered that the proteins in the mouse serum were
competitively displacing the BSA block on the membranes, which resulted in high
background staining of the membrane (Figure A3.4), making the blots difficult to
interpret. To address this, the protocol was altered in two ways, first by performing
the incubation at room temperature, and also by diluting the serum in the same
blocking buffer used in the ELISA assays. The results of this modification are most
evident when comparing the immunoblots in the O26 serogroups, which can be seen
in the supplementary Figure A3.8.

Figure 4.1. ELISA results from a C57BL/6 mouse immunized with O45 bacterial antigens.
Due to the post immune response this mouse was selected for hybridoma development.
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Table 4.1. Immunoblot summary analysis of C57BL/6 mouse inoculated with O45 bacterial
antigens.
C57BL/6 mouse
Pre-Inoculated

July 16, 2014

O111:B4
O157
O45
1x PBS/5% BSA

Whole
LPS
+
+
-

September 04, 2014

O111:B4
O157
O45
1x PBS/5% BSA

+
-

LPS subtype

Post-Inoculated

O-ag

Lipid A

+
+
+
-

-

-

-

Whole
LPS
+
+
++
-

O-ag

Lipid A

+
+
+
-

+
+
-

++
-

++
-

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’,
blue highlighted regions indicate the target serogroup.

The C57BL/6 mouse was selected for hybridoma development. The initial cell
fusion resulted in 25 clones that were screened for activity. The signal to noise ratio
for these clones is plotted in Figure 4.2A, where the signal is the activity of the
antibody as a measure of absorbance in the ELISA assay, and the noise is the nonspecific activity of the supernatant measured against a ground beef tissue lysate.
Three clones (1C7, 2B2, and 1D5) were selected for subcloning from the first round
of screening. After two procedures, (activity was monitored in between) we obtained
a subclone (2BB.E10.D3) with higher activity than the others (Figure 4.2B).

Figure 4.2. Signal to noise ratios of O45 hybridomas. A. First round of clone screening
produced 25 clones. B. Activity of subclones produced from original O45 hybridomas.
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Clone 2B2.E10.D3 was selected for antibody production, the line expanded,
then frozen down in aliquots. 1.0 L of culture supernatant was purified with protein A
purification techniques. However, when the purification resulted in less than 1.0 mg
of antibody, the resulting product was tested and discovered to be an
immunoglobulin M (IgM) instead of an immunoglobulin G (IgG). Clones that produce
anti-LPS IgM’s in response to a long term immunization protocol have been
previously documented.34 However, IgM’s are difficult to purify due to their pH
sensitivity, larger molecular weight (IgG ~ 150 kDa vs. pentameric IgM ~ 960 kDa),
and tendency to denature during purification.35 Another frozen stock of cells was
expanded, and adapted to be grown in serum free media to facilitate size exclusion
purification, without having to additionally purify the large proteins found in serumsupplemented media. Resulting antibodies will be tested for cross-reactivity using
ELISAs and multiple strains of bacterial cells.
STEC O26, O103, O111, O121 and O145. For serogroups O26, O103, and
O111, the mice were on the same immunization schedule. The BALB/c mice
consistently exhibited the best immune response as compared to C57BL/6 and
Swiss Webster mice in these serogroups (Figure A3.9, A3.11, A3.15, A3.17, A3.21,
and A3.23). The results for the ELISA serum screens using the BALB/c mice in both
the O26 and O111 serogroups is seen in Figure 4.3. After the second round of
inoculation, these mice were sacrificed for hbridoma development. The BALB/c
mouse in the O103 serogroup (Figure 4.3B) was immunized four times prior to
being used for making antibodies. The immunoblots for these mice (Table 4.2)
showed good correspondence with the ELISAs as all of the post-inoculated serums
demonstrated moderate to intense response as compared to the pre-inoculated
serums. We relied heavily on the immunoblot response for the both the O103 and
O111 serogroups as the O-ag promptly developed within 1 minute of adding
substrate, despite lower responses in the ELISAs. Although some of the mice
showed good response to the antigens, no viable clones were produced from any of
the mice. C57BL/6 and Swiss Webster mice are continuing the long term
immunization protocol, and serum will be screened when available. Additionally, we
have begun immunization of rats for each bacterial serogroup as the immune
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response can be different between animals. For serogroups O121 and O145, all
three mice have each been inoculated twice and screened. Mice in these groups
have exhibited a low antibody response even after the second round, and were
subjected to a third immunization. All ELISAs and immunoblot results to date for this
ongoing effort are reported in Appendix 3, Figures A3.25-A3.35.
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BALB/c – O26 Serogroup

A
BALB/c – O103 Serogroup

B
BALB/c – O111 Serogroup

C
Figure 4.3. ELISA results for serum screens from BALB/c mice. A-C. Screens for O26, O103,
and O111 serogroups, respectively.
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Table 4.2. Immunoblot summary analysis of BALB/c mice inoculated with O26, O103, and
O111 bacterial antigens.
BALB/c mouse
Pre-Inoculated

Post-Inoculated

LPS subtype
O111:B4
O157
O26
1x PBS/5% BSA

Whole
LPS
-

O-ag
+
+
-

Lipid A
NA
+

Sept. 02, 2015

O111:B4
O157
O103
1x PBS/5% BSA

-

+
-

Sept. 02, 2015

O111:B4
O157
O111
1x PBS/5% BSA

-

+
-

Sept. 02, 2015

Whole
LPS
+
++
-

O-ag
+
+++
-

Lipid A
+
NA
++

NA
NA
-

+
++
++
-

+
+++
-

NA
NA
+

NA
+

+
+
+
-

++
++
-

NA
NA
+++

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’,
NA = control antigens were not available for testing. Blue highlighted regions indicate the target
serogroup.

4.4.2 Assays for testing antibody specificity
We examined methods to improve upon the physiological presentation of LPS
O-ag to detection antibodies in the ELISA format. By coating the surfaces of ELISA
plates with serum lipoproteins, we were able to eliminate the need for costly capture
antibodies. The lipid A group of LPS associates with serum lipoproteins 30,36,37 and
therefore by using serum to coat ELISA plates we take advantage of better coating
of the polystyrene surfaces with the serum proteins,26 and the sequestering of the
lipid A group into the hydrophobic pockets of serum proteins. In the serum screening
assays we used a cross-reactive polyclonal antibody as a capture molecule. Using
serum lipoproteins offers multiple advantages as compared to capture antibodies
because serum is more cost effective, provides an additional blocking effect against
nonspecific binding of reporter antibodies, and binds the lipid A molecule of LPS to
present LPS O-ag in a conformationally relevant manner. By complexing LPS with
lipoproteins, it also results in stability of LPS conformation by preventing disparate
micelle formations in aqueous matrices. We saw excellent signal to noise ratios in
the assays we tested with mouse serum and LPS O104 (Figure 3.36 A), but also
saw decreased standard deviations when we used donkey serum instead of mouse
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serum (Figure 3.36 B). Using donkey serum as compared to mouse serum provides
a better detection platform for testing of murine monoclonal antibodies as the antimouse reporter antibody does not cross-react with the proteins in donkey serum.
Additionally, serum serves a secondary role by providing an effective blocking step
to the plate surface which minimizes background noise from the nonspecific binding
of the secondary antibody.
Membrane insertion assays for LPS O157 have previously been developed
and tested in beef lysates using a waveguide-based optical biosensor.29 Membrane
insertion uses a waveguide functionalized with lipid bilayers to facilitate the
partitioning of the hydrophobic lipid A into the lipid bilayer, which leaves the O-ag
exposed in the aqueous matrix. This method is advantageous as it facilitates
detection of the O-ag while minimizing the availability of the lipid A epitopes. We
tested multiple serogroups of LPS using membrane insertion and the same pAb
O157 used in the ELISA capture assays. The average of the assay replicates for all
serogroups, except LPS O111:B4, demonstrated signal to noise ratios from 2-10
(Figure 4.4). Despite these promising results, the signal responses for many of the
LPS subtypes are quite close, therefore highlighting the need for more specific
antibodies. Previously we have shown that implementing a specific polyclonal
antibody in these assays can increase the signal by more than a factor of two, 29 and
so we wanted to test a highly cross-reactive monoclonal antibody to see if we could
increase the signal. Monoclonal anti-LPS O26 has been demonstrated to exhibit
broad cross-reactivity to many of the LPS subtypes,15 so we selected this as a test
antigen. However, when we compared the signal of LPS O26 with the pAb O157
versus the mAb O26, (Figure 4.5) we saw absolutely no difference in signal
between the nonspecific binding of the mAb O26 and the specific binding. This is a
good indication that mAb O26 binds an epitope, such as lipid A, that does not
present in membrane insertion. To confirm this result, we tested LPS O26 with the
mAb O26 in the lipoprotein capture ELISA assays, and determined that the specific
binding could not be discriminated from that of the no antigen control (Figure
A3.37). This serves as further evidence that antibodies specific to the O-ag epitope
are required to facilitate discriminatory detection of STEC antigens.

93

Figure 4.4. Serogroup specific LPS membrane insertion assays. A. Membrane insertion assays
of multiple serogroups of LPS detected with the cross reactive pAb O157-af647. Serogroups are
indicated by colored lines, and NSB (black line) is the nonspecific binding of the pAb O157-af647.

Figure 4.5. Performance of mAb O26 for O-ag targeted detection. Detection of LPS O26 with both
pAb O157-af647 is also seen in (4.4), but here we demonstrate the lack of response using the
‘specific’ mAb O26-af647. Orange and black lines are the specific and NSB of the pAb O157-af647,
while blue and purple represent the signals of the mAb O26-af647.

94

4.5 Conclusion
The importance of detecting and typing STEC pathogens in the food supply
cannot be overstated. Currently, the primary method for serogroup identification
relies on commercial antibodies. Many of the available antibodies for non-O157
STEC are highly cross-reactive and expensive. We have worked to develop
monoclonal antibodies against the O-ag of six serogroups of STEC using ELISAs
and immunoblotting to screen the clones. We have tested the detection of LPS
serogroups using membrane insertion and commercial antibodies to demonstrate
both assay feasibility and areas of improvement for existing monoclonal antibodies.

4.6 Future directions
Due to the lack of immune response to some of the antigens in mice, we have
opted to begin immunization of a rat for each of the remaining antigens (O25, O103,
O111, O121, and O145). This process is already underway. The inoculation and
boosting of mice will continue, until a satisfactory antibody with desired specificity
results for each LPS serogroup. The methods for implementation of this are already
in place. Once antibodies have been purified, they will need to be tested for
specificity in assay platforms using the established methods described in Sections
4.3.3. and 4.2.2 Testing for cross reactivity also needs to be performed, both in
complex matrices like beef lysate, and against multiple bacterial species and
antigens. This will provide more information about antibody specificity, and validate
performance in applicable assay platforms. An ideal application of these antibodies
would be to affix them to latex beads to facilitate rapid identification of serogroup
with latex agglutination tests. To address the cost associated problems with using
antibodies, these antibodies should be made available to other STEC collaborators
by depositing them in a repository, such as BEI Resources.
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5.1 Abstract
Lipopolysaccharide (LPS) is a unique lipoglycan, with two major physiological
roles: (i) as a major structural component of the outer membrane of Gram-negative
bacteria and (ii) as a highly potent mammalian toxin when released from cells into
solution (“endotoxin”). LPS is an amphiphile that spontaneously inserts into the outer
leaflet of lipid bilayers to bury its hydrophobic lipidic domain, leaving the hydrophilic
polysaccharide chain exposed to the exterior polar solvent. Divalent cations have
long been known to neutralize and stabilize LPS in the outer membrane, whereas
LPS in the presence of monovalent cations forms highly mobile negatively-charged
aggregates. Yet, much of our understanding of LPS and its interactions with the cell
membrane does not take into account its amphiphilic biochemistry and charge
polarization. Herein, we report fluorescence microscopy and atomic force
microscopy analysis of the interaction between LPS and fluid-phase supported lipid
bilayer assemblies (sLBAs), as model membranes. Depending on cation availability,
LPS induces three remarkably different effects on simple sLBAs. Net negative LPSNa+ leads to the formation of 100 µm-long flexible lipid tubules from surface
associated lipid vesicles and the destabilization of the sLBA resulting in micron-size
hole formation. Neutral LPS-Ca2+ gives rise to 100 µm-wide single- or multi-lamellar
planar sheets of lipid and LPS formed from surface associated lipid vesicles. Our
findings have important implications about the physical interactions between LPS
and lipids and demonstrate that sLBAs can be useful platforms to study the
interactions of amphiphilic virulence factors with cell membranes. Additionally, our
study supports the general phenomenon that lipids with highly charged or bulky
headgroups can promote highly curved membrane architectures due to electrostatic
and/or steric repulsions.

5.2 Introduction
Lipopolysaccharide (LPS) is of major medical importance, firstly, because it
forms the outer surface of many pathogenic bacteria and, secondly, because LPS is
a highly potent toxin when released from cells. The outer membrane of Gramnegative bacteria is a highly asymmetrical complex lipid bilayer, comprised of an
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inner leaflet of various common phospholipids and the outer leaflet of the unique
glycolipid, LPS.1-3 An Escherichia coli (E. coli) cell contains several million LPS
molecules, covering 75% of the outer membrane surface, with the remaining area
being occupied by proteins.1 LPS has several important functions for the bacteria
including acting as a permeability barrier between the cell and the exterior, for
structural stability of the membrane and for protecting against foreign particles (antimicrobial peptides, drugs, toxic heavy metals, salts and enzymes).4,5 LPS is critical
to many pathogens’ ability to cause disease and is released from the outer
membrane of the bacterium during infection. LPS, historically known as ‘endotoxin’,
can cause over-activation of the immune system in toxic shock syndrome at µg/ kg
LPS/ body mass ratios.6,7 Thus, LPS is an excellent target for diagnostics, vaccines
and treatment strategies against these pathogens.3,7
The structure of LPS has been studied for many years.8 LPS is an amphiphilic
molecule comprised of a hydrophobic domain named ‘lipid A’, covalently linked to a
hydrophilic polysaccharide chain that extends away from the cell. The lipid A
component contains six saturated fatty acid chains linked to a phosphate-substituted
disaccharide.2,9 This is linked to the relatively conserved ‘core-oligosaccharide’ and
the variable ‘O-polysaccharide’ of 0-50 oligosaccharide repeat units, dependent on
the particular bacterial species and strain. LPS preparations are heterogeneous, and
a mixture of LPS structures are found in each preparation with partial modifications
depending on growth conditions.3 Each LPS molecule has multiple negatively
charged groups from phosphate and acid groups in the lipid A and corepolysaccharide. In the current study, we use LPS from E. coli serotype O111:B4,
structure shown in Figure 5.1, details in refs.3,10-12 There are at least 6 negatively
charged groups per LPS and a range of 1–18 O-polysaccharide repeat units. In the
bacterial outer membrane, divalent cations such as Mg2+ and Ca2+ are essential to
neutralize this negative charge, allowing cross-linking between LPS molecules,
which maintains an effective barrier to drugs and other damaging molecules. 2,13-16
Chelation of divalent cations leads to increased permeability to drugs, LPS release
and rapid disintegration of the outer membrane.14,17 In comparison to the common
phospholipid 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), LPS contains a
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much larger hydrophobic domain containing saturated fatty acids. In addition, LPS
has a large hydrophilic, negatively-charged head-group, whereas DOPC has a small
zwitterionic head-group (Figure 5.1).

Figure 5.1. Comparison of the chemical structure of lipopolysaccharide from E. coli serotype
O111 and the phospholipid 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). Partial covalent
modifications, which may result in additional phosphate groups are shown with dotted lines
(dependent on growth conditions and other factors). Number of repeat units in the O-chain, n, ranges
from 1-18. COL, colitose (3,6-dideoxy-L-xylo-hexose); GAL, galactopyranose; GLC, glucopyranose;
GLCN, 2-amino-2-deoxyglucopyranose; HEP, L-glycero-D-manno-heptopyranose; KDO, 3-deoxy-Dmanno-oct-2-ulopyranosonic acid; P, phosphate.

LPS has previously been shown to form very different structures depending
on its local ionic environment, observed in cell-free LPS extracts and reconstituted
LPS-lipid membranes. LPS aggregates exposed to Na+ are not fully neutralized and
have a net negative charge,16 resulting in formation of long tubular structures which
were converted into bilayers by exposure to Ca2+ ions.18 Multiple studies have
shown that divalent cations reduced the mobility of LPS aggregates and increased
the rigidity of LPS bilayers, decreasing their permeability.18-24 Additionally, divalent
cations have led to formation of highly ordered, stacked multilamellar LPS
structures.20,21 The physiological activity of LPS also depends on its ion associations
and LPS isolates rich in Na+ and K+ cations are significantly more active as an
endotoxin than those with Mg2+ or Ca2+ ions.25 The more rigid, multilamellar LPS
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formations induced by divalent cations were determined to be inactive as opposed to
more freely mobile aggregates in monovalent cation rich environments. 26 These
studies together indicate that the effect of cations on LPS structure and aggregate
formation is an important factor that should be considered when studying the
manifestation of endotoxic shock.
In studies where hybrid membranes were prepared by combining LPS with
different lipids, LPS distribution and incorporation27 and the membrane fluidity28 was
found to depend on lipid composition. The structure of LPS from different strains or
species can be dramatically different. Studies have observed that LPS structural
changes, self-association, toxicity all depend on LPS subtype.8,22,29,30 In the human
body, LPS interacts with intermediary factors of the human immune system including
LPS Binding Protein, which has been shown to affect LPS interaction with
membranes.31-33 Our current study focuses on the direct interaction of E. coli O111
LPS aggregates with fluid phase DOPC membranes as a model for LPS-membrane
interactions.
While many studies have investigated the structures resulting from
reconstitution of LPS-lipid membranes, the dynamic interaction of LPS with
membrane architectures remains poorly characterized. In giant unilamellar vesicles
(GUVs) formed from LPS and lipids, LPS was found to segregate into gel-like
domains, showing that LPS lateral rearrangement and self-association of LPS
molecules can occur within the lipid bilayer.29 Soluble LPS has been shown to insert
into preformed lipid GUVs and cause shape changes and vesicle fission. 34
Supported lipid bilayer assemblies (sLBAs) have been used for many years as
models for biological phospholipid bilayers, as planar membrane systems with lateral
lipid mobility.35-37 To our knowledge, there has not been direct visualization of the
dynamic effects of ‘free’ LPS aggregates on a sLBA, as a simple platform for
evaluation of the interaction of amphiphilic toxins with membrane architectures.
Herein, we evaluate the direct interaction of LPS with sLBAs using a combination of
fluorescence microscopy and atomic force microscopy (AFM), powerful tools for
investigating membrane organization.38-41 Our experiments were performed with
concentrations of LPS ranging from 5 to 500 µg/mL, highly comparable to the lethal
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doses for various species ranging from 1 to 200 mg/ kg body weight. 6 Our findings
could have significant ramifications on our understanding of the action of the
important toxin LPS, and have general implications that should be considered for all
amphiphilic pathogenic molecules.
5.3 Materials and Methods
5.3.1 Materials
All materials were used as received without further purification. Organic
solvents were HPLC grade (Fisher Scientific, Waltham, MA). Phosphate buffered
saline (PBS), HEPES, EDTA, NaCl and CaCl2 were purchased from Fisher
Scientific. All aqueous buffers were prepared using 18 MΩ•cm H2O (Barnstead
Nanopure filter) and then passed through 0.22 µm filter membranes (Millipore,
Billerica, MA). All lipids and fluorescence dyes were purchased in dry powdered
form. 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) was purchased from Avanti
Polar Lipids (Alabaster, AL). Lipid-based dyes used for doping the lipid membranes
were as follows: 2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine (C5-BODIPY FL HPC) or
Texas Red 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine,
triethylammonium salt (Texas Red DHPE) (Molecular Probes, Eugene, OR). The
standard LPS used in this study unless otherwise mentioned was from E. coli
serotype O111:B4 (phenol extract); a FITC-conjugate of LPS from E. coli serotype
O111:B4 was used for direct tracking (Sigma-Aldrich, St. Louis, MO).
5.3.2 Liposome and Supported Lipid Bilayer Formation
The standard DOPC liposome preparation contained 99.5% (mol/mol) DOPC
and 0.5% C5-BODIPY-HPC or 0.5% Texas Red DHPE. Lipids and lipid dyes in
chloroform were mixed in the desired molar ratios, dried overnight under vacuum
and rehydrated in buffer solution. The lipid suspension was subjected to three
freeze-thaw cycles followed by probe sonication for 10 min in an ice bath to form
small liposomes.41 Hydrophilic glass coverslips were used as substrates (cleaned
with ‘piranha’ solution of 3:1 H2SO4/30% H2O2). Hydrophobic ultrathin adhesive
‘imaging spacers’ (0.12 mm depth, 9 mm diameter) were attached to substrates to
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create small wells to confine a droplet of buffer (Electron Microscopy Sciences,
Hatfield, PA), for an ‘open’ sample set-up to allow multiple buffer exchanges and
top-down access for atomic force microscopy. sLBAs were formed by deposition of
liposomes onto the substrate. After 20 min incubation at room temperature, the
sLBA was washed by exchanging the buffer solution ten times to remove excess
liposomes, although significant numbers of associated lipid vesicles evidently
remain.
5.3.3 Treatment of surfaces with LPS
LPS was handled as per manufacturer’s guidelines, dissolved into buffer at 5
mg/ mL, stored in silanized glass vials at 4 °C and, before each usage, stocks were
vortexed and bath sonicated (15 min) at room temperature to homogenize
immediately prior to sLBA treatment. sLBAs of DOPC were prepared and washed
with buffer. The DOPC sLBA was then treated with LPS and analyzed with
microscopy as described in the Results section. For experiments testing LPS in the
presence of monovalent cations, the buffer used was PBS (137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 10 mM KH2PO4, pH 7.4), whereas for testing LPS in the
presence of divalent cations “Ca2+ buffer” was used (150 mM CaCl2 and 20 mM
HEPES, pH 7.5). For experiments testing the effects of cation concentration, buffers
containing 20 mM TRIS-HCl (pH 7.5) and 10–900 mM NaCl or 10–900 mM CaCl2
were used. Control experiments confirmed that buffering with phosphates, HEPES
and TRIS were equivalent for our studies (data not shown). Control experiments
found that common small molecule contaminants had no observable effect on our
sLBAs (RNA from baker’s yeast, bovine serum albumin, fetal bovine serum) (data
not shown), compared to the effects of LPS under the same conditions.
5.3.4 Microscopy of LPS-treated sLBAs
Lipid bilayers were imaged with laser scanning confocal fluorescence
microscopy (LSCM), epifluorescence microscopy, total internal reflection
fluorescence microscopy (TIRFM) and AFM. Samples were kept hydrated and never
allowed to dry either during preparation or analysis.
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LSCM used an FV-1000 inverted optical microscope (Olympus, Tokyo,
Japan) equipped with multi-channel photomultiplier detectors, operated in ‘photoncounting mode’ (very low background noise, 0-2 counts), acquiring 512 x 512 pixel
images unless otherwise stated. A 40 x air objective (NA = 0.95) was used for the
majority of experiments and a 60 x water-immersion objective (NA = 1.20) was used
for higher resolution confirmation. Excitation was provided by a multi line Ar laser
(488 nm, for BODIPY), a HeNe laser (543 nm, for Texas Red), or a diode laser (635
nm, for AlexaFluor 647). Appropriate high performance band-pass emission filters
were used (505-525 nm for BODIPY and FITC; 655-755 nm for Texas Red and
AlexaFluor 647). Fluorescence recovery after photobleaching (FRAP) was
performed using manufacturer’s provided software.
Epifluorescence was performed using an IX-81 inverted optical microscope
with a Hamamatsu model C11440-22C CCD camera. A 100 x oil-immersion
objective (NA = 1.40) was used. Excitation was provided by a 200W metal-halide
lamp and a FITC filter set and appropriate ND filters were used. Images and movies
were acquired at 1024 x 1024 pixels using the software.
TIRFM was performed using an Olympus IX-71 inverted optical microscope
equipped with a Hamamatsu model C7780-20C CCD camera (1344 X 1032 pixels).
A 100 x oil-immersion TIRFM objective (NA = 1.45) was used. Excitation was
provided by a 488 nm Ar ion laser and a green filter set and appropriate ND filters
were used.
AFM was performed using an MFP-3D-SA system, equipped with a closed
loop XY scanner and all-digital ARC2 Controller (Asylum Research, Santa Barbara,
CA). All imaging was performed under fluid using Bruker SNL probes, sharpened Si
tip on a triangular SiN cantilever (k ~ 0.12 N/m). High quality topographs were
generally acquired at 512 x 512 pixels and 1 Hz scan speed. Images were
processed using the manufacturer’s provided Igor Pro-based software.
5.4 Results
sLBAs were formed on glass substrates by deposition of small unilamellar
vesicles comprised of 99.5% DOPC and 0.5% C5-BODIPY FL HPC.41 AFM
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confirmed that the bilayers are continuous and defect free over many microns with a
few small protrusions (Figure 5.2 A). LSCM showed a relatively homogenous
fluorescence with small numbers of higher intensity dots (Figure 5.2 B before LPS).
The fluidity of DOPC sLBAs at room temperature was confirmed by fluorescence
recovery after photobleaching (FRAP) (data not shown). The higher intensity
fluorescence dots and protrusions in AFM data represent lipid vesicles that remain
loosely associated with the surface even after rinsing with buffers. Lipid vesicles
have an average size of ~50 nm in solution (Figure A4.1); the largest may be
resolved as surface-associated vesicles in LSCM. Sequential images show that
surface-associated vesicles are highly mobile and independent of the underlying
sLBA (Movie A4.1).

5.4.1 Lipid tubule formation is induced by LPS in PBS
In order to test the effect of soluble LPS on our model lipid bilayer system,
experiments were first performed in PBS, containing monovalent cations (Na +).
LSCM fluorescence images (time lapse series) obtained after addition of 100 µg/ mL
LPS in PBS to sLBA are shown in Figure 5.2 B and Movie A4.2. The surfaceassociated vesicles that originally exist were observed to split into multiple vesicles,
leading to an increase in mobility and the formation of fluorescent strand-like
structures. Initially disordered webs of strands stretch out over a few minutes into
elongated strands that we term ‘lipid tubules’, analogous to the tubules characterized
by other studies of membrane-perturbing molecules.42,43 The lipid tubules retain a
point of association to the membrane surface and often extend up to 100 µm in
length and span many microns above the surface, as shown by epifluorescence
microscopy (Figure 5.2 C). Movies of sequential epifluorescence images confirmed
the high degree of mobility of lipid tubules (Movie A4.3). The lipid tubules stretch
away from the boundary of the substrate, to orient in a radial organization during the
course of the experiment, suggesting that fluid flow plays a role in tubule extension
(Figure A4.2).
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Figure 5.2. Lipid tubule formation induced by LPS in PBS. (A) AFM topographs showing a
DOPC supported lipid bilayer assembly in PBS buffer at low and high magnification. A height profile
across the lower image (dashed white line) shows a relatively flat surface. (B) LSCM of the DOPC
sLBA (doped with 0.5% green fluorescent lipids) in PBS before and after addition of 100 μg/ mL
LPS. Sequential images are shown at selected time periods after addition of the LPS. (C)
Representative epifluorescence microscopy image of lipid tubules. (D) Representative TIRFM image
showing long tubules. The background of green fluorescence suggested a homogenous lipid bilayer
(note, 45° periodic noise is an optical artifact that should be ignored).

AFM imaging of LPS-treated sLBAs revealed a flat surface (data not shown)
and no lipid tubules were observed, as may be expected because of the relatively
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poor stability and high mobility of these formations. Membrane-inserted LPS was not
detected by AFM, which could be due to the instability of the protruding
polysaccharide chain that can be ‘pushed aside’ by the AFM probe44 or due to the
transient nature of LPS insertion into lipid bilayers, previously observed in GUVs 34
TIRFM, which has higher signal/ noise and restricted penetration depth of excitation,
was used in an attempt to observe any subtle height variations in the sLBA, such as
bubbles, ripples or other perturbations that may not have been observed with other
optical techniques. TIRFM images (Figure 5.2 D) did not show any evidence of
disruptions to the underlying lipid bilayer, but both lipid tubules and surfaceassociated vesicles were prominent. The lack of any observable changes to the
underlying lipid bilayer by both AFM and TIRFM indicate that it is either intact, or that
any perturbations cannot be observed by these strategies.
5.4.2 Hole formation in the sLBA after LPS treatment in PBS and washing
After treatment of the sLBA with LPS in PBS, the DOPC bilayer was washed
to remove any residual unassociated LPS. This resulted in the unexpected formation
of voids lacking fluorescence of approximately 1-5 µm in width (Figure 5.3 A).
Intensity profiles from single photon counting (SPC) LSCM data shows that there is
essentially zero fluorescence at the centre of these voids (Figure 5.3 B). The
fluorescence intensity of membrane areas other than voids was roughly similar
before and after LPS treatment, suggesting a continuous membrane interface. It
should be noted that these voids were stable, with no detectable change in shape or
size over the course of 80 min at the ~250 nm resolution of our microscope (Figure
A4.3). In order to test whether the voids of fluorescence were actually physical holes
in the lipid bilayer, AFM was performed on an LPS-treated sample in PBS. The
DOPC bilayer appeared as a relatively smooth film with many holes of ~5 nm depth
via AFM, consistent with expected height of a sLBA (Figure 5.3 E). The lateral size
of holes varied from less than 1 µm up to 5 µm in width. High resolution topographs
(Figure 5.3 F) demonstrated that holes are essentially empty with only small
amounts of debris visible, which correlated with the SPC fluorescence data. TIRFM
(Figure 5.3 C) images were likewise consistent with LSCM and AFM. FRAP showed
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that lipids had lateral mobility within the remaining membrane, with holes
unperturbed (Figure 5.3 D). These observations support the notion of static holes
within an otherwise continuous fluid lipid bilayer.

Figure 5.3. Holes in sLBAs after LPS treatment and washing. (A) LSCM fluorescence images
showing DOPC sLBAs after treatment with 100 μg/ mL LPS in PBS followed by washing the surface
(PBS, ten changes). (B) Higher magnification LSCM image. A profile of the fluorescence intensity
(below) shows the SPC counts along a line drawn across the image (white dashed line). (C) A
representative TIRFM image of a similar sample. (D) FRAP experiment from the sample in (A). A
circular region was photobleached and then sequential images acquired to show the lateral diffusion
of fluorescent lipids. (E) AFM topograph showing accurate width and depth of holes induced by LPS,
similar sample to (A). Height profiles (below, red lines) show the height data across white dashed
lines in the image, chosen to show the depth of holes in the lipid bilayer. (F) Higher magnification
topograph from the field of holes in (E).

Hole formation was found to depend on both LPS concentration and
incubation time. To test concentration effects, sLBAs were treated with different
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concentrations of LPS for a standard 20 min and then rinsed. Above 20 µg/ mL,
which is higher than the critical micelle concentration (CMC) of LPS (10-14 µg/
mL),45,46 hole formation increased with LPS concentration (Figure 5.4 A-C). Holes
were not initially detected using LPS at concentrations ≤ 20 µg/ mL. To test
incubation time effects, sLBAs were treated with a standard LPS concentration and
then rinsed with buffer after different time periods (Figure 5.4 D-F). At sub-CMC
concentration, (5 µg/ mL), the number and size of holes increased with LPS
incubation time from 20 to 180 min as the numbers of surface-associated vesicles
decreased (related to their increased conversion to tubules and removal after
rinsing). Thus, hole formation can occur above or below the CMC of LPS, however
more time is necessary for hole formation at sub-CMC concentrations.

Figure 5.4. LPS concentration and time dependence on hole formation. LSCM fluorescence
images of a DOPC sLBA treated for 20 min with LPS at varying concentrations of LPS in PBS, (A)
500 μg/ mL, (B) 100 μg/ mL or (C) 20 μg/ mL, and then washed with PBS, showing decreasing
numbers of holes with LPS concentration. Parallel samples were treated with 5 μg/ mL LPS in PBS
for (D) 20 min, (E) 60 min or (F) 180 min, and then washed and imaged immediately. More holes are
observed with increased incubation time. These images were acquired at higher pixel density (4096 x
4096) in order to resolve small holes. Inset (D-F), digitally magnified areas of these images showing
small holes more clearly.

Although AFM showed that holes in the DOPC bilayer were mostly empty, we
could not rule out whether small amounts of LPS were present but undetected by
AFM. To directly detect the presence of LPS, a FITC-labeled LPS was used with a
DOPC sLBA doped with Texas Red DHPE lipid dye (Figure A4.4). A fluid lipid
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bilayer was observed with low background in the FITC channel. Addition of FITCLPS (100 to 500 µg/ mL) resulted in a significant FITC signal increase.
Unfortunately, we were unable to discriminate FITC-LPS in solution (or in lipid
tubules) from that interacting with the surface, due to the overwhelming signal. After
surface rinsing holes were observed, with no enhanced FITC fluorescence in holes
relative to background counts. This suggests that little or no LPS remained
associated with the lipid bilayer or in solution after rinsing.

5.4.3 LPS in Ca2+ buffer induces lamellar sheet formation instead of lipid tubules
The action of LPS on lipid membranes under different cation conditions was
tested using LPS in “Ca2+ buffer” (divalent cations, see section 5.4). Time-lapse
LSCM fluorescence images were acquired during treatment of DOPC sLBAs with
100 µg/ mL LPS in Ca2+ buffer (Figure 5.5 A, Movie A4.4). Within seconds, small
patches of fluorescence were observed that slowly grew in size over the course of
minutes. SPC fluorescence intensity profiles from LSCM data show that these LPSinduced membranes had fluorescence intensity of roughly double that of the normal
lipid bilayers (Figure 5.5 B), suggesting a second lipid-containing bilayer stacked on
top of the original sLBA. Overlapping sheets with fluorescence intensity at multiples
of the original lipid bilayer were observed (Figure 5.5 C), indicating that LPS can
induce formation of multiple lipid-LPS membranes stacked on top of each other, in
the presence of Ca2+. FRAP experiments revealed slightly reduced lateral lipid
mobility in the newly-formed lamellar sheets and underlying sLBA compared to a
DOPC sLBA before LPS-Ca2+ treatment (Figure A4.5 A-C). Recovery of
fluorescence indicative of multi-layers after almost complete photobleaching of
stacked membranes suggests that lipids can exchange from the underlying sLBA
into the lipid-LPS stacks (Figure A4.5 D-E). Multilamellar membranes were not
observed by AFM, instead a smooth surface expected to represent the original lipid
bilayer was found (data not shown), implying that these membranes were too
unstable for AFM imaging. LSCM fluorescence images after washing the surface
with fresh Ca2+ buffer showed the apparent removal of LPS-induced lamellar
membranes (Figure 5.5 D), confirming their lack of stability.
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Figure 5.5. LPS in Ca2+ buffer causes formation and growth of multilamellar stacks. (A) LSCM
of the DOPC sLBA in Ca2+ buffer before and after addition of 100 μg/ mL LPS in Ca2+ buffer.
Sequential images are shown from selected time points after addition of the LPS. Fluorescent
patches are observed in images immediately after LPS addition (10 s) and continue to grow in size
over the following minutes (1 min – 23 min). (B) Image at high magnification showing a patch of
contiguous fluorescence of approximately double the intensity of the DOPC bilayer. (C) Image at a
high magnification showing a fluorescent patch with multiple distinct step-changes in the intensity.
Numbers (2), (4) and (6) indicate expected stacked bilayers with multiples of intensity of a single
bilayer (1). (D) Fluorescence image after washing the LPS-Ca2+-treated surface with ten changes of
Ca2+ buffer. Note, images (C) acquired with lower exposure settings than (B) and (D), hence, lower
fluorescence intensity.

114

Formation of lipid-LPS-Ca2+ membranes was dependent on the concentration
of LPS. Patches formed using 5 µg/ mL LPS in Ca2+ buffer were smaller, fewer in
number and less stable, appearing to disintegrate over time (Figure A4.6), relative
to the larger, more stable patches formed at higher concentrations. This LPS
concentration dependence confirms the direct relationship between LPS (Ca 2+) and
sheet formation.

Figure 5.6. Schematic of the mechanism of LPS-induced lipid bilayer deformation. See text for
description. LPS is represented by a simplified molecular structure showing the hydrophobic domain
with six fatty acid tails linked to ‘core’ sugar units and the extended ‘O’ chain. Sugar units are
represented by their cyclic rings. Note that for clarity side groups are not displayed and the
polysaccharide chain is greatly shortened, represented by (…). ‘Normal’ phospholipids are
represented by their two fatty acid tails linked to a head-group (green boxes represent BODIPY dye).
Negatively charged groups of LPS are represented by blue (-) charge symbols. Cations that associate
with LPS are represented by their elemental symbol and single or double charge, (+) or (+)(+)
symbols in red. The cyan lines represent electrostatic repulsion.
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Concentration of cations also modified the effect of LPS, as observed when
sLBAs were treated with 100 µg/ mL LPS in buffers at a range of NaCl or CaCl2
concentrations (Figure A4.7). Concentrations from 10 to 300 mM NaCl all produced
lipid tubules, whereas at and above 450 mM NaCl both lipid tubules and potential
lamellar sheets were observed (Figure A4.7 A). Holes were always observed with
NaCl buffers after rinsing the surface. In contrast, all concentrations of CaCl2 from 10
to 900 mM produced lipid sheets, which were removed without hole formation by
rinsing the surface (Figure A4.7 B). Lipid sheet size increased with CaCl2
concentration, and the largest sheets were over 100 µm in width (Figure A4.7 C).
5.5 Discussion
5.5.1 Considerations of the model membrane system
sLBAs are model membranes that are relatively stable, robust and relevant to
biological systems. Previous studies have demonstrated the ability of a single
component sLBA to form highly curved structures, including curved lipid caps and
vesicle budding.41 In the current study, we report that LPS, a biological toxin of
significant concern, can cause three remarkably different deformations by insertion
into the controlled environment of a model lipid membrane. LPS insertion into
membranes, as observed in previous studies,34 may be driven by LPS in aggregates
in a polar solvent transferring into a more thermodynamically favorable environment
as the large hydrophobic lipid A tail of LPS becomes buried in the hydrophobic core
of lipid bilayer. LPS insertion occurs into both surface-associated vesicles and the
solid-supported LBA. Once inserted, the effect of LPS varies due to differences in
membrane curvature, interactions with the support and the local ionic environment.
The first two effects (lipid tubules and holes in the sLBA) were generated by
exposure of DOPC sLBAs to LPS in the presence of (<450 mM) monovalent cations
(LPS-Na+). The third effect (lamellar membranes) was observed by exposing the
same DOPC system to LPS in the presence of divalent cations (LPS-Ca2+) or very
high (≥450 mM) monovalent cation concentration. It is clear that ionic strength and
valency influence both the structure of LPS, and its interaction with lipidic
architectures. Hundreds of publications have investigated the nature of different
membrane deformations induced by biological or synthetic nanoparticles, including
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theoretical simulations.47,48 We focus on how LPS could induce such changes,
discussing examples of similar membrane rearrangements.
5.5.2 Membrane effects induced by LPS-Na+
Treatment of sLBAs with Na+-LPS induced the formation of highly mobile,
fluorescent lipid-based tubules (Figure 5.2; Movie A4.2 and A4.3). Tubules are
known to form when there is a high degree of local membrane curvature and an
abundant supply of lipids.42,43 sLBAs can have multiple ‘surface-associated
liposomes’, observed as brighter spots in fluorescence images and protrusions in
AFM topography, even after washing the surface. We established the presence of
surface-associated lipid vesicles on our sLBAs in Figure 5.2 A, A4.1, and Movie
A4.1. We conclude that the surface-associated lipid vesicles and any remaining
solution-based vesicles are the source of lipids in formation of tubules, along with
LPS, based on the following evidence. Firstly, in some images we can observe
apparent tubule nucleation from surface-associated liposomes (Figure 5.2 B; Movie
A4.2). Secondly, if multiple cycles of LPS treatment are performed, fewer tubules
are formed each time as surface-associated vesicles are ‘used up’ (Figure A4.8 A).
We can estimate the amount of lipids required for an average tubule by calculating
the outer surface area of a tubule (modeling as a cylinder) and equating this to the
surface area of multiple liposomes (modeling as a sphere). A tubule of 10 microns in
length and 25 nm in diameter (as previously reported for LPS tubes18) would require
~100 vesicles of 50 nm diameter. This could represent, for example, 50 DOPC lipid
vesicles and 50 LPS aggregates, a reasonable quantity considering that LSCM may
resolve only the larger surface-associated vesicles. LPS appears to promote fusion
of multiple lipid-LPS vesicles leading to the observed growth of tubular structures.
We postulate that the destabilizing inserting/ excising effect of LPS34 and its natural
propensity to form tubules on its own,18 could cause nanoscale membrane defects
which increase the exposure of lipids to the external environment, promoting further
lipid-lipid associations and vesicle fusion, however, further studies are needed to
confirm this. Fluid flow due to convection currents within an open droplet, as
described by studies of the “coffee-ring effect”,49-51 may then direct the stretching out
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of these tubules observed in LSCM (Figure A4.2). In contrast, tubules observed by
TIRFM, where a closed-box sample enclosure was employed, appeared to rest onto
the sLBA surface (Figure 5.2 D), possibly due to a reduction in fluid flow.
Upon rinsing the surface of LPS-Na+-treated sLBA with fresh buffer, holes
devoid of lipids were observed in a concentration and time dependent manner
(Figure 5.3-5.4). In addition to the removal of lipid tubules, these observations
indicate that LPS accumulates in the sLBA over time. Apart from holes, the
remaining lipid appeared to be in the form of a normal sLBA with high lateral mobility
of lipids and flat, continuous membrane. This evidence, along with the fact that LPS
is not found to be associated with the sLBA after hole formation (Figure A4.4),
suggests that LPS clusters into large domains that are then dislodged from the
surface during the rinsing process. If LPS induces membrane curvature in surfaceassociated liposomes resulting in tubules it is logical that LPS could insert and
disrupt the sLBA, although the LPS-treated sLBA appears ‘flat’ by microscopy. The
likely explanation is that LPS causes minor curvature in sLBAs below the detection
limit of our instruments, and that we only observe the result of this destabilization
when holes are formed after rinsing the surface. Subtle, LPS-induced membrane
curvature could lead to separation of the lipid bilayer and the solid support by only a
few nanometers, which would not be resolved by optical measurements. LPS
insertion into lipid bilayers may be highly transient, as previously reported,34,44 which
would hinder detection of membrane deformations by AFM. The interaction of the
sLBA and the solid support could also limit curvature and cause a strained system
as compared to the relatively unrestricted surface-associated liposomes. Based on
these arguments, we conclude that LPS induces subtle membrane curvature in
sLBAs which leads to localized delamination sufficient to form holes upon washing
the surface.
We expect that tubules and holes are different manifestations of similar
effects of LPS-Na+ acting on different starting material, either surface-associated
liposomes or a sLBA. Both require: (i) LPS insertion into the outer leaflet of lipid
membranes, (ii) LPS self-association or clustering and (iii) LPS induction of
membrane curvature. We will briefly describe other studies in which one or more of
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these effects are observed, supporting our conclusions. Spontaneous insertion of
LPS from solution into the lipid membranes has been previously observed in GUVs
whereupon it appeared to induce subtle, localized curvature resulting in shape
changes from spherical to pear-shaped or pearls-on-a-string vesicles.34 Other
studies have shown that short-length LPS can self-associate to form gel-like
domains.29 While we are using full-length LPS, for which these authors did not
observe phase segregation, self-association of LPS in our sLBA system may be
transient or on smaller scales. LPS has been observed to form highly curved
structures depending on its ionic environment. Exposure of native LPS to Na+
resulted in formation of long tubular LPS-based structures of 9-18 nm diameter, as
observed by electron microscopy.18 These could be related to the membrane
curvature and lipid tubules formed in our experiments with LPS in the Na+-containing
buffer PBS. Each LPS molecule contains at least six negatively-charged groups,
phosphate and carboxylate12 (Figure 5.1), which typically cannot be fully neutralized
by monovalent cations due to electrostatic repulsion of individual ions, resulting in
LPS with a net negative charge.16 The authors concluded that incomplete charge
neutralization leads to electrostatic repulsion between LPS chains, causing a high
degree of curvature and formation of LPS tubes. We extend these previous findings
to show that not only does LPS-Na+ form tubules in isolation but can also induce
curvature in preformed sLBAs. In our sLBA system, attractive hydrophobic selfassociations of saturated fatty acids in the lipid A domains of LPS in contrast to
unsaturated DOPC lipids and size/shape mismatch may drive phase segregation of
LPS away from DOPC lipids, outweighing the electrostatic repulsion that would
otherwise drive negatively-charged LPS apart into a maximally separated
configuration. Then, the negative charge-charge repulsion of the membrane extrinsic
hydrophilic domains of nearby LPS would induce membrane curvature.
We may compare our findings of membrane curvature induced by proteins in
both natural and artificial systems. In nature, lipid tubules and vesicle budding is
found in multiple specific situations, e.g. endocytosis, exocytosis, phagocytosis,
endoplasmic reticulum- and cytoskeleton- associated protein trafficking.52-54 In each
case, specific proteins are targeted to a local area of the membrane leading to either
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the budding off of vesicles or the protrusion of long tubules from the membrane.
Common mechanisms involve insertion of amphiphilic protein helices and wedge
shaped proteins into the cellular lipid membranes,55-59 which could be related to LPS
insertion. Lipid tubules have been induced in vitro from lipid GUVs by promoting
protein crowding at a localized point on the vesicle surface; tubule growth was
observed to occur in real time from the point of protein binding.42,43 Relevant to our
study is the finding that any generic protein was sufficient to induce tubule formation
so long as it leads to the build-up of a sufficient high density of protein packing. This
lead to the conclusion that steric repulsion between any bulky particles packed at the
surface has the potential to cause severe membrane bending. Crowding of LPS
could have an analogous effect due to the bulky polysaccharide chain, however it
seems that electrostatic rather than steric repulsive effects dominate in the case of
LPS.
Perforation of lipid membranes by LPS was suggested by previous indirect
evidence of electrical resistance of lipid membranes stretched across an aperture
where treatment with LPS (110 to 720 µg/ mL) led to a decreased resistance and
eventual collapse.60 Holes and other lesions can be formed in lipid bilayers by
various small molecules, including pore-forming protein toxins (61), highly charged
synthetic nanoparticles62-66 and polycationic polymers.67-71 Hole formation in each
case is dependent on the specific interactions between the membrane and the
disruptive molecule of interest. It appears that LPS belongs to this list of membranedisruptive molecules.
5.5.3 Membrane effects induced by LPS-Ca2+
LPS is known to change its structure, aggregation state and mobility
depending on the availability and concentration of monovalent and divalent
cations.18-24 In our experiments, we conclude that LPS-Ca2+ inserts into surface
adsorbed liposomes and causes these LPS-lipid assemblies to fuse, resulting in very
different structures in comparison to LPS-Na+ of similar concentrations. Whereas
LPS-Na+ induces membrane curvature, LPS-Ca2+ induces planar membrane
formation (Figure 5.5). We find that surface-associated and solution-based vesicles
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are the source of lipids along with LPS for planar sheet formation, analogous to lipid
tubule formation, with evidence provided by multiple cycles of LPS (Ca 2+) treatment
(Figure A4.8 B). Furthermore, increasing Ca2+ concentration (10–900 mM) results in
increasing the extent of multilamellar formation (Figure A4.7 B). In contrast,
concentrations of ≥450 mM Na+ are required for LPS to induce even small lamellar
sheets, which occur in addition to tubules and holes (Figure A4.7 A), suggesting
that LPS induces planar membranes only at very high Na+ and even then not as
extensive as those observed with Ca2+. Although we were unable to verify the
topography of these structures by AFM, due to their seemingly unstable nature, we
are able to infer their multilamellar membrane-like nature from fluorescence data.
The slight decreased lateral lipid mobility in planar lamellar membranes compared to
a normal DOPC sLBA (Figure A4.5) suggests that LPS-Ca2+ within the lipid bilayers
impedes lipid diffusion or increases the rigidity of the membrane. While the precise
structure of stacked membranes is uncertain, we found that they associated closely
enough to the underlying sLBA for lipid exchange to occur. Previous spectroscopy
and electron microscopy studies found that divalent cations reduce the molecular
mobility of LPS within aggregates and cause LPS to reorganize into stacked multibilayers.18,20,21 Our findings are congruent with these studies and suggest that not
only does LPS change its own organization due to Ca2+ but induces lipids to
rearrange with it.
It is instructive to look at the natural environment of LPS in the outer
membrane of bacteria. LPS is found in the outer leaflet of a lipid bilayer forming a
selectively permeable barrier between the cell and the exterior.4,5 The outer
membrane is relatively flat, when compared with small lipid vesicles, with a gentle
curvature over many hundreds of nanometers to micrometers. Studies have shown
that the outer membrane is enriched in divalent cations relative to the cytoplasmic
membrane16,18 and that divalent cations are essential for outer membrane
stability.2,17 The prevailing view from these studies is that Mg2+ or Ca2+ neutralize the
negative charge of LPS where Na+ cannot at physiological concentrations. This
allows the self-association of LPS where otherwise it would be electrostatically
unfavorable, and LPS-LPS bridging and linkages to transmembrane proteins
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stabilize the membrane.72 Our current findings agree with this consensus and further
demonstrate that LPS can spontaneously insert into lipid membranes and induce
self-assembly into an outer-membrane-like structure in the presence of Ca2+ at low
concentration (10 mM), whereas much higher Na+ (450 mM) is required for similar
effects. Divalent ions are known to be significantly more effective at screening
electrostatic interactions at lower concentrations when compared to similar solutions
of simple monovalent ions73 and our results confirm that this applies to the
neutralization of LPS, visualizing the biological importance of divalent cations.

5.5.4 Understanding LPS-sLBA interaction
We have demonstrated three very different rearrangements of a simple,
single component lipid system, all caused by one membrane-inserting amphiphile in
different local environments. A schematic of LPS-induced rearrangements of lipid
membranes dependent on monovalent or divalent cations is shown in Figure 5.6.
The thermodynamically favorable insertion of LPS into the lipid membranes and
clustering leads to a high density of LPS, at which point the net charge of the
extrinsic polysaccharide portion of LPS appears to determine whether this causes
curved or planar structures. The net-negative LPS-Na+ leads to electrostatic charge
repulsion between adjacent LPS and induces membrane curvature (Figure 5.6 A).
Surface-associated lipid vesicles merge and the high membrane curvature drives
formation and elongation of lipid tubules (Figure 5.6, (1)). In supported lipid bilayers,
LPS-induced curvature disrupts the lipid bilayer’s interaction with the surface support
causing unstable delaminated regions which can be excised from the remainder of
the lipid bilayer by washing the surface, leading to hole formation (Figure 5.6, (2)).
In contrast, even low concentrations of Ca2+ promote planar self-associations of LPS
(Figure 5.6 B). Fusion of surface-associated lipid vesicles in this case leads to
growth of planar lamellar sheets of lipid and LPS on top of the sLBA surface (Figure
5.6, (3)). In order to form multi-layers, we postulate that mobile lipid-LPS particles
deposit on top of the first lipid-LPS planar sheet, leading to growth of a second layer
and potentially further layers, held together by inter-layer interactions between LPS.
The ability of LPS to switch from curvature-inducing to planar-sheet formation simply
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by changing its net charge by adjusting the buffering cations indicates that LPSinduced membrane curvature is due to electrostatic repulsion rather than steric
repulsive effects.42,43
Previous studies with another amphiphilic pathogenic molecule,
lipoarabinomannan, detected insertion into lipid membranes without any disruption. 74
Lipoarabinomannan and LPS are both amphiphilic virulence factors that each
interact with similar factors when they infect a mammalian host (TLR2, TLR4, HDL). 3
Structurally, they share similarities, both with hydrophobic fatty acid tails and a
membrane extrinsic domain, but they evidently interact very differently with sLBAs.
Whereas lipoarabinomannan inserts passively without destabilizing the membrane, 74
LPS causes major disruptions, as shown by our current study. Thus, each
membrane-inserting amphiphile may cause very different effects depending on their
unique physical properties.
Finally, we consider three examples of other complex lipids that have been
reported to induce membrane curvature. Firstly, studies on poly(ethylene glycol)derivatized-lipids (PEG-lipids) at low concentration within fluid lipid bilayers in
hydrogels75,76 are informative because of similarities between LPS and PEG-lipids
(negatively-charged headgroup, bulky hydrophilic domain). PEG-lipids were found to
phase segregate into domains that stabilize regions of high curvature based on
steric and electrostatic repulsions.76 Secondly, gangliosides, lipids with a single
negative charge and a bulky aromatic headgroup, have also been reported to induce
formation of tubules and pearls in DOPC GUVs.77 Thirdly, multivalent cationic lipids
(MVLs) have been shown to cause formation of narrow tubules and ‘pearling
instabilities’ in DOPC lipid vesicles.78-80 In these studies, the authors hypothesized
that increased membrane tension due to electrostatic repulsion between the highlypositively charged lipid headgroups leads to phase segregation whereby curved
regions become enriched in and stabilized by MVLs. In common with our findings on
LPS, screening of MVL charges by increased salt concentrations lead to a transition
from tubular to multilamellar stacked membranes.79 It is remarkable that both
cationic (MVLs) and anionic lipids (gangliosides, PEG-lipids, LPS) can induce similar
effects, bolstering suggestions of a general phenomenon78 that lipids with highly-
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charged (or very bulky) headgroups have the potential to cause dramatic membrane
curvature and reorganizations, dependent on repulsive effects: electrostatic, steric,
or a combination of both.
5.6 Conclusions
We have demonstrated that LPS, a biologically important molecule, causes
dynamic rearrangements of DOPC lipid bilayers dependent upon cation availability,
indicating potential driving forces behind physiological effects. It was not the purpose
of this study to investigate physiological effects of LPS, which are influenced by a
myriad of immunological and other factors in the human body, however it is our hope
that the work presented will facilitate the future design of experimental systems to
investigate the role of this complex toxin on the host cells. The continuum of effects
observed suggests an ability to tune the membrane deformation by adjusting
conditions and components. Further variations may exist if one used different lipid
mixtures (e.g. charged or gel-phase), LPS from different bacteria or alternative
cations. Our study supports the general notion that highly curved membrane
architectures can be generated by clustering of membrane amphiphiles that have an
effectively conical shape, due to charged or bulky headgroups, causing electrostatic
and/or steric repulsions.
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6.1 Abstract
Shiga toxin-producing Escherichia coli is an important cause of foodborne
illness, with cases attributable to beef, fresh produce and other sources. Many
serotypes of the pathogen cause disease, and differentiating one serotype from
another relies on the specific identification of the O antigen, which consists of sugar
repeats on the distal end of the amphiphilic biomarker, lipopolysaccharide (LPS).
The structure of LPS, which includes large carbohydrate groups and lipid tails, poses
a challenge when using classical detection methods not optimized for lipoglycans.
However, it is this structure that allows LPS to partition into a lipid bilayer, leaving
the hydrophilic O antigen extended into the aqueous environment. The association
of LPS with a lipid bilayer allows for a reliable, qualitative detection approach, called
membrane insertion, where the exposed antigen can be targeted for detection. Here,
we demonstrate the use of membrane insertion assays on a waveguide-based
optical biosensor platform for the detection of LPS from E coli O157:H7 in ground
beef. Also demonstrated is the serogroup-specific detection of LPS by targeting the
exposed O antigen group. Membrane insertion allows for qualitative and reliable
detection of amphiphilic LPS in complex samples like beef homogenates with
minimal sample preparation. Additionally, we report on the biophysical interactions of
LPS with lipid bilayers inside a flow cell environment to evaluate endotoxin-induced
hole formation under the conditions of our detection assay. These results
demonstrate that hole formation does not occur under the conditions of the
membrane insertion assay, and further evaluate hole-formation between different
LPS subgroups, which may have future ramifications on the understanding of
endotoxin activity. Together, these findings describe the sensitive and serotypespecific detection of amphiphilic biomarkers like LPS in complex samples using a
membrane insertion assay.

6.2 Introduction
Shiga toxin-producing Escherichia coli (STEC) is an important cause of
foodborne illness with cases attributable to beef and fresh produce, among other
sources.1 There are many serotypes of STEC with a wide range of virulence, which
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are capable of infecting humans. Identification in part has relied upon detection of
serotype, which in turn, relies on the identification of external biomarkers on the
bacterial cell.
Lipopolysaccharide (LPS) is the primary component of the outer membrane of
Gram-negative bacteria, and a key stimulator of the mammalian innate immune
system.2-4 LPS is among a class of molecules called pathogen-associated molecular
patterns (PAMPs). PAMPs are bacterial products, often with redundant molecular
structure, that are recognized by many host immune receptors, e.g., Toll-like
receptors.5,6 The bacterial membrane of an Escherichia coli (E. coli) cell is
comprised of approximately 106 LPS molecules, or about 75% of the outer
membrane.7-9 LPS, and more specifically the lipid A moiety is also known as
endotoxin, and can induce septic shock in a variety of mammalian hosts through the
activation of monocytes and macrophages that release a series of inflammatory
cytokines10-15 in response to invading pathogens.
The structure and signaling mechanism of LPS has been well studied. 16 LPS
is a negatively charged amphiphilic molecule that consists of three primary
components (Figure 6.1). The hydrophobic lipid A tail is a highly conserved
molecule consisting of 6-7 fatty acid tails.8 The endotoxic effects of lipid A9,16,17 are
initiated by the binding of this component to host receptors and serum binding
proteins in vivo.13,18,19 Lipid A is covalently attached to the less conserved core
polysaccharide region, which in turn extends to the hypervariable O polysaccharide
antigen (O-ag).16,17,20,21 Typically, the O-ag consists of 1-50 subunits made of 1-7
glycosyl residues.20,21 Among different serotypes and species, the O-ag can vary
greatly in both identity and degree of branching of the glycosyl residues. 21 This
variability is therefore used for classifying a bacterial serotype. Interestingly, many of
the PAMPs that stimulate host innate immune recognition, such as
lipoarabinomannan from Mycobacterium tuberculosis, share a similar amphipathic
structure.22,23 Beyond LPS, detection of such amphiphilic signatures is critical to the
understanding of host-pathogen biology.
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Figure 6.1. Representative structure of the molecular components of LPS. The conserved,
hydrophobic lipid A group, core polysaccharide, and hypervariable O polysaccharide antigen. The
lipid A group of most E. coli strains has 6 fatty acid tails which anchors LPS into the bacterial cell
membrane, and is recognized by host receptor proteins.

Detection of LPS and identification of the O-ag is not always straightforward
because of the variability in structure, and the possibility for conserved epitopes to
present on multiple serogroups of LPS.16,21,24 Additionally, many immunoassay
techniques used for detection of protein antigens are not optimized for the
amphiphilic biochemistry of LPS, resulting in low sensitivity of detection.

25,26

Factors

such as conserved fatty acids, micelle aggregation, and poor binding affinity make
lipoglycans difficult targets for detection using conventional immunoassay methods
designed for detection of protein antigens.25,27 Detection of the O-ag with classical
methods such as latex agglutination or immunomagnetic separation utilizes
polyclonal antibodies, which leads to cross reactivity and misidentification of the
serogroup.28-32 Enzyme-linked immunosorbent assays for detection of both LPS and
O-ag serogroup identification have also been developed, but require extensive
sample preparation and multiple antibodies, and yet suffer from non-specific
interactions of the antibodies.33-37 Polymerase chain reaction is also a method for
detecting the specific LPS transport and polysaccharide biosynthesis genes.
However, cross reactivity between specific genes of particular serotypes has been
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noted,38-40 leading to misidentification of those serotypes. Additionally, residual
nucleic acids can indicate false positive results due to the presence of non-viable
bacteria in samples.41
Thus there is a need to improve current detection methods for identification of
both LPS and STEC. It has been well documented that amphiphiles, like LPS,
interact both with lipid components of artificial membranes, as well as host serumbinding proteins.13,19,42-46 Our team has explored the amphiphilic biochemistry of
biomarkers such as LPS and lipoarabinomannan, and developed a tailored method,
membrane insertion, for their detection.43,44,47 Previously, we have reported on the
detection of lipoarabinomannan using membrane insertion and sandwich
immunoassays, and characterized the interaction of the amphiphile with lipid bilayers
by atomic force microscopy (AFM).43,44,47-49 Our approach utilized a waveguidebased optical biosensor platform that was developed specifically for the ultrasensitive detection of biomarkers.29,49,50 This platform uses single mode planar
optical waveguides functionalized with a lipid bilayer inside a flow cell to facilitate
detection through the use of evanescent sensing and a fluorescently conjugated
antibody.50-54 This technique is based on the principle of exponential decay of the
evanescent wave away from the surface of the waveguide material, which results in
an excitation field that extends only 200 nm from the surface of the waveguide.
Therefore, only samples and fluorophores within the evanescent field are illuminated
by incident light. This minimizes background signal, thereby increasing the signal-tonoise (s:n) ratio of excited antibody-fluorophore conjugates bound to antigen at or
near the surface of the waveguide. Waveguides are functionalized with supported
lipid bilayer assemblies. Upon exposure to the amphipathic biomarker, the
hydrocarbon tails (e.g. lipid A) passively diffuse through the aqueous matrix, and
associate with the lipid bilayer, eliminating the need for capture antibodies. 44,47 In
this manuscript, we show waveguide-based membrane insertion assays for
detection of LPS O157 in ground beef lysate. Also presented are membrane
insertion assays for detection of LPS from other serogroups, demonstrating broad
applicability of this platform. Due to the heterogeneous nature of LPS, the inability to
determine an accurate molecular weight or conformation of the antigens restricts the
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quantitative capability of these membrane insertion assays. Yet, they offer a reliable
and direct strategy for the detection of amphiphilic targets in complex backgrounds
with minimal sample preparation at a high s:n levels and low (μg/mL) limits of
detection.
To identify, describe, and delineate assay parameters, we have used
biophysical methods to characterize the interaction of LPS with lipid bilayers. Lipid
bilayers have been previously used to study the interactions of LPS in simple
biomimetic systems.42,55 Recent work from our team demonstrated LPS-induced
deformations in 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) lipid bilayers
based on ionic conditions.10 These findings raised questions on the dynamics of the
interaction of amphiphilic LPS with bilayers in membrane insertion assays. Since the
detection antibodies would bind to the open glass substrate caused by hole
formation, a high signal would result, which in the given scenario could be an artifact
of hole formation. In this manuscript, we address that question by devising a flow cell
mimetic chamber to explore the interactions of LPS with lipid bilayers at conditions
synonymous with our detection assays. Finally, we examine LPS-lipid bilayer
dynamics using multiple serogroups of LPS to determine if the variable O-ag
structure of the molecule affects the interactions with lipid bilayers, and explore the
relevance to detection assays and the study of host-pathogen biology.

6.3 Materials and Methods
6.3.1 Materials
Lipopolysaccharides from six strains of non-O157 STEC (DEC10B [O26:H11],
B8227-C8 [O45:H2], MT#80 [O103:H2], 0201 9611 [O111:H11], MDCH-4
[O113:H21], DA-37 [O121:H21], GS G5578620 [O145:NM], and TY-2482 [O104:H4])
were selected and prepared by hot phenol extraction and tested for antigen activity
as we have previously described.32 LPS O157:H7 was purchased from List
Biological Labs (Campbell, CA), and LPS O111:B4, bovine serum albumin (BSA),
Dulbecco’s phosphate buffered saline (PBS), Ethylenediaminetetraacetic acid
(EDTA), and potassium chloride were from Sigma Aldrich (St. Louis, MO). Polyclonal
antibody (pAb) anti-E. coli O157 (pAb O157) was from LifeSpan Biosciences
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(Seattle, WA). pAb E. coli O104, as well as monoclonal antibody (mAb) for E. coli
O111 were from Abraxis Inc. (Warminster, PA). 1,2-Dioleoyl-sn-glycero-3phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N(cap biotinyl) (sodium salt) (cap-Biotin) were obtained from Avanti® Polar Lipids
(Alabaster, AL). C5-BODIPY® FL HPC (2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4adiaza-s-indacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine) was
purchased from Molecular Probes® (Eugene, OR). Sylgard® silicone elastomer kit
(Dow Corning, Midland, MI) was used to pour a 90/10 mix of polydimethylsiloxane
(PDMS). Alexa Fluor® 647 labeling kits, UltraPure™ Glycerol, and HEPES were all
from Life Technologies (Thermo Fisher Scientific, Grand Island, NY). Silicon
oxynitrite waveguides were purchased from nGimat (Norcross, GA) and the
functional surface of silicon dioxide was maintained by Spectrum Thin Films
(Hauppauge, NY). Silicone gaskets for waveguide assembly were from Grace BioLabs (Bend, OR) and Secure seal spacers (9 mm diameter x 0.12 mm deep) were
from Electron Microscopy Sciences (Hatfield, PA). Glass microscope slides, Gold
Seal™ cover glass, and sucrose were purchased from Thermo Fisher Scientific
(Rockford, IL). Epoxy was from Gorilla Glue, Inc., (Cincinnati, OH), and Simple
Truth® organic ground beef was purchased from the local Kroger Stores (Los
Alamos, NM). All reagents were of the highest quality for their intended purpose.

6.3.2 Waveguide preparation
Single mode planar optical waveguides were cleaned and prepared as
previously described.29,50,51,53,56,57 In brief, the waveguides and coverslides were
cleaned by bath sonication for 5 min each in chloroform, ethanol, then water.
Waveguides and coverslides were dried under an argon stream and exposed to UVozone (UVOCS Inc., Montgomeryville, PA) for 40 min. Flow cells for immunoassays
were immediately assembled using cleaned waveguides and coverslips which were
bonded together by a silicone gasket with a laser cut channel in the center.
Following assembly, the flow cells were injected with a preparation of lipid micelles,
then incubated overnight at room temperature (RT), to facilitate vesicle fusion.53
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6.3.3 Micelle preparation
Micelles for waveguide membrane insertion experiments were prepared by
probe sonication as previously described.29,50,51,57 2 mM DOPC and 1% (mol/mol)
cap-Biotin were prepared by deposition of chloroform-dissolved lipids into glass
tubes, and evaporation of solvent under an argon stream. Biotin incorporation allows
for the evaluation of bilayer integrity at the conclusion of assays.47,53 Lipids were
rehydrated in phosphate buffered saline (PBS), stirred for 2 hours (hr) at RT, 120
revolutions per minute (rpm) on an orbital shaker, followed by 10 freeze-thaw cycles.
Finally lipids were probe sonicated for 6 min (1.0 s pulse on/off, 15% amplitude)
using a Branson ultrasonic generator.
Micelles for fluorescent imaging were prepared in a similar fashion as those
for waveguide experiments with the addition of 0.5-1% (mol/mol) of C5-BODIPY FL
HPC to serve as a fluorescent marker for imaging. Lipids in chloroform were vacuum
dessicated overnight and subsequently prepared in PBS, followed by 6 freeze-thaw
cycles and 10 minutes of continuous probe sonication (tip dia. = 3 cm, 12 watts)
(Sonicator 3000, Misonix, Farmingdale, NY)

6.3.4 Lipopolysaccharides, beef samples, and antibodies
Except in the cases of concentration dependence assays, LPS stocks (5
mg/mL) were thawed and bath sonicated for 15 min, diluted to the working
concentration in PBS and sonication was repeated prior to injection in the flow cell.
For the benchmark assays on concentration dependence of LPS, the stocks were
sonicated for 5 min, diluted to working concentration in PBS and resonicated for an
additional 5 min prior to injection.
Ground beef was flash frozen in liquid nitrogen, and freeze-dried on a Schlenk
line for 48 hr. Dried material was crushed using a mortar and pestle, then
homogenized in lysis buffer (0.5 M sucrose, 10 mM HEPES, 25 mM KCl, 1 mM
EDTA, 10% v/v glycerol, 5 mg/mL concentration).29 The suspension was alternately
vortexed (30 sec) and bath sonicated (30 s) until large protein aggregates were
eliminated. Samples were diluted to 1 mg/mL in PBS immediately before use. The
beef homogenate was used as a negative control, in order to evaluate background
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fluorescence and assess antibody cross-reactivity with a crude matrix that simulates
an actual test sample. Additionally we also spiked LPS directly into homogenates to
determine detection capabilities in a beef sample.29
Reporter antibodies for LPS were pAb anti-E. coli LPS O157 (pAb O157), pAb
anti-E. coli LPS O104:H4 (pAb O104) and mAb anti-E.coli O111:H11 (mAb O111).
All reporter antibodies were fluorescently labeled with Alexa Fluor® 647 (af647) per
kit instructions. Molar ratio of dye to protein was measured using a NanoDrop™
1000 (Thermo Scientific) and calculated (3.68 for LPS concentration assays, and
7.37 for beef lysate assays) per Alexa Fluor® kit instructions. Degree of labeling for
pAb O104-af647 was 3.17 and that for mAb O111-af647 was 7. After labeling,
antibodies were checked for activity using immunoblotting of 5 mg/mL LPS antigens
onto nitrocellulose, and compared with immunoblotting results for antibodies prior to
labeling.

6.3.5 LPS membrane insertion assays
Concentration dependent LPS insertion assays were repeated at least three
times using LPS O157 and 25 nM pAb O157-af647 as the reporter antibody. Flow
cells were prepared as described and blocked for 1 hr with 2% (w/v) BSA, then
rinsed with 0.5% BSA/PBS. Incident light from a 635 nm laser, (power 440-443 µW)
was coupled into the waveguide using a diffraction grating. The response signal was
adjusted for maximum peak intensity using a spectrometer (USB2000, Ocean
Optics, Winter Park, FL) interfaced with the instrument and an optical power meter
(Thor Labs, Newton, NJ).29,50,51,54 The background signal associated with the lipid
bilayer and protein block was recorded after which the flow cell was incubated (90
min) with pAb O157-af647 to determine NSB between the antibody and the lipid
bilayer. The flow cell was rinsed with 2 mL of wash buffer (0.5% BSA/PBS) after all
incubations. Incubation times for LPS were optimized to 2 hr to allow maximal
association with the supported lipid bilayer. Excess LPS micelles were removed by
washing and the signal recorded. Subsequently, reporter antibody was incubated for
90 min and rinsed, and the specific signal associated with antibody bound to LPS
captured on the bilayer was recorded.
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Membrane insertion assays for serogroups of LPS were performed in
triplicate at a concentration of 25 μg/mL, using pAb O157-af647 as the reporter
antibody. This approach exploits the cross-reactivity of a polyclonal antibody to the
conserved regions of different serogroups of LPS.32 However, we raised the
hypothesis that by use of antibodies specific for a particular LPS serogroup, we
could potentially enhance the sensitivity and selectivity of detection by targeting the
variable O-ag region. To evaluate this, LPS O104 was tested under identical
conditions using 25 nM pAb O104-af647 as the reporter, and then compared to the
signal using the non-specific pAb O157-af647. Additionally we also tested whether
using mAb specific to the O-ag would increase the specific signal and tested LPS
O111:H11 with its respective mAbs.
To determine NSB of the detection antibody with the beef lysate, a 1 mg/mL
beef homogenate sample was prepared by diluting in PBS and incubating with the
bilayer for 2 hr. NSB of the reporter antibody was assessed against the beef lysate
after a 90 min incubation, and then LPS (6.25, 25, or 50 µg/mL) was spiked into beef
lysate and incubated for 2 hr. Specific signal was recorded after 90 min incubation
with the reporter antibody.

6.3.6 Imaging inside of a flow cell
We established a flow cell mimic to investigate the interactions of LPS with
DOPC bilayers inside a flow cell of identical dimensions and functionalized surfaces
as our waveguide biosensor (Figure 6.5 A-B). For this, two holes were drilled into a
glass slide and a 24x50 mm cover glass was used in place of the waveguide piece
to allow imaging. Glass was cleaned in 30:10 sulfuric oxides for 40 min then rinsed
repeatedly and bath sonicated 3 times (5 min/each) in deionized water. The flow cell
model was constructed from the two glass pieces with the addition of an attached
outflow tube and a rubber septum to allow buffer exchange. PDMS (90:10
elastomer:curing agent) was poured into plastic petri dishes to a final height of ~4
mm, allowed to cure, and then cut into a square (~1 cm x 1 cm). To create an
injection port, a rubber septum was inserted into the PDMS when it was
approximately halfway cured. For the fluid outflow port, a 2 mm hole was made in a
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1 cm2 of self-adhesive silicone using a biopsy punch and tubing was inserted
through the hole. PDMS and flow cell assembly was then exposed to UV-Ozone for
2 min after which PDMS/septum assembly and silicone were stuck to the glass slide
and seams were sealed using epoxy. Epoxy was allowed to cure for 1 hr prior to
deposition of 2 mM DOPC + 1% biotin + BODIPY® labeled lipid micelles. Lipids
were deposited into the flow cell, the outflow tube was clamped shut, and the
apparatus was incubated O/N at 4˚ C in the dark. Flow cell was rinsed with 10 mL
PBS and imaged on an Olympus IX-81 motorized inverted microscope with
excitation provided by a 488 nm Argon ion laser and green filter set. Fluorescence
recovery after photobleaching (FRAP) was used to confirm lateral fluidity of lipid
bilayers. LPS membrane insertion assays were then performed in the same manner
as the waveguide assays, with images recorded to determine hole formation (or lack
thereof) under these conditions. In most cases, images were recorded at 1024 x
1024 pixels at a scan rate of 12.5 µs/pixel. FRAP was performed on 512 x 512 pixel
frames, using 5x zoom, at a scan rate of 10 µs/pixel.

6.3.7 Imaging LPS on glass slides
To determine differential interactions of various LPS serogroups on DOPC
lipid bilayers, 9 mm secure seal spacers were adhered to clean glass cover slides
and 2 mM DOPC + BODIPY® micelles were deposited and incubated for 20 min as
previously described.10 Free lipid vesicles were rinsed away using 10 exchanges of
PBS buffer (1 mL total volume) and then LPS was prepared and incubated with the
bilayers for 20 min at RT, after which free LPS was rinsed away with 10 exchanges
of buffer. FRAP and fluorescence imaging was used to determine the effect of the
LPS groups on the fluidity and conformation of the bilayers. Data was optimized for
contrast and brightness using ImageJ 1.48.

6.3.8 Data processing
Resulting spectra from the waveguide biosensor were processed and
graphed using Igor Pro 6.37. Due to NSB signals that were nearly equivalent to
background values, the data for the membrane insertion assays of LPS O104:H4
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and O111:H11 were not background corrected, and were integrated as raw spectral
curves between 550 and 850 nm and then averaged. In all other cases, individual
spectra replicates were integrated between the wavelengths of 550 – 850 nm, where
the significant signal appears for detection with af647 and a long pass 647 nm filter,
and then corrected for background noise levels. Integrated values were then
averaged and used to calculate a s:n ratio. LoD were obtained by taking the average
integrated NSB for all replicates in a set, determining the standard deviation (σ) of
the replicates, adding 3σ, then multiplying by the sample concentration (µg/mL), and
dividing by the integrated average specific signal for that concentration (see
Equation 6.1).

LoD =

(NSB + 3s )[Sample]
Specific

Equation 6.1

6.3.9 Statistical Analysis
Linear regression was used to relate the logarithm of the raw integrated
intensities according to LPS concentration (LPSc), waveguide ID (wg#), power
coupled (power), and type of measurement (background (mBG), non-specific
(mNSB), specific, and specific (mSP)). Analysis of variance (ANOVA) was then used
to determine the significance of the variables at the 5% level, (Table A5.1).
Subsequently, to explain the observed heteroscedasticity, we regressed the
absolute value of the residuals from the previous regression analysis onto the same
set of explanatory variables (Table A5.2). Model selection was performed using
Akaike information criterion to determine the significance of the variables. Absolute
values of the residuals of the means for LPSc, wg#, and power were processed with
regression analysis (Table A5.3) using the type of measurement as a covariate.

6.4 Results and Discussion
6.4.1 Detection of LPS with membrane insertion
To determine the concentration range over which LPS can be reliably
detected by membrane insertion, assays of LPS O157 were performed a minimum
of three times over a concentration range of 6.25 – 200 µg/mL LPS (Figure 6.2 A),
using polyclonal antibody (pAb) anti-E. coli O157 (O157) labeled with Alexa Fluor®
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647 (af647) as the detection antibody (pAb O157-af647). The limits of detection
(LoD) for LPS O157 were calculated to be 4.80 µg/mL using Equation 6.1 with the
specific signal intensity values from the lowest concentration. The results indicated
that membrane insertion consistently detects a broad concentration range of LPS
with low non-specific binding (NSB) of the reporter antibody. However, the detection
trend is non-linear (Figure 6.2 B) with larger variability at higher concentrations. This
lack of linearity is expected, and can be explained by the biochemical properties of
amphiphilic LPS which significantly affect the size and conformational presentation
of the molecule. For one, LPS will present in a micellar conformation in aqueous
solutions.17,58-60 Beyond the critical micelle concentration (CMC) of LPS O157, the
amphiphile would exist both as monomers and aggregates,61,62 making repeatable
quantitation challenging.61 LPS micelles can further vary based on the size of the Oag chains, which can be full-length, truncated, or absent entirely, depending on
bacterial strain and growth phase.17,58,63 Furthermore, LPS can also present in
different shapes of micelles, such as lamellar, cubic, and hexagonal inverted
structures,64-67 which are dependent on antigen structure, pH, ion concentration,
solution composition, and temperature.10,17,65,68 All of the above factors contribute to
the size or shape of the micelles, and influence the binding availability of epitopes for
detection, which in turn affects the inter-assay variability (Figure 6.2 B). While
reasonable efforts to control for the size of micelles in the preparations was taken
(e.g. extended bath sonication66 during testing of serogroup and beef lysate assays),
we cannot be certain that LPS micelles in our assay systems are homogenous. This
biochemical variability has limited the quantitative measurement of amphiphilic
biomarkers in general.47,67 Lastly, due to the stability of endotoxin69,70 we cannot
entirely discount the potential of endogenous endotoxin that may have been present
on glassware, either from previous assays or other environmental bacteria, even
though rigorous cleaning procedures were employed. This is also a relevant concern
in beef lysates. We therefore only demonstrate the concentration range over which
LPS can be reliably and repeatedly detected using membrane insertion. Membrane
insertion is not intended to provide a quantitative measurement of concentration, but
to accurately detect LPS with minimal sample processing in complex samples such
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as beef lysates. To determine that the variability between assays was caused by the
variable nature of LPS, we employed rigorous statistical analysis of the data.
Statistical regression analysis of the uncorrected data sets and the residuals (Tables
A5.1-5.3) from multiple experiments demonstrate that factors such as antigen (LPS)
concentration, choice of waveguide, power coupled into the waveguide, non-specific
interaction of the antibodies with the lipid bilayer, and other systematic parameters
do not account for the large deviations seen in detecting specific concentrations of
LPS. The only significant factor resulting from the analysis is the antigen itself,
though we also saw some significance associated with a single waveguide (Table
A5.3). This suggests that variations in the CMC of the amphiphile, due to the
heterogeneous nature and other biophysical properties, affect the interaction of LPS
with the lipid bilayer and the detection antibody. This is further substantiated by
measurements of protein binding on the same instrumentation in this and previous
studies that do not present with such variability. Therefore, we conclude that the
variability in signal at specific concentrations is primarily dependent on the
conformation of the LPS antigens, and not variability associated with the detection
platform, methods, or other reagents.

Figure 6.2. Membrane insertion for detection of LPS O157. (A) Spectral curves demonstrating
detection of various concentrations of LPS O157. (B) Integrated values of spectral curves plotted as
single points with standard error of the mean. Closed diamonds indicate averaged integrated signal
intensity, and open diamonds are integrated NSB.
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To assess application for detecting contamination in food products, assays
were performed in a complex sample matrix (e.g. beef lysate). Membrane insertion
assays were performed in 1 mg/mL ground beef lysate at three concentrations over
the range of 6.25 – 50 µg/mL LPS O157 (Figure 6.3). LoD for this assay was
calculated to be 4.2 µg/mL LPS O157. The ratios between specific signal and NSB
(s:n) at 6.25 µg/mL (~4), and at 50 µg/mL (~27) are comparable, albeit slightly
higher, to the those seen in the benchmark assay (Table 6.1). However, the ratio at
25 µg/mL (s:n~10) was lower than that observed in the benchmark assay (Table
6.1). The changes in the presentation and micellar properties of the antigen in
complex physiological backgrounds can account for both observations. We attribute
the increased signal at 6.25 and 50 µg/mL to the possibility that LPS is known to
associate with lipoproteins,13,19,43,47,49 such as low-density and high-density
lipoproteins (LDL and HDL respectively), in serum and muscle tissue.71 Since these
lipoproteins carry amphiphiles and can insert them into cell membranes,45,72 it is
possible that HDL and LDL are serving to insert monomeric LPS or LPS-lipoprotein
complexes into the DOPC lipid bilayer. HDL is a critical factor for both treatment and
prognosis of septic patients,73,74 because of its ability to shuttle amphiphilic LPS in
hosts. No data is readily available on the CMC of LPS O157, however, it is
reasonable to assume it to be somewhat similar to the CMC of LPS O111:B4 (22
µg/mL).17 This means that at 6.25 µg/mL, LPS would be present mostly as a
monomer, and above 25 µg/mL, aggregates would be the primary conformation. At
25 µg/mL mL the change in the s:n ratio between the two assays could also be
caused by the difference in solution composition between the beef lysate and
benchmark (PBS) assays, which could affect micelle conformation. It is tempting to
speculate about the conformation of LPS at this specific concentration. This is
especially important to consider when detecting multiple subtypes of LPS in complex
matrices. Since conformation will vary slightly between different LPS antigens, the
enhanced s:n ratios we see in the beef lysate will aid in the detection of multiple
serogroups of LPS associated with STEC or other Gram-negative species. While we
have begun preliminary biophysical characterization of this specific concentration of
LPS O157 using AFM, there are still numerous unanswered questions about the
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conformations LPS adapts while interacting with lipids, which could be affecting
quantitative detection capabilities. Further, we used much milder sonication
conditions for these assays, compared to subsequent measurements of different
serotypes of STEC LPS, which may contribute to some of the variability. Finally, the
epitopes recognized by the detection antibodies, and their presentation can change
significantly depending on the micellar conformation of LPS, which may contribute to
the variability. Thus, several factors can affect variation in measured detection
signals of intact amphiphilic biomarkers such as LPS, and should be taken into
account for the design and evaluation of diagnostic assays as well as the
understanding of host-pathogen biology.
Table 6.1. Signal to Noise Ratios of
LPS Membrane Insertion Assays

Signal:Noise Ratios
LPS
µg/mL

benchmark

6.25

beef lysate*

2.6

4.1

12.5

5.2

--------

25

13.4

9.8

50

8.8

26.9

100
200

23.3
29.5

---------------

*LPS O157 was tested at 3 concentrations in
beef lysates

Figure 6.3. Concentration dependent detection of LPS O157 in 1 mg/mL beef lysates.
Detection of LPS in beef lysates shows an increase in signal to noise ratios (Table 6.1) as compared
to those seen in the benchmark assay.

To demonstrate the broad applicability of membrane insertion assays, we
tested LPS from other pathogenic E. coli (LPS O104:H4 and LPS O111:H11) using
af647 labeled detection antibodies targeted against the specific O-ag (Figure 6.4),
Sensitive detection is demonstrated in both cases with LPS O104 demonstrating a
significantly higher (s:n~39) response than LPS O111 (s:n~6). This difference can
largely be attributed to the sensitivity of the respective antibodies.32 Due to the large
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difference in s:n ratios in these assays, the limits of detection also demonstrate the
same pattern (0.77 and 7.36 µg/mL respectively). This is due in part to the low NSB
of both antibodies, but also the specificity of the antibodies for their specific epitopes.
Both LoDs fall within the reported range for physiologically relevant concentrations of
LPS.72 We observed a much lower variability between the assay replicates (Figure
A5.1) as compared to the benchmark assay at 25 µg/mL LPS. We attribute this
primarily to the increased sonication time during antigen preparation that was
implemented here, but also acknowledge that the O-ag of these LPS subtypes are
much different from O157 and therefore may be more homogenous at this
concentration.

Figure 6.4. O-ag targeted detection of LPS. Using membrane insertion, two types of LPS were
detected using their complement antibodies, polyclonal anti-E. coli O104 (pAb O104) and monoclonal
anti-E.coli O111 (mAb O111) labeled with af647.

A key factor that affects performance of any antibody-based assay is the
sensitivity and specificity of the antibody being used. In membrane insertion, the
amphiphilic antigen is presented partitioned into a lipid bilayer, which mimics the
physiological presentation of such antigens in vivo. The antibody targeting LPS
O104 is a polyclonal, extracted from an animal immunized with whole bacteria, and
likely is more suitable for recognizing LPS when presented in a lipid carrier interface.
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In contrast, the antibody against LPS O111:H11, is monoclonal, and was raised in
vitro. Also, pAb have multiple paratopes that can bind several different epitopes on
the antigen, as compared to mAbs that target a single epitope. The source animal
for antibodies may also play a large role in antibody affinity and specificity, since it
has been demonstrated that different animal types exhibit varied levels of sensitivity
to LPS,11,75 which would affect antibody expression. The above factors in antibody
specificity and sensitivity are not unique to the two that are discussed here or to the
membrane insertion approach, but indeed should be considered in the development
of all assays involving detection antibodies.

6.4.2 Imaging LPS-lipid bilayer interactions inside a flow cell
We have used fluorescence microscopy10 as a tool to characterize
amphiphile-lipid interactions, thereby building more robust membrane insertion
assays for these difficult antigens. Previously, we have shown that LPS O111:B4
can form holes in supported lipid bilayers10,76 using fluorescence microscopy. It
therefore became imperative to determine whether LPS forms holes in a supported
bilayer under the conditions of the membrane insertion assay. To investigate this, we
developed an imaging compatible flow cell model (Figure 6.5 A) that replicated the
internal dimensions and functional surfaces of the flow cell used in our waveguidebased assays (Figure 6.5 B). This model enabled direct imaging of lipid bilayers, as
well as the specific binding of the fluorescent antibodies to LPS (Figure 6.5 C-F).
We investigated the effects of LPS O111:B4 (Figure 6.5 C-D) and LPS O157 at 100
µg/mL, 50 µg/mL, and 25 µg/mL (Figure 6.5 E-F), under the same conditions as the
waveguide assays. We found that with LPS O157, the lipids maintained excellent
lateral fluidity (Figure A5.3) and there was no hole formation in the bilayers at any of
the tested concentrations, thereby eliminating our concerns. LPS O111:B4, on the
other hand, formed holes in lipid bilayers (Figure 6.5 C) within the flow cell, but only
at higher concentrations of antigen (>50 µg/mL) (Figure 6.5 D). No hole formation
was observed at lower, more physiologically relevant concentrations of LPS (Figure
6.5 D). We were also able to generate composite images of the fluorescent lipids
and the specific binding of pAb O157-af647 (Figure 6.5 E-F) at localized spots
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within the flow cell for LPS O157. As demonstrated by the lack of overall red
fluorescence (Figure A5.4) in the images, the NSB of the antibody is quite low, while
the specific binding intensity is saturated at localized positions. This data supports
the low NSB signals seen in the membrane insertion assays.

Figure 6.5. Assay performance inside flow cells. Schematics of (A) imaging flow cell and (B)
waveguide flow cell. Major differences between these two flow cells include replacement of the
waveguide glass substrate with a thin glass coverslip for imaging, and the addition of PDMS and
silicone pedestals to create an airtight environment to preserve lipid integrity throughout an assay. (C)
100 µg/mL and (D) 50 µg/mL LPS O111:B4 incubated with BODIPY labeled DOPC lipids. Composite
images of (E) 50 µg/mL and (F) 25 µg/mL LPS O157 bound by fluorescently labeled pAb O157-af647.

6.4.3 Imaging LPS subtypes on glass slides
We evaluated the effect of 50 µg/mL LPS from various serogroups (O26,
O45, O103, O104, O111, O113, O121, and O145) on open cover slides to observe
membrane dynamics. LPS is an indicator of bacterial virulence, which in turn varies
significantly between serotypes. Thus, our simplistic model may provide some
insight into bacterial virulence. Surprisingly, no membrane deformation was
observed in any of the LPS serogroups (Figures 6.6 and A5.5), except LPS
O111:B4 (Figure A5.5), as anticipated.10 The variability between these sub-types of
LPS, and the difference in interactions with a simple lipid bilayer, are intriguing.
Since the structure of the O-ag chain affects the CMC of LPS,17 the size and shape
of the micelle produced in an aqueous medium can be different between serotypes.
Additionally, differences in O-ag structure combined with possible chemical
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signature differences in the core polysaccharide of LPS77 between strains could
contribute to a variable charge distribution in the LPS.78,79 This, in turn, could affect
the delamination of the lipid bilayer by LPS micelles. Lastly, there is the potential for
capsular K polysaccharide antigens to be co-expressed in these different
preparations of LPS,80 which we are working to confirm with nuclear magnetic
resonance spectroscopy. In addition, we are exploring the effect of factors such as
complex lipids, temperature, and pH on hole formation with different serogroups of
LPS, to be reported in future studies.

Figure 6.6. Imaging LPS O157 with lipid bilayers. (A) Bilayer prior to incubating with LPS O157. 50
µg/mL LPS (B) O157, (C) O104, and (D) O111:H11.

6.5 Conclusion
In conclusion, we have shown that LPS can be sensitively detected in
complex beef lysate samples using membrane insertion with higher s:n ratios than
those seen in the benchmark assays. The micellar properties of LPS in aqueous
media, be it buffer or complex samples, affect the interaction at high concentrations,
causing the assay to be non-linear. However, we can consistently and reliably
measure LPS in complex samples using this method, making this an effective tool
for detection of amphipathic biomarkers in complex backgrounds.
We have also shown that LPS from multiple serotypes do not induce
membrane deformation in supported lipid bilayers at concentrations less than 50
µg/mL at room temperature. The imaging of amphiphilic interactions with supported
lipid bilayers in a closed system (a.k.a. a flow cell) is a useful experimental tool that
can be utilized for many similar studies. Since LPS is globally used as an immune
stimulant and a key indicator of bacterial infection, the continued study of this
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molecule is critical for understanding host-pathogen interactions and developing
better amphiphilic detection platforms.
These studies demonstrate the challenges associated with the measurement
of amphiphilic biomarkers such as LPS. Previous studies reporting the poor
sensitivity of assays for the direct detection of LPS and other biomarkers in aqueous
mileau, such as blood, have ignored their amphipathic biochemistry. With this
manuscript and others, we hope to unravel the challenges associated with the
detection of such biomarkers in clinically relevant samples, and develop strategies to
overcome them effectively in the future.
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Chapter 7.
Understanding the in vitro effects of differential LPS presentation
7.1 Introduction
In bacteria, LPS serves to protect cells by reducing membrane permeability
against foreign materials, such as antibiotics, peptides, enzymes, and protecting
from changes in pH.1,2 LPS also defines pathogen serogroup and is a key indicator
of virulence.3-5 In mammals, LPS falls into a special category of bacterial antigens
called pathogen associated molecular patterns (PAMPs). PAMPs are evolutionarily
conserved molecules which bind innate immune receptors in the host to facilitate the
initial and adaptive immune response.6-10 Low concentrations of LPS serve as an
early indicator of infection through stimulation of Toll-like receptor 4 (TLR4) to induce
immune response.11-13 Because of this function, derivatives of LPS have also been
tested as vaccine adjuvants,14 and often LPS is used to study the pathways of
immune diseases.15-17 The continued study of LPS interactions with biomimetic
systems is critical for advancing our understanding of this complex molecule and its
physiological interactions.
Structurally, LPS is an amphiphilic molecule made up of three primary
components, the hydrophobic lipid A, also called endotoxin, the core polysaccharide,
and the O polysaccharide antigen18,19. The amphipathic nature of LPS is not to be
trivialized. This unique biochemistry allows association of the molecule with several
structures, such as; the outer membrane of Gram-negative pathogens,20 membranes
of eukaryotic cells,21 liposomes,22,23 lipid bilayers,24 giant unilamellar vesicles,25
serum binding proteins,26,27 antibiotics,28 and a host of other molecules which
specifically bind the lipid A component.29-34 In addition to this, LPS is often found as
a micelle in aqueous systems,35-37 as the hydrophobic lipid A group sequesters away
from the hydrophilic media to lower the free energy of the structures. In physiological
in vivo systems, the hydrophobic portion of LPS allows it to be taken up by serum
carrier proteins such as high- and low- density lipoproteins (HDL, LDL)27,38-40 as well
as LPS Binding protein (LBP).26,41,42 HDL and LDL are known to specifically
sequester lipid A into the lipoprotein nanodisc structure, composed of cholesterol
and triaglyerides.43,44 LBP has a hydrophobic binding pocket where it binds lipid A,
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but has also been demonstrated to transfer other phospholipids as well. 23,45-47
Together, these lipoproteins facilitate clearance of LPS through the liver, 42,48,49 or
transfer LPS to receptors on immune cells.23,50 It is also through the mechanisms of
these carrier proteins by which protective or inflammatory outcomes can result, 51
depending on the circumstances by which LPS is introduced to the host.52,53. While it
is well know that these serum carriers bind and are responsible for presenting LPS
to cells,51 many studies present LPS to cells in an aqueous buffer system rather than
with its physiological protein carriers, which can attenuate cytokine response. 51 Upon
presentation and subsequent activation of TLR4, LPS induces a pro-inflammatory
cascade of cytokines, which serve many functions. However, over stimulation of the
immune system by LPS, can result in a severe condition known as sepsis, in which
tissues and organs start to degrade.54 The cytokines typically associated with an
LPS induced response are IL-1, TNF, and IL-6, but other cytokines such as IL-12,
IP-10, and MIP-2 have also been demonstrated to be expressed in macrophages. 52
A simplified version of LPS-induced cytokine expression begins with
activation of the TLR4 receptor. This activation results in the de novo synthesis of IL1 in macrophages. IL-1 is often referred to as a damage associated molecular
pattern (DAMP). The primary function of DAMPs is to signal to immune cells the
presence of danger signals, which cause the cell to undergo a form of programmed
cell death. When IL-1 binds its receptor, it causes recruitment of proteins that leads
to the activation of nuclear factor kappa beta (NF-k). NF-k then binds to receptors
on the nucleus to initiate transcription and translation of other cytokines, such as IL1, TNF, IL-6, and IL-12. Together with a host of other chemokines, these signals
work to recruit other cells to deal with infection and build an adaptive immune
response.55,56 However, there are many conflicting reports on LPS-mediated
induction of cytokines and chemokines, which makes it difficult to interpret the
biological significance of these findings.
There is mounting evidence that a direct mechanism of LPS interacting with
cell membranes may exist. The interaction of LPS with simple biomimetic systems,
such as supported lipid bilayer assemblies (sLBAs), has been shown to cause
dynamic deformation of these membranes.24,57 Other researchers have documented
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the presence of fluorescent LPS micelles inside cells,21 indicating possibility of
passive diffusion. Schromm et al.58 demonstrated a CD14 independent mechanism
by which LPS was transferred directly into a phospholipid membrane. Another
amphiphilic lipopeptide called surfactin has been demonstrated to induce leakage in
phospholipid vesicles.59 Thus, it can be speculated that direct interaction of LPS with
phospholipids can cause cell membrane damage and altered cytokine response.
With all the inherent variability, it is clear that the choice of model system
dramatically impacts the outcome of any study that uses LPS. Addressing all these
potential variations is beyond the scope of this research. Our goal is to simply
demonstrate the significance of the choice of model system for amphiphilic LPS. For
the purposes of this dissertation, we asked two simple questions and designed
experimental systems to specifically answer them.
1) Does the complexity of cell membranes inhibit LPS induced deformation? To
address this, we created sLBAs with increasing complexity and studied the
effect of this modification on LPS-induced hole formation.
2) Does presentation of LPS in physiological systems affect its interaction with
membranes and associated innate immune receptors? To address this, we
chose to compare LPS-mediated cytokine and chemokine induction in cell
lines with/without TLR4 when the antigen was presented in serum vs. buffer.

7.1.1 Model sLBAs
sLBAs are simple systems, which do not accurately represent the complexity
of the surface of a cell. Model membranes often combine different lipids of varying
fluid transition temperatures, or membrane proteins to simulate a more complex
membrane surface.60,61 Such membranes have been used to study the effects of
direct incorporation of LPS, and its effects on membrane fluidity.62,63 LBP has also
been used to study the interaction of LPS with lipids and membranes. 64,65 To the
best of our knowledge, no one has investigated whether LPS forms holes or other
deformities in model sLBAs. We began with simple sLBAs and gradually increased
their complexity by enriching with biomimetic lipids, such as sphingomyelin and
cholesterol. This approach evaluated whether the degree of membrane complexity

160

can prevent or affect the mechanism of LPS-induced hole formation, and provides
us with information about developing biomimetic sensors for LPS, as well as the in
vivo mechanisms of inflammation.

7.1.2 Cell lines with and without TLR4
We analyzed the LPS-induced inflammatory cytokines in both TLR4(+) and
TLR4(–) cell lines in the presence of murine serum, delipidated serum, and no
serum (buffer control). Since LPS is associated with serum proteins in physiological
systems, we wanted to explore the impact of this association and its ability to
stimulate innate immune response. Also, we asked the question if LPS in buffer can
induce deformities in cells, irrespective of the presence of TLRs. Cytokines or
chemokines expressed by a TLR4 deficient cell line could be one potential indicator
of direct cell membrane damage. Taken together, these findings could have
significant impact on our understanding of the mechanisms of LPS signaling, thereby
effecting bacterial targeting, immunology, and vaccine research. These experiments
not only address the specific questions outlined above, but also provide valuable
information for the future design of amphiphilic detection assays.

7.2 Materials and Methods
7.2.1 Materials
Lipids and fluorescence dyes were purchased in powdered form and
reconstituted per manufacturer’s instructions. 1,2-dioleoyl-sn-glycero-3phosphocholine (DOPC), 5-cholesten-3ß-ol 12-[(7-nitro-2-1,3-benzoxadiazol-4yl)amino]dodecanoate (NBD-Cholesterol), egg sphingomyelin (SM), and cholesterol
from ovine wool were all purchased from Avanti® Polar Lipids. Fluorescent dyes for
doping the lipids were as follows: 2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-sindacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine (BODIPY) or
Texas Red 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine,
triethylammonium salt (Texas Red DHPE) (Molecular Probes). An AlexaFluor 488conjugate of LPS from E. coli serotype O111:B4 was used to assess LPS uptake
into bilayers (Molecular Probes). Studies with lipid bilayers and in vitro 12-plex
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cytokine assays used LPS O111:B4 (phenol extract, Sigma Aldrich). For in vitro 25plex cytokine assays, ULTRA PURE LPS O111:B4 (List Labs) was used to minimize
the potential for protein contamination. All other forms of LPS used were purified by
us as previously described.66 Antibodies used for immunodepletion; polyclonal antiapolipoprotein A-I (pAb ApoAI), polyclonal anti-apolipoprotein B (pAb ApoB), and
polyclonal anti-lipopolysaccharide binding protein (pAb LBP) were from AntibodiesOnline. Monoclonal anti-LBP (clone U54.R.mLBP.2, immunoglobulin M, rat) was
from BEI Resources NIAID NIH. SPHERO™ carboxyl cross-linked magnetic
particles (dia. 1.22 µm, Spherotech™) were used for immunomagnetic separation
(IMS). Chemicals for preparation of IMS beads were: N-hydroxysulfosuccinimide
(Sulfo-NHS), sodium azide, sodium tetraborate (all from ThermoFisher Scientific);
and phosphate buffered saline (PBS), 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (WSC), Boric acid, glycine, and (3-(Nmorpholino)propanesulfonic acid) (MOPS) (all from Sigma Aldrich).

7.2.2 Lipid and bilayer preparations
DOPC liposome preparations were prepared as 99.5% (mol/mol) DOPC to
0.5% BODIPY or 0.5% TR-DHPE. Lipids and dyes were mixed to the desired ratio,
then dried overnight under vacuum and prepared to a final concentration of 2 mM
DOPC in PBS. Liposomes containing (5%-15%) sphingomyelin, (25-50%)
cholesterol, or (25-50%) NBD-cholesterol were prepared in a similar manner. When
calculating the molar ratio of NBD-cholesterol we excluded the molecular weight of
the NBD head group to obtain a more accurate ratio of cholesterol:DOPC. We also
prepared liposomes with mixtures of sphingomyelin and cholesterol. The lipid
suspensions were subjected to six freeze-thaw cycles followed by probe sonication
for 10 min in an ice bath to form small liposomes. Glass coverslips were cleaned
with a 3:1 solution of H2SO4/30% H2O2 for 40 min and then rinsed three times with
deionized water. Hydrophobic imaging spacers (0.12 mm x 9 mm, Electron
Microscopy Sciences) were placed on substrates to confine the lipid bilayers. Lipids
were deposited into the wells created by the spaces, and incubated for 20 min, R/T.
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To remove excess liposomes, sLBAs were washed by pipetting 1x PBS, ten times
over the lipids.

7.2.3 LPS interactions with sLBAs
Prior to treatment of sLBAs with LPS, the LPS stocks (5 mg/mL) were bath
sonicated for 15 min, diluted with PBS to a working concentration and then
sonicated an additional 15 min. The sLBAs were then treated with LPS, for 20 min at
R/T, unless otherwise specified. To perform experiments at elevated temperatures,
substrates with LPS were covered in glass petri dishes and a droplet of water was
added every 30 min to account for evaporated water and maintain the LPS
concentration. After incubation with LPS, the sLBAs were rinsed with 6 exchanges of
PBS and then assessed for fluidity using Fluorescence Recovery After
Photobleaching (FRAP).
7.2.4 Microscopy
Lipid bilayers were imaged with laser scanning confocal fluorescence
microscopy (LSCM) and fluorescence microscopy. Samples were kept hydrated and
never allowed to dry either during preparation or analysis. LSCM was performed with
an FV-1000 inverted optical microscope (Olympus) equipped with photomultiplier
detectors, and operated in ‘photon-counting mode’. Images were acquired using a
40x objective, at 1024 x 1024 or 2048 x 2048 pixels using a 12.5 µm/sec scan rate.
FRAP movies were obtained at 512 x 512, 10 µm/sec, using the manufacturer’s
provided software. Excitation was provided by a multi line Ar laser (488 nm, for
BODIPY), a HeNe laser (543 nm, for TR-DHPE), or a diode laser (635 nm, for
AlexaFluor 647). Band-pass emission filters were used (505-525 nm for BODIPY
and FITC; 655-755 nm for TR-DHPE and AlexaFluor 647. Images were processed
using ImageJ 1.48v.

7.2.5 Preparation of IMS beads
SPHERO™ carboxyl cross-linked magnetic particles were prepared for
covalent antibody coupling first by rinsing the beads in sterile PBS, and then
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washing twice in activation buffer (MOPS, pH 4.5). Beads were suspended (10
mg/mL) in fresh MOPS buffer, and 10 mg/mL of water-soluble carbodiimide, and
2.50 mg/mL of NHS-Sulfo was added to the solution and allowed to spin on a tube
rotisserie for 30 min, at 25 ˚C (R/T). Particles were washed twice in coupling buffer
(borate buffer, pH 7.2) and then re-suspended in fresh buffer. Required protein
concentration for particle coating was determined by assuming a smooth particle
surface, and a mean particle diameter of 1.22 µm. We used ten times the amount of
protein necessary to obtain a monolayer protein coat on the particles. Antibodies
were added to the bead suspension and mixed for 3 h at R/T. For anti-LBP particles
we used a 2:1 mix of pAb LBP to mAb LBP due to the low concentration of the mAb
LBP. The reaction was quenched for 1 h at R/T using a solution of 100 mM glycine +
0.05% BSA. The beads were rinsed with sterile PBS and then stored in 0.05% BSA
+ 0.02% sodium azide. Prior to use, beads were rinsed three times with PBS. To test
the activity of the beads, they were immunoblotted with mouse serum, using a
1:1000 dilution of beads in PBS as the primary antibody.
7.2.6 Immunodepletion of serum proteins from mouse serum
To explore how the lipoprotein composition of serum affects cell lines we
chose to immunodeplete the serum of the respective proteins ApoAI, ApoB, and
LBP. To do this 5 mL of mouse serum (Sigma Aldrich) was mixed with 70 mg of the
appropriate IMS beads. Beads were incubated with serum for 24 h at 4 ˚C on a
rotisserie, and the serum poured off and retained. Beads were rinsed two times with
PBS, and then the protein was eluted two times using 500 mM glycine buffer, and 30
min incubations at R/T. The separation process was repeated two more times for
each aliquot of mouse serum, until enough serum was obtained. This was repeated
for other lipoproteins using previously depleted serum (e.g. serum depleted of
ApoAI, was then used for depletion of LBP to obtain ApoAI (–) LBP (–) serum).
Serum was then assessed on SDS-PAGE gels and immunoblots to determine
whether lipoproteins remained in the preparations. Serum aliquots were syringe
filtered (0.2 µm) under laminar flow conditions prior to use in the cytokine assays.
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We also assayed the serum preparations for cholesterol levels using an
HDL/LDL/VLDL cholesterol assay kit (Abcam).
7.2.7 Cell lines
The IC-21 (TLR4 (+)) cell line was selected for the comparative study based
on the Mus musculus strain from which the TLR4(–) cell line was originally derived,
C57BL. Many studies use a similar murine macrophage, RAW 264.7, which is
derived from BALB/c mice, but the IC-21 cells are specifically described as
displaying normal macrophage behavior and antigens. TLR4(+) murine
macrophages were grown in Dulbecco’s modification of Eagle’s medium (DMEM,
Corning Cellgro®) supplemented with 10% fetal bovine serum (FBS, Sigma). Cells
were cultured to 90% confluence and then harvested using a silicone cell scraper
and split 1:4 as needed. LADMAC murine macrophages were grown in eagle’s
minimum essential medium (MEM, Corning Cellgro®) supplemented with 10% FBS
and spun down every 4 days to harvest the media supernatant. Harvested media
was sterile filtered using Autofil 0.1 µm vacuum flasks (USA Scientific) to eliminate
the possibility of mycoplasma contamination. Media for the 23ScCr, TLR4(–), murine
macrophages was made with DMEM + 10% FBS + 20% LADMAC media. No
antibiotics or antimycotics were used at any time for any of the cell lines. 23ScCr’s
cells were split 1:4 as needed. 23ScCr and IC-21 cells were harvested after the
seventh pass and then plated 1.0x106 cells per well in 12-well plates (Costar®).
Cells were incubated overnight at 37˚C, 5% CO2, and then rinsed two times with
serum free media prior to LPS exposure. All experimental groups for cytokine
assays were performed in triplicate.

7.2.8 LPS induced cytokine expression in TLR4(+) and TLR4(–) cell lines
For 12-plex cytokine assays, LPS stocks were sonicated for 15 min, diluted to
100 ng/mL in serum free media, resonicated and then applied to wells. To use a
serum supplemented system, sonicated LPS was spiked into mouse serum,
vortexed intermittently for 2 min, then incubated overnight at 4˚C to allow for
association of LPS with lipoproteins. Cells were rinsed two times with serum free
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media before application of media supplemented with 50% mouse serum + LPS.
Negative control cells received DMEM + 50% mouse serum, but no LPS.
For the experiments using the 25-plex assays, the ULTRA PURE LPS was
prepared as described above and added to the serum variants (experimental
conditions defined in Table 7.1) immediately prior to dosing the cells. This was
based on the low response we saw when using LPS that was allowed to incubate
overnight with serum (Figure A6.9). Delipidated serum (d.serum, MP Biomedicals)
was applied with the same method as whole serum, and was used as an additional
control.
Table 7.1 Experimental groups for cytokine studies.
Serum variants
50% mouse serum + 100 ng/mL LPS
50% mouse serum (no LPS)
50% delipidated mouse serum + 100 ng/mL LPS
50% delipidated mouse serum (no LPS)
no serum + LPS (buffer control)
no serum (no LPS) (buffer control)

Abbreviation
serum + LPS
serum
d.serum + LPS
d.serum
‘no serum’ + LPS
‘no serum’

Except for the time course assays (Figure A6.8 A), cells were incubated (37˚,
5% CO2) for 8 h, after which media supernatant was collected and assayed for
cytokine levels using either a 12-plex mouse inflammatory cytokines multi-analyte
ELISArray™ kit (Qiagen®), or a 25-plex Milliplex® MAP mouse cytokine/chemokine
Magnetic Kit (EMD Millipore). ELISA results were measured on a SpectraMax M5
(Molecular Devices) and plotted as the mean absorbance values with standard
deviations of the replicates. 25-plex cytokine results were obtained using a
MAGPIX® (Luminex), and standards were process per manufacturer’s instructions
using a 5 parameter logistic function (5PL) on myassays.com. The resulting
functions were used to calculate the concentration of expressed cytokines in pg/mL.
We also wanted to investigate the effect of FBS on murine cells, as previous
studies we did demonstrated that 50% murine serum caused the adherent IC-21 cell
line to detach from the substrate. Thus, by simply adding FBS we hoped to establish
a new method for detaching the cells. We assayed these simultaneously with the 25-
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plex cytokine kit to determine if there was an unforeseen effect caused by increasing
the FBS serum concentration to 50%.
7.3 Results and discussion
7.3.1 Model sLBAs: Increasing the complexity of sLBAs
We investigated the effects of LPS-induced hole formation using three
different compositions of complex bilayers: 25-50% cholesterol, 5-15%
sphingomyelin, and combinations of the two. We evaluated a physiologically relevant
(25%) to a high (50%) cholesterol concentration, to investigate the parameters under
which hole formation may be affected. The average concentration of sphingomyelin
in cell membranes is between 2-15%.67 While these two components alone do not
create a membrane mimetic bilayer, they are both essential to the formation of lipid
rafts and TLR4 signaling,67,68 and thus were the first choice of materials to use for
increasing bilayer complexity. Cholesterol is especially important in LPS trafficking.
Membrane cholesterol facilitates formation of lipid rafts, without which CD14dependent, LPS signal transduction could not occur.68 Presence of free cholesterol
in membranes has been linked to increased TLR4 induced inflammation,

69-71

and

less cholesterol led to attenuated expression of NFand inflammation.72-75
Sphingomyelin also has special roles in mediating signaling of LPS through
formation of cholesterol and sphingomyelin rich lipid rafts.74 It has been
demonstrated that a deficiency in sphingomyelin synthase caused reduced
recruitment of TLR4 and its co-receptors, also resulting in less expression of
NF76-79 There is also another mechanism by which sphingomyelin regulates
TLR4 mediated inflammation. When LPS activates the TLR4 receptor, the release of
the cytokine TNF, causes activation of the sphingomyelinase enzyme. This enzyme
works to break down the membrane sphingomyelin into simple ceramides.
Ceramides have been demonstrated to have an anti-inflammatory effect,80,81 which
may be due to the overall reduction in the total concentration of sphingomyelin within
the membrane; thereby inhibiting the formation of lipid rafts and continued TLR4
signaling.68,82
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7.3.2 Cholesterol model bilayers
In our experiments, lipid bilayers enriched with 25% (Figure 7.1) and 50%
cholesterol (Figure A6.2) incubated with LPS exhibited hole formation at most
concentrations. However, at the lowest concentration of LPS (25 µg/mL, Figure 7.1
D, and Figure A6.2 D), hole formation was completely inhibited in bilayers with both
25 or 50% cholesterol. 25 µg/mL LPS formed holes in the uniform DOPC control lipid
bilayers (Figure A6.1) under identical conditions, in the absence of cholesterol. This
study, validated in multiple repeats, clearly indicates that cholesterol can inhibit hole
formation even in this simplistic system under certain conditions. Cholesterol itself
also appears to be resistant to removal by LPS (Figure A6.3 A-C), as it remains on
the periphery of the LPS-induced holes in the sLBAs, though at this point we are
unable to quantitate the remaining cholesterol. Cholesterol could be functioning to
increase membrane rigidity and stabilize regions of the bilayers,83 so that at lower
concentrations of LPS, the mechanism of hole formation is inhibited.

Figure 7.1 DOPC lipid bilayers with 25% cholesterol. Bilayers (A-D) were incubated with 200,
100, 50, and 25 µg/mL (respectively) LPS O111:B4 for 20 min at R/T and then rinsed and imaged.

7.3.3 Spingomyelin model bilayers
The presence of sphingomyelin alone did not impede hole formation under
any of the concentrations tested. We observed hole formation under all
concentrations of LPS when incubated with model sLBAs enriched with 15% (Figure
7.2) and 5% sphingomyelin (Figure A6.4). From this we conclude that the presence
of sphingomyelin alone does not inhibit the formation of LPS-induced holes under
our experimental conditions. The structures of sphingomyelin and cholesterol are
very different. Cholesterol is a small rigid sterol with a polar group, while
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sphingomyelin has a chemical structure much more similar to DOPC.67 The
hydrophobic cylindrical shaped tails allow it to form bilayers, however the transition
temperature is comparatively high to DOPC. So at room temperature it may present
in a liquid-ordered phase.67 Our research has demonstrated that LPS interacts with
fluid phase bilayers with high lateral mobility. As sphingomyelin is likely to be
unevenly distributed through the bilayer due to its higher melting temperature, it is
likely that LPS is just interacting with the regions of DOPC to form holes.

Figure 7.2 DOPC lipid bilayers with 15% sphingomyelin. Bilayers (A-D) were incubated with 200,
100, 50, and 25 µg/mL (respectively) LPS O111:B4 for 20 min at R/T and then rinsed and imaged.

7.3.4 Mixed sphingomyelin and cholesterol model bilayers
We prepared sLBAs with varying combinations of sphingomyelin and
cholesterol and studied LPS induced hole formation under these conditions.
Interestingly enough, when we prepared sLBAs with 5% sphingomyelin and 50%
cholesterol (Figure 7.3), we noted that there were infrequent small holes formed at
both 50 and 25 µg/mL LPS (Figure 7.3 C-D). The appearance of these holes could
indicate a region where LPS interacted with a DOPC/sphingomyelin area, but this
needs further investigation. The borders of the holes were also not as sharp as
those that occurred in the cholesterol bilayers. While the infrequent appearance of
these holes (Figure A6.5 C-D) was consistent between repeat experiments, we
cannot be entirely certain that these are not an artifact which occurs due to washing
of the bilayers with the pipette. We have previously noted issues with the formation
of these holes in relation to the direction of fluid flow associated with the washing
mechanism.24 These results demonstrate that the pattern of hole formation changes
depending on the complexity of the lipid bilayer architecture employed.
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Figure 7.3. DOPC lipid bilayers with 5% sphingomyelin and 50% cholesterol. Bilayers (A-D)
were incubated with 200, 100, 50, and 25 µg/mL (respectively) LPS O111:B4 for 20 min at R/T and
then rinsed and imaged.

7.3.5 Effect of temperature and LPS serogroup on hole formation in DOPC bilayers
Historically, we have performed all of our characterization studies at R/T (25
˚C), when DOPC is in a disordered fluid phase (transition temperature = -20 ˚C). We
investigated the ability of multiple types of LPS (from pathogenic E. coli isolates) to
form holes in sLBAs at room temperature, and discovered that there was no induced
hole formation (Figure A5.5) in any LPS subgroup except O111:B4.84 We
speculated that using physiologically relevant temperatures (37 ˚C = humans, ~40
˚C = ruminants) may change the behavior of LPS micelles with these bilayers. The
positive control, LPS O111:B4, formed holes at all temperatures (Figure 7.4 A and
7.4 E), though frequency of hole formation actually appeared to decrease at 40 ˚C.
In the experimental groups, we found that 25 µg/mL LPS, isolated from pathogenic
E. coli serotypes (O104:H4, O111:H11, O157:H7), had absolutely no effect on the
bilayers at R/T or at 37 ˚C after two hours of exposure (Figure 7.4). This data is in in
agreement with our previous results with nine different LPS types at R/T for 20
minutes each, where we found no defects in the bilayers, or decreases in bilayer
fluidity (Figure A5.5).84 However, when temperature was increased to 40 ˚C, all of
the pathogenic LPS types induced hole formation. The hole formation of LPS
O111:H11 most matched that of O111:B4 at 37 ˚C (Figure 7.4 A,E,G), while the
frequency and size of the holes in LPS O104:H4 and O157:H7 sLBA systems were
more closely matched (Figure 7.4 F and H).
Our findings demonstrate a temperature-dependence in hole formation
induced by LPS, which differs between LPS subtypes. Even though these
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experiments were performed in the homogenous DOPC bilayers, the results may
have physiological relevance. Our results raise many interesting questions about the
mechanisms of bacterial virulence, ruminant physiology, as well as immune studies.
This is especially significant in the context of ruminant physiology, as cattle are
natural hosts for this pathogen. The temperature of the rumen in cattle is 39 ˚C.
Cattle get the majority of their protein from digesting bacteria in one of their
stomachs. The specific LPS subtypes we are examining are from virulent, acid
resistant pathogens, which are not digested, but instead get passed through the
digestive system of cattle. It would be interesting to determine if the same
mechanism of hole formation occurs at this temperature (39 ˚C) as well. If the
difference of a single degree Celsius made the difference between hole formation
vs. no hole formation, it could reveal a new mechanism by which these pathogens
evade digestion. This is also important since many studies use the LPS O111:B4 as
an immune stimulant.17 Thus, the temperature dependence of LPS action, and its
physiological relevance need further investigation. These results, show for the first
time, the differential activity of LPS with sLBAs at increasing temperatures.

Figure 7.4. The effect of temperature and serogroup on LPS-induced hole formation in
sLBAs. TR doped DOPC bilayers were incubated with 25 µg/mL of LPS for two hours at room
temperature (not shown), 37 ˚C (A-D), and 40 ˚C (E-H). data courtesy of K. Swingle & G. Montaño
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7.3.6 Cell studies: effect of murine serum on LPS-induced cytokine expression
Model bilayers are an effective tool for studying molecular interactions and
lipid rafts.85 However, they are limited in their capacity to assess the physiological
response. To further investigate the question of LPS induced hole formation and how
it may affect living systems, we advanced to cells in order to study these
mechanisms. All of our investigations with sLBAs have been in buffer to date, but
this is not representative of the complex milieu in vivo. LPS is not presented to cells
as micelles, but is instead delivered to the receptors by serum carrier proteins. 26,31,8688

Therefore we wanted to determine if the manner in which LPS is presented affects

the outcome in cells.
To determine this we picked two murine macrophage cell lines to perform our
experiments in. One line is capable of normal inflammatory response (TLR4+) and
the other is a knockout cell line (TLR4-) which has been demonstrated to not
respond to LPS stimulation.89 Using these cell lines, we then looked at LPS
presented under three conditions: buffer, serum, and delipidated serum (conditions
in Table 7.1). Our first steps to assess TLR4 independent LPS signaling were to
optimize the exposure time and LPS concentration. There is a broad array of
conditions by which researchers expose LPS to cells from the picogram-microgram
range, anywhere from 2-24 hours.17,41,90,91 We did our initial experiments with LPS
diluted in buffer, over a time course, and determined that 100 ng/mL LPS, for eight
hours (Figure A6.8 B) would be sufficient for examining differential presentation
methods of LPS. At this time, we saw the hallmark cytokines, TNF and IL-6, of an
LPS-induced inflammatory response.92
Using these optimized parameters, we performed further experiments to
compare LPS presentation in the different serum conditions. To examine if there was
a different response when LPS was presented in serum we pre-incubated LPS with
serum overnight and then exposed cells to the mixture. We discovered that cytokine
induction was almost completely inhibited when LPS was ‘presented’ to the cells in
mouse serum, as there was very little difference in the cytokine profile between the
50% mouse serum with LPS and serum with no LPS (Figure A6.9). This data is in
agreement with those published by Flegel et al.93 when they performed a similar
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experiment on human monocytes, and pre-incubated their LPS with serum. They
saw a reduced expression of cytokines in their experimental group as compared to
their control with no lipoproteins. Thus, presentation of LPS in serum negatively
impacts cytokine production, and the amount of time that LPS is allowed to incubate
with serum prior to dosing cells also impacts this mechanism.93 The investigators
concluded that LPS association with serum lipoproteins (specifically LDL and HDL)
was responsible for this attenuated cytokine expression. This association with HDL
is confirmed by data which shows that LPS injected into rats or mice, localizes to the
liver within 5-10 minutes of injection.48,49 This result is due to the association of LPS
with serum lipoproteins such as HDL, LDL, and LBP. However, the role of these
serum carrier proteins is not always protective. These proteins are also responsible
for carrying LPS to TLR4 receptors and inducing the innate immune response. 94
7.3.6.1 No serum (buffer control) group
There is a dramatic pattern in the increase of TLR4(+) cytokine expression
when LPS is added to the ‘no serum’ group and incubated with the cells (Figure
7.5). Since the protective mechanism of lipoproteins is absent from this group, this is
the response we would expect to see. The pro-inflammatory cytokines TNF, IL1and IL-6 are all consistently upregulated in response to the LPS stimulation
(Figure 7.6 A,B) in this group. We also noted minor increases in the levels of IL-12
and IFN, which probably just demonstrates the beginning of upregulation for these
cytokines.94 This pattern of expression compared similarly to our previous
experiments using a buffer control to deliver LPS (Figure A6.8 B). Some differences
in expression profiles are expected between our initial experiment in buffer and
these results because we used a different assay kit for each of these studies, and
also used ultra pure LPS for the comparative experiments. LPS is often purified with
phenol and the resulting product is found to be contaminated with proteins or other
PAMPs,95,96 which may attenuate or induce the cytokine expression, and we chose
to avoid any effects associated with such contamination for these experiments.
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Figure 7.5. The effect of serum on LPS induced cytokine expression. ‘no serum’ indicates that
only DMEM + buffer was used as a negative control or to deliver LPS. Delipidated serum (d.serum)
was also investigated both with and without LPS. The final condition was 50% mouse serum (serum).
Results are plotted as the MFI with standard deviations of three replicates.

7.3.3.2 Delipidated serum group
In the TLR4(+) cells we saw the highest level of cytokines expressed in the
d.serum groups (Figure 7.6 C,D). Interestingly, d.serum with no LPS was able to
induce expression of TNF, IL-1and IL-6, with some induction also seen in IL-12
and IFN (as compared to the no serum control, Figure 7.6 A). When LPS was
prepared in d.serum, the concentration of TNFincreased by a magnitude of 1.5x.
IL-1increased by 2x, and IL-6 increased 2.4x. So overall, we saw a significant
increase in cytokine levels (approximately 2x) that of the negative LPS control
(Figure 7.6 D). There are a couple possible explanations of this data. (1) LBP is not
actually a lipoprotein and so the effect of delipidating the serum would not inhibit the
function of this protein. In fact, the serum concentration of LBP in mouse serum is
quite high,41 and when LBP was added to buffer, it was demonstrated to enhance
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the stimulation of CD14 cells as much as 100-1000x.41,97,98 (2) The inflammatory
cytokine levels in the no LPS group are also high, especially in comparison to the ‘no
serum’ and serum control groups (Figure 7.6 A,F). We have previously
demonstrated that the serum of mice can exhibit an immune responsive to LPS
antigens (Appendix 3, Tables A3.1-A3.13, pre-inoculated immunoblots), thus
indicating some level of exposure to endogenous endotoxin in their controlled
environment. It has also been documented that commercial preparations of fetal
bovine serum can be contaminated with endotoxin.99 From this, it does not seem
unreasonable to assume that mouse serum could also be contaminated with LPS.
Therefore, the addition of more LPS to the system would effectively increase the
cytokine expression as we saw in the d.serum + LPS group. Endotoxin
contamination is a often a problem in the laboratory setting.100,101 While we find this
to be a likely reason for the elevated cytokine levels, we have not confirmed this with
an endotoxin test. This is another consideration that should be taken into account
when designing in vitro studies to assess cytokine expression.
7.3.3.3 Whole serum group
As predicted, we saw very minor, if any, cytokine induction between the LPS
group and the negative serum control group (Figure 7.6 F,G), when the antigen was
presented in serum. There was no difference in the trend between either of the
groups with or without LPS, irrespective of cell type. Together these results imply
that there is a difference in critical cytokine expression depending on how
amphiphilic LPS is presented. This is especially true when comparing the results
between the LPS groups with ‘no serum’ and serum, as there is a clear attenuation
of cytokine induction in the serum + LPS group as compared to the ‘no serum’ + LPS
groups and the negative controls. Beyond any argument of which is the correct
methodology or choice of cell line, this result iterates a simple yet salient fact:
association of amphiphiic PAMPs with carrier proteins in aqueous serum has a
major impact on innate immunity.
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Figure 7.6 Subset graphs of LPS-induced cytokine expression. Y-axis is the mean fluorescence
intensity (MFI). Results are plotted as the MFI with standard deviations of three replicates. Numbers
above each bar correlate to the calculated concentration of cytokine expressed in pg/mL Bars without
numbers above them fall outside of the range of the 5PL curve and the concentration cannot be
directly calculated. TLR4(+) response is on the left side of the graph and TLR4(-) response is on the
right side. Graphs A,C,F (left side) are the variations of serum with no LPS, while graphs B,D,G are
the same corresponding variations of serum with LPS exposure.

This conclusion is supported by similar studies in the literature that have
looked at expression of cytokines in murine macrophages (Table 7.2). For instance,
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Lamping et al.41 added merely 1% serum to their LPS preparations and noticed a 2fold reduction in expression of TNFCavaillon et al.102 investigated the effect of
lipoproteins on cytokine expression and determined supplementing with lipoproteins
could reduce the levels of expressed TNF and IL-6 by more than a factor of 10.
One of the more interesting things we did see was induction of IL-6 in the
TLR4(–) cells. The levels of expression between the negative control, and the LPS
group were not significantly different. The exact reasons for this induction are not
known, but warrant investigation in future studies. Our closest available parallel to
this is a study performed in buffer by Zughaier et al.103 In their assessement of
myeloid differentiation factor 88 (MyD88, a requisite cofactor for TLR4 signaling)
they determined that no MyD88-dependent or independent signaling occurred in the
same TLR4(–) murine cell line when they stimulated with LPS.
Table 7.2 Murine macrophage cytokine responses seen as a result of E. coli LPS
stimulation
Shanmugam et
Lamping et al.,
Cavaillon et al., 1990
Our research
Reference

Cell Type: IC-21
Cytokines and
Chemokines

Serum +
LPS

Free
LPS

(pg/mL)

al., 2012
Cell Type: RAW
264.7
Unknown

1998
Cell Type: RAW
264.7
1% serum
+ LPS

IDV

IL-1α
TNF-α
IL-6
IL-12 (p70)
IFN-γ

12.62
3.26
13.71
9.32

90.96
26.81
52.63
1.45
2.70

6000
8500
15000
7000
*

RANTES
MIP-2
MIP-1b
MIP-1a
KC
MCP-1
IP-10
IL-9
G-CSF
GM-CSF

11.31
3.56
7.83
16.94
99.90
258
-

0.36
553
934
1002
5.12
65.94
54.49
137
16.31

13000
*
22000
20000
*
20000
*
*
10000
0

Free
LPS

ng/mL
*
2
*
*
*

Cell Type: Primary
murine macrophages
LP + LPS

Free LPS

U/mL (activity)
*
4
*
*
*

*
84
120
*
*

*
1460
120
*
*

LP = lipoproteins, - = does not fall within the calculable assay range, * = not measured, IDV = defined as the
density of spots compared to the density of positive controls
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7.3.3.4. Comparison of chemokine expression
Since we are investigating the potential for alternative signaling mechanisms
of LPS in serum free systems, we also measured the profiles of several chemokines
in our serum groups (Table 7.1) and compared them to what was available in the
literature (Table 7.2, Shanmugam et al.104). Shanmugam et al.104 represents one of
the few studies that measured chemokine profiles in murine cells, however the exact
conditions (serum or ‘no serum’) of this experiment were not described. By
comparing the outcomes of this study with our own results (a subset shown in Table
7.2) it appears that Shanmugam et al.104 were most likely using a serum free
system. Under the “Free LPS”, aka (‘no serum’) conditions, the results of this study
and ours are very consistent and the only disparity is in the measurement of GMCSF (16.31 pg/mL in our assay vs. zero in theirs). Since the cell lines are different
and the sensitivity of each assay kit and associated antibodies is different, this may
simply be an experimental limitation rather than observed difference.
When we look at the response of these chemokines in the TLR4(+) vs
TLR4(–) cell lines, a different expression profile is revealed. We saw no calculable
levels of RANTES, GM-CSF, or macrophage inflammatory proteins (MIP), MIP-2,
MIP-1b, and MIP-1a in the TLR4(–) cells (Table 7.3). These chemokines serve
primarily as signaling molecules to recruit neutrophils and granulocytes to the site of
infection in vivo. When looking at KC, MCP-1, and IL-9 there are significantly higher
levels expressed as compared to the TLR4(+) cells. KC and MCP-1 also both
function as chemo-attractants to induce chemotaxis in neutrophils to the site of
inflammation. IL-9 functions as a mediator of apoptosis, and when comparing the ‘no
serum’ to the serum groups in the table, the protective effect of serum in both cell
lines becomes more clear.
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Table 7.3. Calculated cytokine/chemokine expression (pg/mL) in IC-21 and 23ScCr serum/’no serum’ LPS groups.
TLR4 (+)

RANTES

MIP-2

MIP-1b

MIP-1a

KC

MCP-1

IP-10

IL-9

G-CSF

GM-CSF

‘no serum’ + LPS

0.3553

553.16

934.5

1002

5.12

serum + LPS

-

11.31

3.563

-

7.83

65.94

-

54.49

137.1

16.31

16.94

99.89

-

257.9

-

‘no serum’ + LPS

-

-

-

-

73.4

195.5

-

164.1

124.0

-

serum + LPS

-

-

-

-

54.3

35.28

64.12

-

324.6

-

TLR4 (-)

7.4 Conclusion
The overarching theme in this work is that LPS can have differential
interactions with systems when presented with its physiological serum carrier
proteins. We have demonstrated that LPS micelles in buffer can cause hole
formation in cholesterol and sphingomyelin enriched lipid bilayers. This supports our
theory that LPS may be having a similar dynamic effect when presented in buffer to
in vitro systems. The protective effect of serum lipoproteins on LPS induced
inflammation is well documented within the literature, but presenting LPS in buffer to
prime immune cells is still a common theme. We have shown here through the use
of TLR4(+) and TLR4(-) cells, that there is a distinct difference between presenting
LPS to cells in buffer versus serum, where native lipoproteins offer a protective
effect. We additionally see high expression when we use d.serum, but it was much
higher than the no serum control, which we concluded was primarily due to the
presence of LBP transferring LPS to CD14. Thus, TLR4 signaling depends on the
composition of serum used. The implications of this should be considered when
designing in vitro studies which utilize LPS.
7.5 Future Directions
Our results clearly demonstrate that 1) increasing complexity of lipid bilayers
affects formation of LPS-induced membrane deformations and 2) presentation of
LPS dramatically modifies the cytokine/chemokine expression in murine cells with
TLRs. These results also raise several questions, warranting further investigation in
each of these experimental models.
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While it is clear that LPS interacts with enriched sLBA systems, we would like
to further examine this mechanism using several methods. First, it is necessary to
evaluate the incorporation of sphingomyelin into the bilayers to assess the
distribution seen in the bilayers. This is especially important for addressing the
asymmetrical hole formation we saw in Figure A6.6. This could be easily performed
using an NBD-labeled sphingomyelin, which we previously demonstrated with
cholesterol (Figure A6.3). We have also previously used AFM as a tool to
characterize DOPC bilayers. By performing topographical analysis of the enriched
bilayers, more information about their composition and distribution of the lipid
components within, both before and after incubation with LPS, would be available.
While AFM should prove efficient enough to characterize the holes, the addition of a
fluorescently labeled protein after rinsing away LPS would also help to determine
whether any unlabeled cholesterol or sphingomyelin remained in the holes.
A systematic approach for characterizing the size and statistical distribution of
the holes formed in the bilayers should also be developed and implemented. A
recommended platform for this would be Matlab, as the software is readily available,
and the image analysis tools could easily facilitate this. This tool would serve to
provide necessary information about LPS micelles and the interactions they have
with a variety of lipid compositions. Implementation of this would allow us to further
analyze the differences that we saw in the temperature- and serogroup- dependent
formation of holes (Figure 7.4).
A direct link between the interaction of LPS with complex lipid bilayers, and
cell membrane damage has already been implied by us. However, a system to
record whether membrane damage actually happens as a result of LPS incubation
would serve to complement the data seen in both the biophysical and cytokine
studies. A relatively simple experiment has been previously performed by Cervantes
et al105 to investigate the membrane damaged induced by Listeria monocytogenes.
This experiment could easily be applied to our TLR4(-) cell system to determine
whether LPS forms holes in cell membranes. First, the cytosol of macrophages is
stained with calcein-am, and free dye is rinsed away. Then cells are incubated with
LPS and propidium iodide. Calcein leakage and propidium iodide uptake could be
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measured via flow cytometry, and confirmation could be obtained with fluorescence
microscopy. This experiment would be crucial to providing evidence of LPS-induced
membrane damage.
A comprehensive review of the literature should be performed and published
to document the recorded cytokine and chemokine expression profiles under specific
conditions. Though it is well documented that experimental conditions have a direct
effect on expressed cytokines, the conditions that researchers use to introduce LPS
to cell systems, is often not made clear. Thus it can be difficult to make direct
comparisons between results. To further elucidate the results we have documented,
analysis of the serum lipoproteins components should be performed to help explain
some of the differences in expression profiles. While this work has already begun,
more development is necessary in order to completely evaluate the results seen in
the cytokine expression profiles of the mouse serum variants, which were depleted
of specific lipoproteins.
Finally, this work needs to be brought full circle to facilitate better detection
methods for LPS and amphiphiles in general. PAMPs are key indicators of early
infection, and the ability to detect infections and diseases earlier will lead to better
outcomes for patient treatment. By characterizing the way PAMPs interact with
membranes, be it direct or indirect, we can develop better surfaces to facilitate their
detection.
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Chapter 8.
Conclusions and Future Directions
8.1 Conclusions
8.1.1 Development of antibodies and antigens for assay development
As discussed in chapter 3, we have developed a suite of purified antigens
(LPS, O-ag and lipid A) from six serotypes of STEC for the purpose of generating
highly specific O-ag monoclonal antibodies. Currently available antibodies
demonstrate high levels of cross reactivity between the conserved regions of LPS.
We are working with the Dana Farber Cancer Institute and the University of
Nebraska-Lincoln to develop a suite of targeted monoclonal antibodies that target
the O-Ag of these serogroups of STEC and can therefore facilitate discriminative
detection in our assay platform. During development it is important to consider the
biochemical nature of the antigenic target. As the case of LPS has demonstrated,
the antigen deposits in different configurations depending on the substrate used
during testing. This has implications for the resulting antibodies, which may prefer
conformational epitopes found in LPS antigens.1,2 Thus, the use of physiologically
relevant testing schemes, which expose only the O-ag maximizes the chances of
obtaining specific antibodies and ensuring their success in physiological assays. The
resulting antibodies will be implemented into our membrane insertion assays to
increase detection signals and facilitate discriminative detection. Additionally, our
collaborators would like to adhere the antibodies to the surface of latex agglutination
beads to use in their lab. It is our intent to deposit both the methods for antigen
development and the resulting hybridomas into a repository where other groups
interested in STEC research can have low cost access to them.

8.1.2 Implication of LPS-induced hole formation in sLBAs
The discovery that LPS could reorganize sLBAs was highlighted the
importance of characterizing the interactions of target antigens with the environment
in the detection platforms. Additionally, it gave us new tools for membrane
patterning, which can be used to develop better detection surfaces for both
amphiphiles and proteins alike. The rearrangements induced in sLBA systems by
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LPS under various conditions has demonstrated that biological molecules can
behave in unpredictable ways, and thus it is critical to characterize their behavior to
ensure assay performance. The implications that this discovery has left us with are
far reaching into the fields of biological materials, microbiology, immunology, and
assay development. The knowledge that hole formation is dependent on time,
concentration, temperature, ionic conditions, and LPS subtype raises extremely
interesting points about the mechanisms of bacterial virulence. Additionally, behavior
of multiple subtypes of LPS at different temperatures or under varying conditions
begs the question of how this molecule responds in vivo during infection. This
information not only influences detection strategies but also has an impact on the
development of vaccine adjuvants and in vitro immune studies.

8.1.3 Membrane insertion of LPS
Membrane insertion has demonstrated our ability to discriminatively detect
LPS. The hydrophobic association of lipid A with the lipid bilayer during membrane
insertion implies that the O-ag can be presented more effectively to detection
antibodies. Additionally, by implementing an O-ag specific antibody we can increase
the sensitivity of detection, validating the need for better reagents. This amphiphilic
nature of the molecule demonstrates to be an advantage for discriminative detection,
but a hurdle to quantitative measurements. The amphipathic properties of LPS need
to be accounted for during sample preparation in order to maximize the homogeneity
of the micelles to ensure statistically significant results. Using these techniques, we
have demonstrated that membrane insertion of LPS works in minimally prepared,
highly complex samples like beef lysates. Lastly, we developed a model system to
further characterize and visualize the interactions of amphiphiles in enclosed lipid
systems. The experiments done within the flow-cell model provide an opportunity for
cross-talk between fluorescence-based detection assays and imaging systems. This
can be used as an external method to validate assay performance, characterize
antibody-binding behavior, and investigate new functional surfaces within the context
of membrane insertion assays.
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8.1.4 Differential presentation LPS in vitro
The inflammatory effects of LPS both in vitro and in vivo are presented in the
existing literature. In vivo, the primary response is that LPS is immediately taken up
by serum binding proteins, such as HDL, and carried to the liver for clearance or
presented to TLRs for innate immune induction. LPS being amphiphilic cannot exist
in monomeric form in blood. Yet, this biochemistry and the physiological association
with carrier proteins are conveniently ignored in the design and execution of cell
studies. Using TLR4(+) and TLR(-) cells, we have successfully demonstrated that
the expression profiles of cytokines and chemokines generated in response to LPS
induction vary significantly depending on the serum solution LPS is presented in.
Additionally, the expression level of cytokines can be impacted simply by altering the
amount time of time LPS is allowed to pre-incubate with serum, as it determines the
level of association with serum proteins prior to exposure. These results indicate that
there are many interactions between LPS amphiphiles and cells that are still not well
characterized. This is especially important to consider when designing studies aimed
at being translational to in vivo models, as the observations we witness in vitro can
be drastically altered based on experimental conditions.

8.2 Future directions
Taken as a whole, this work describes from beginning to end, the process
and considerations for developing discriminative targeted assays against the O-ag of
LPS from STEC. The principles we have established here can be transitioned to
other amphiphiles. Summarized below are some suggested advancements and
applications for this technology. Some of these new ideas are already being tested,
while others are just concepts.

8.2.1 Advancements for screening antibody clones
In Chapter 4, we a presented a new method specifically designed to screen
mouse serum or hybridoma culture supernatants for specific antibodies against LPS
O-ag. There have been many attempts in the literature to address this, but in general
using purified proteins3 or special functionalization techniques4,5 is going to be costly
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and time consuming. We simplified the functionalization strategy using the principle
of lipoprotein capture of LPS.6,7 When ELISA plates were coated with 50% serum we
were abled to demonstrate O-ag specific detection of LPS using monoclonal
antibodies. The preliminary results have shown comparatively lower standard
deviations between the replicates indicating that LPS binds the serum in a set ratio.
The serum lipoproteins bind and effectively sequester the lipid A antigen, which
minimizes cross reactive binding during the screening. Serum is also plentiful, easy
to obtain, relatively inexpensive, and serves as an additional blocking reagent to
minimize nonspecific interactions of the detection antibody. Using physiological
methods to present the O-ag to the antibodies will maximize the likelihood that
isolated antibodies will be specific to the target antigen. The results of this new
method are promising, but the technique is still in its infancy. Eventually, we hope to
be able to implement this as a new method to improve specificity of antibodies
against the O-ag.
8.2.2 Improved membrane insertion methods for LPS detection
Currently, membrane insertion of LPS is presented as a reliable, qualitative
method for detection. There are a few techniques that could be implemented to
achieve faster, and more repeatable results. Treating the LPS standards with a weak
solution of surfactant or solvent prior to running the assay is a relatively simple
option. This treatment could serve to homogenize the size distribution of LPS
micelles. We have previously performed other assays with weak solutions of
buffered Tween, DMSO and ethanol8,9 and have not seen any disturbance of the
lipid bilayers. In fact, the addition of Tween during the sonication of LPS samples
helped improve the consistency and reproducibility of our LPS ELISA screening
assays.
Passive diffusion of the LPS into the lipid bilayer is an inherently slow
process, and strategies to enhance this association may help decrease time per
assay. We have observed that using a mixture of fluid-gel phase lipids will cause
LPS to migrate to the interface of those lipids in a rapid manner.10 While the process
still technically relies on diffusion, there is likely an exposed hydrophobic region in
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the effectively ‘taller’ lipids, which acts as a driving force to attract LPS. This process
could easily be imaged using the flow cell model that we have established and then
implemented into the waveguide platform if it is effective. Increasing the speed of
these assays would facilitate higher throughput, testing of more samples, and faster
implementation of preventative strategies for food safety,
8.2.3 Membrane insertion for detection of Shiga toxin
The virulence of pathogens is co-dependent on other biomarkers and toxins
as well. In the case of the STEC, the primary virulence biomarkers are Shiga toxins,
more specifically, Shiga toxin 1 (stx1) and Shiga toxin 2 (stx2). Shiga toxins are
pentameric protein toxins, which bind an amphiphilic receptor called
globotriosylceramide 3 (Gb3) on the surface of host cells.11 To date, methods for
direct and discriminative detection of stx1 from stx2 has been limited by the
availability of specific antibodies against both variants of the proteins. To facilitate
waveguide-based discriminative detection of stx1 and stx2, our original approach
was to use a synthetic variant of Gb3, but there was no commercial source for it.
Instead, we performed detection of Shiga toxin by using biotin-avidin chemistry to
link antibodies to the surface of the lipid bilayer, to create a capture site. To date, the
limitation of available antibodies has only allowed for non-specific capture. It has
been demonstrated that LPS from E. coli serogroup O107 and O117 will selectively
bind stx2, but not stx1.12 Isolating this LPS and incorporating it into a membrane
insertion assay for capture of stx2 is a natural path forward for our work. A capture
antibody could be incorporated for stx1, and specific mAb’s could be used to
facilitate discriminative detection. This also highlights the advantage of using a
platform, the waveguide biosensor that is amenable to various transduction schemes
in parallel. This assay still pairs well with membrane insertion for detection of LPS,
provided that O-ag specific antibodies are used. This approach takes advantage of
the natural association of LPS with bilayers both to facilitate specific detection of
LPS and create a discriminate ligand-binding site for stx2. Since individual capture
methods are used for stx1, stx2, and LPS, the assay would be easy to multiplex
using different fluorescent labels or quantum dots. The prevalence of virulent strains
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of LPS O107 and O117 is low,13 but should they be present in a sample, a drawback
to this system is that it could not be tuned for the detection of these two serogroups.
However, the positive identification of Shiga toxin is enough to determine the
pathogenicity of bacterial isolates.
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Appendix 1
Section A1.1 Additional information for Chapter 1

Figure A1.1 Structures of Gram-negative lipid A molecules. Common substitutions are indicated
by grey lines. Endotoxic activities is indicated by ‘+++’ for strongest activity and ‘-‘ for no activity
and is intended only as a qualitative guide only. Reprinted from Erridge et al. 2002 with
permission from Elsevier.
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Appendix 2
Section A2.1 Chapter 3 supplementary tables and figures
Table A2.1. Extracted and purified amounts of LPS from dried bacteria.
Strain

O-group Dry Bacteria (g)

Crude Extract (g)

Starting Product (g)

Final Product (g)

DEC10B

O26

11.1

1.10

0.40

0.067

B8227-C8

O45

22.2

3.55

0.54

0.025

MT#80

O103

22.4

1.30

0.48

0.078

TY-2482

O104

38.9

1.07

2.45

0.028

0201 9611

O111

28.9

1.81

1.45

0.121

MDCH-4

O113

36.5

5.88

4.31

0.021

GS G5578620

O145

53.3

4.90

3.98

0.013

Crude extract has been phenol extracted from dried bacteria, dialyzed, and freeze dried. Starting product is the
amount of purified extract post-ultracentrifugation that went into CTAB/ethanol precipitation and the resulting
final dry product weights after removal of nucleic acids.

Figure A2.1. Immunoblots of LPS antigens. Results for O-ag and whole LPS are summarized in
Table 3.2, and lipid A results are summarized in Table A1.2. Rows are the serogroup of LPS and
columns are the antigenic portion being tested against the designated antibody.
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Table A2.2. Immunoblotting antibody activity against isolated lipid A fractions from LPS
antigens.

Antigen
LPS lipid A

Antigen Serogroup
O111:B O157 O26 O45 O103 O104 O111 O113 O145
ID # Antibody
4
1 Lipid A - O157
++
++ +++ − +++
−
++
+
−
2 LPS - O157
++
++ +++ + +++
−
+++
+
−
3 E. coli 'O' & 'K'
4 E. coli LPS

+

+

++

+

++

−

++

+

−

+

+

++

+

++

−

+

+

+

5 O104
6 O26

−

+

++

−

++

−

−

−

−

+

+

+

−

+

+

−

−

−

7 O45
8 O103

−

−

−

+

−

−

−

−

−

−

−

−

−

−

−

−

−

−

9 O111
10 O145

−

−

−

−

−

−

+++

−

−

−

−

−

−

−

−

−

−

11 O157
12 O121

−
−

−
−

−
−

−
−

−
−

−
−

−
−

−
−

−
−

+++ = intensely positive, ++ = moderately positive, + = weakly positive, − = negative result.

1
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Figure A2.2. Eosin stained SDS-PAGE of LPS extracts. Lane (1) protein standard (2) 94µM BSA,
lanes 3-6 LPS O157: (3) 3.33mg/mL, (4) 2.5mg/mL, (5) 500µg/mL, (6) 250µg/mL, (7) 1:1 dilution of
O157 O-ag prep, (8) 1:1 dilution of O157 lipid A prep. Lanes 9-12 LPS O111:B4: (9) 3.33mg/mL, (10)
2.5mg/mL, (11) 500µg/mL, (12) 250µg/mL, (13) 1:1 dilution of O111:B4 O-ag prep, (14) 1:1 dilution of
O111:B4 lipid A prep. Black arrows indicate the location of bands. 1 and 2 are the predicted core
polysaccharide of LPS O157, 3 is the O-ag ladder pattern of LPS O111:B4, 4 is core polysaccharide
and 5 is the lipid A.
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Appendix 3
Section A3.1 Longitudinal results for mouse serum screens
Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)
No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.1. ELISA results for a BALB/C mouse in O45 serogroup. Three serum screens were
performed over time on a BALB/c mouse that was repeatedly immunized with serogroup O45
bacterial antigens. ELISA results performed on June 30, 2015 were performed to analyze mouse
immune response after an extended period. No immunoblot was performed for this mouse.
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Table A3.1 Immunoblot summary analysis of BALB/c mouse inoculated with O45 bacterial
antigens.
BALB/c mouse
PreInoculated
July 16, 2014

Sept. 04, 2014

LPS subtype
O111:B4
O157
O45
1x PBS/5% BSA

Whole LPS
+
-

PostInoculated
O-ag
+
+
-

Lipid A
+
+
-

Whole LPS
+
+
++
-

O-ag
+
+
+
-

Lipid A
+
+
+

O111:B4
+
+
++
++
O157
+
+
+
+
O45
1x PBS/5% BSA
No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’ Blue
highlighted regions indicates the targeted antigen.

Pre-inoculated

Post-Inoculated

July 16, 2014

Sept. 04, 2014

Figure A3.2. Images of longitudinal dot blots for a BALB/c mouse in O45 serogroup.
A summary analysis of these images is presented in Table A3.1.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.3. ELISA results for a C57BL/6 mouse in O45 serogroup. Two serum screens were
performed over time on a C57BL/6 mouse that was repeatedly immunized with serogroup O45
bacterial antigens.
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Table A3.2 Immunoblot summary analysis of C57BL/6 mouse inoculated with O45 bacterial
antigens.
C57BL/6 mouse
PreInoculated

July 16, 2014

Sept. 04, 2014

PostInoculated

LPS subtype
O111:B4
O157
O45
1x PBS/5% BSA

Whole LPS
+
+
-

O-ag
+
+
+
-

Lipid A
-

Whole LPS
+
+
++
-

O-ag
+
+
+
-

Lipid A
+
+
-

O111:B4
O157
O45
1x PBS/5% BSA

+
-

-

-

-

++
-

++
-

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’ Blue
highlighted regions indicates the targeted antigen.

Pre-inoculated

Post-Inoculated

July 16, 2014

Sept. 04, 2014

Figure A3.4 Images of longitudinal dot blots for a C57BL/6 mouse in O45 serogroup.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.5. ELISA results for a Swiss Webster mouse in O45 serogroup. Two serum screens
were performed over time on a Swiss Webster mouse that was repeatedly immunized with serogroup
O45 bacterial antigens.
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Table A3.3 Immunoblot summary of Swiss Webster mouse inoculated with O45 bacterial
antigens.
Swiss Webster mouse
PreInoculated

July 16, 2014

Sept. 04, 2014

PostInoculated

LPS subtype
O111:B4
O157
O45
1x PBS/5% BSA

Whole LPS
+
-

O-ag
+
+
+
-

Lipid A
+
-

Whole LPS
+
-

O-ag
+
+
+
-

Lipid A
-

O111:B4
O157
O45
1x PBS/5% BSA

+++
+
-

-

-

+
-

-

+
-

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’ Blue
highlighted regions indicates the targeted antigen.

Pre-inoculated

Post-Inoculated

July 16, 2014

Sept. 04, 2014

Figure A3.6 Images of longitudinal dot blots for a Swiss Webster mouse in O45 serogroup.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.7. ELISA results for a BALB/C mouse in O26 serogroup. Two serum screens were
performed over time on a BALB/c mouse that was repeatedly immunized with serogroup O26
bacterial antigens. This mouse was selected for hybridoma fusion after the second screening was
completed.
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Table A3.4 Immunoblot summary of a BALB/c mouse inoculated with O26 bacterial antigens.
BALB/c mouse
PreInoculated

June 23, 2015

Sept. 02, 2015

PostInoculated

LPS subtype
O111:B4
O157
O26
1x PBS/5% BSA

Whole LPS
+
-

O-ag
+
+
-

Lipid A
-

Whole LPS
+
-

O-ag
+
+
-

Lipid A
+
+

O111:B4
O157
O26
1x PBS/5% BSA

-

+
+
-

NA
+

+
++
-

+
+++
-

+
NA
++

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’,
NA = control antigens were not available for testing. Blue highlighted regions indicates the
targeted antigen.

Pre-inoculated

Post-Inoculated

June 23, 2015

Sept. 02, 2015

Figure A3.8 Images of longitudinal dot blots for a BALB/c mouse in the O26 serogroup. A
new immunoblotting protocol was implemented on September 2, 2015, which resulted in much
lower background staining of the nitrocellulose membranes. X’s indicate the absence of an antigen
blot in that square.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre
inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Postinoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.9 (A-B). ELISA results for a C57BL/6 mouse in O26 serogroup. A-B. First set of
two graphs for serum screens performed over time on a C57BL/6 mouse that was repeatedly
immunized with serogroup O26 bacterial antigens. C-D. Second set of 2 graphs in the
longitudinal serum screen. Graphs C-D appear on the following page.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre
inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Postinoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.9 (C-D). ELISA results for a C57BL/6 mouse in O26 serogroup. A-B. First set of
four graphs for serum screens performed over time on a C57BL/6 mouse that was repeatedly
immunized with serogroup O26 bacterial antigens. Graphs A-B appear on the previous page. CD. Second set of 2 graphs in the longitudinal serum screen.
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Table A3.5 Immunoblot summary analysis of C57BL/6 mouse inoculated with O26 bacterial
antigens.
C57BL/6 mouse
PreInoculated

PostInoculated

LPS subtype
O111:B4
O157
O26
1x PBS/5% BSA

Whole LPS
+
-

O-ag
+
-

Lipid A
-

Whole LPS
+
+
-

O-ag
+
+
-

Lipid A
+
+

Sept. 02, 2015

O111:B4
O157
O26
1x PBS/5% BSA

+
-

+
-

NA
NA
+

+
+
++
-

++
+++
-

NA
NA
++

Dec. 01, 2015

O111:B4
O157
O26
1x PBS/5% BSA

+
++
-

+
++
-

NA
NA
-

+
++
-

++
+++
-

NA
NA
++

Jan. 23, 2016

NA
NA
O111:B4
NA
++
NA
O157
++
+
++
+
O26
+++
++
1x PBS/5% BSA
No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. PBS control on January 23, 2016 became
contaminated during the blotting procedure. Blue highlighted regions indicates the targeted
antigen.

June 23, 2015
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Pre-inoculated

Post-Inoculated

June 23, 2015

Sept. 02, 2015

Dec. 01, 2015

Jan. 23, 2016

Figure A3.10 Images of longitudinal dot blots for a C57BL/6 mouse in the O26 serogroup.
X’s indicate the absence of an antigen blot in that square.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.11 (A-B). ELISA results for a Swiss Webster mouse in O26 serogroup. A-B. First set
of four graphs for serum screens performed over time on a mouse that was repeatedly immunized
with serogroup O26 bacterial antigens. C-D. Second set of 2 graphs in the longitudinal serum
screen. Graphs C-D appear on the following page.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.11 (C-D). ELISA results for a Swiss Webster mouse in O26 serogroup. C-D. Second
set of four graphs for serum screens performed over time on a mouse that was repeatedly
immunized with serogroup O26 bacterial antigens. Graphs C-D appear on the previous page.
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Table A3.6 Immunoblot summary analysis of a Swiss Webster mouse inoculated with O26
bacterial antigens.
Swiss Webster mouse
PreInoculated

PostInoculated

LPS subtype
O111:B4
O157
O26
1x PBS/5% BSA

Whole LPS
-

O-ag
+
-

Lipid A
+
-

Whole LPS
+
++
-

O-ag
+
++
-

Lipid A
+
+

Sept. 02, 2015

O111:B4
O157
O26
1x PBS/5% BSA

+
+
-

+
+
-

NA
NA
+

+
+
+
-

+
++
+++
-

+
NA
++

Dec. 01, 2015

O111:B4
O157
O26
1x PBS/5% BSA

++
-

++
-

NA
NA
-

+
-

++
+++
-

NA
NA
+

Jan. 23, 2016

NA
+
NA
O111:B4
+
NA
+
NA
O157
+
+
++
O26
++
++
1x PBS/5% BSA
No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. PBS control on January 23, 2016 became
contaminated during the blotting procedure. Blue highlighted regions indicates the targeted
antigen.

June 23, 2015
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Pre-inoculated

Post-Inoculated

June 23, 2015

Sept. 02, 2015

Dec. 01, 2015

Jan. 23, 2016

Figure A3.12 Images of longitudinal dot blots for a Swiss Webster mouse in the O26
serogroup. X’s indicate the absence of an antigen blot in that square.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)

No Ag (Post-inoculated)
No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.13 (A-B). ELISA results for a BALB/c mouse in O103 serogroup. A-B. First set of four
graphs for serum screens performed over time on a mouse that was repeatedly immunized with
serogroup O103 bacterial antigens. Graphs C-D appear on the following page.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.13 (C-D). ELISA results for a BALB/c mouse in O103 serogroup. C-D. Second set of
four graphs for serum screens performed over time on a mouse that was repeatedly immunized with
serogroup O103 bacterial antigens. Graphs A-B appear on the previous page. Mouse was sacrificed
to perform a hybridoma fusion.
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Table A3.7 Immunoblot summary analysis of a BALB/c mouse inoculated with O103 bacterial
antigens.
BALB/c mouse
PreInoculated

PostInoculated

LPS subtype
O111:B4
O157
O103
1x PBS/5% BSA

Whole LPS
+
-

O-ag
+
++
-

Lipid A
+
-

Whole LPS
+
+
-

O-ag
+
+++
+++
-

Lipid A
+
+
+

June 23, 2015

O111:B4
O157
O103
1x PBS/5% BSA

NA
NA
NA
NA

NA
NA
NA
NA

NA
NA
NA

++
+
+
-

+
+
-

-

Sept. 02, 2015

O111:B4
O157
O103
1x PBS/5% BSA

-

+
-

NA
NA
-

+
++
++
-

+
+++
-

NA
NA
+

March 09, 2015

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. June 23, 2015 pre-inoculated blot not performed.
Blue highlighted regions indicates the targeted antigen.

217

Pre-inoculated

Post-Inoculated

March 09, 2015

June 23, 2015

Blot was not performed

Sept. 02, 2015

Figure A3.14 Images of longitudinal dot blots for a BALB/c mouse in the O103 serogroup.
X’s indicate the absence of an antigen blot in that square.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.15. ELISA results for a C57BL/6 mouse in the O103 serogroup. A-C. Results of first
three screens appear on the previous page. D-E. Results of indirect ELISA of 5 serum screens
performed over time on a C57BL/6 mouse that was repeatedly immunized with serogroup O103
bacterial antigens.
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Table A3.8 Immunoblot summary analysis of C57BL/6 mouse inoculated with O103 bacterial
antigens.
C57BL/6 mouse
PreInoculated

PostInoculated

LPS subtype
O111:B4
O157
O103
1x PBS/5% BSA

Whole LPS
+
-

O-ag
+
+
+
-

Lipid A
-

Whole LPS
+
+
-

O-ag
+
++
++
-

Lipid A
+
+
+

June 23, 2015

O111:B4
O157
O103
1x PBS/5% BSA

NA
NA
NA
NA

NA
NA
NA
NA

NA
NA
NA

+
+
+
-

+
+
+
-

-

Sept. 02, 2015

O111:B4
O157
O103
1x PBS/5% BSA

-

-

NA
NA
-

+
+
++
-

+
++
-

+
NA
+

Jan. 23, 2016

O111:B4
O157
O103
1x PBS/5% BSA

++

-

NA
NA
-

+

++
++
-

NA
NA
+

March 09, 2015

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. June 23, 2015 pre-inoculated blot not performed.
PBS control on January 23, 2016 became contaminated during the blotting procedure. Blue
highlighted regions indicates the targeted antigen.
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Pre-inoculated

Post-Inoculated

March 09, 2015

June 23, 2015

Blot was not performed

Sept. 02, 2015

Jan. 23, 2016

Figure A3.16 Images of longitudinal dot blots for a C57BL/6 mouse in the O103 serogroup.
X’s indicate the absence of an antigen blot in that square. June 23, 2015 pre-inoculated blot was
not performed.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)
No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.17. ELISA results for a Swiss Webster mouse in the O103 serogroup. Five serum
screens performed over time on a Swiss Webster mouse that was repeatedly immunized with
serogroup O103 bacterial antigens. A-C. Results of first three screens appear on the previous page.
D-E. Results of most recent ELISA serum screens.
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Table A3.9 Immunoblot summary analysis of a Swiss Webster mouse inoculated with O103
bacterial antigens.
Swiss Webster mouse
PreInoculated

PostInoculated

LPS subtype
O111:B4
O157
O103
1x PBS/5% BSA

Whole LPS
+
-

O-ag
+
+
-

Lipid A
-

Whole LPS
+
+
-

O-ag
+
+++
++
-

Lipid A
+
+
+++

June 23, 2015

O111:B4
O157
O103
1x PBS/5% BSA

NA
NA
NA
NA

NA
NA
NA
NA

NA
NA
NA

+
+
+
-

+
+
-

+
+

Sept. 02, 2015

O111:B4
O157
O103
1x PBS/5% BSA

+
-

+
+
-

NA
NA
-

+
-

++
+++
-

+
NA
++

Jan. 23, 2016

O111:B4
O157
O103
1x PBS/5% BSA

++

-

NA
NA
-

++

++
++
-

NA
NA
+

March 09, 2015

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. June 23, 2015 pre-inoculated blot not performed.
PBS control on January 23, 2016 became contaminated during the blotting procedure. Blue
highlighted regions indicate the targeted antigen
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Pre-inoculated

Post-Inoculated

March 09, 2015

June 23, 2015

Blot was not performed

Sept. 02, 2015

Jan. 23, 2016

Figure A3.18 Images of longitudinal dot blots for a Swiss Webster mouse in the O103
serogroup. X’s indicate the absence of an antigen blot in that square. June 23, 2015 preinoculated blot was not performed.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.19. ELISA results for a BALB/c mouse in O111 serogroup. Results of 2 serum
screens performed over time on a BALB/c mouse that was repeatedly immunized with serogroup
O111 bacterial antigens. Mouse was selected for hybridoma fusion based on the immunoblot
results.
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Table A3.10 Immunoblot summary analysis of a BALB/c mouse inoculated with O111 bacterial
antigens.
BALB/c mouse
PreInoculated

June 23, 2015

Sept. 02, 2015

PostInoculated

LPS subtype
O111:B4
O157
O111
1x PBS/5% BSA

Whole LPS
-

O-ag
+
-

Lipid A
-

Whole LPS
-

O-ag
+
-

Lipid A
+
+

O111:B4
O157
O111
1x PBS/5% BSA

-

+
-

NA
+

+
+
+
-

++
++
-

NA
NA
+++

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. Blue highlighted regions indicate the targeted
antigen

Pre-inoculated

Post-Inoculated

June 23, 2015

Sept. 02, 2015

Figure A3.20 Images of longitudinal dot blots for a BALB/C mouse in the O111 serogroup.
X’s indicate the absence of an antigen blot in that square.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.21. ELISA results for a C57BL/6 mouse in O111 serogroup. A-B. ELISA results of first
two of four serum screens performed over time on a C57BL/6 mouse that was repeatedly immunized
with serogroup O111 bacterial antigens. C-D. Second set of results are reported on the following
page.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.21. ELISA results for a C57BL/6 mouse in O111 serogroup. A-B. Reported on
previous page. ELISA results of first two of four serum screens performed over time on a C57BL/6
mouse that was repeatedly immunized with serogroup O111 bacterial antigens. C-D. Second set of
results for the serum screen.
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Table A3.11 Immunoblot summary analysis of a C57BL/6 mouse inoculated with O111
bacterial antigens.
C57BL/6 mouse
PreInoculated

PostInoculated

LPS subtype
O111:B4
O157
O111
1x PBS/5% BSA

Whole LPS
-

O-ag
+
+
-

Lipid A
-

Whole LPS
-

O-ag
+
-

Lipid A
-

Sept. 02, 2015

O111:B4
O157
O111
1x PBS/5% BSA

-

+
-

NA
+

+
-

+
++
-

NA
NA
++

Dec. 01, 2015

O111:B4
O157
O111
1x PBS/5% BSA

-

++
-

NA
NA
++

-

+
++
-

NA
NA
++

Jan. 23, 2016

NA
NA
O111:B4
NA
+
NA
O157
+
+
+
+
O111
+++
1x PBS/5% BSA
No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. PBS control on January 23, 2016 became
contaminated during the blotting procedure. Blue highlighted regions indicate the targeted antigen

June 23, 2015
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Pre-inoculated

Post-Inoculated

June 23, 2015

Sept. 02, 2015

Dec. 01, 2015

Jan. 23, 2016

Figure A3.22 Images of longitudinal dot blots for a C57BL/6 mouse in the O111
serogroup.
X’s indicate the absence of an antigen blot in that square.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.23. ELISA results for a Swiss Webster mouse in O111 serogroup. A-B. ELISA results
of first two of four serum screens performed over time on a Swiss Webster mouse that was
repeatedly immunized with serogroup O111 bacterial antigens. C-D. Second set of results are
reported on the following page.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.23. ELISA results for a Swiss Webster mouse in O111 serogroup. A-B. Reported on
previous page. ELISA results of first two of four serum screens performed over time on a Swiss
Webster mouse that was repeatedly immunized with serogroup O111 bacterial antigens. C-D.
Second set of results for the serum screen.
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Table A3.12 Immunoblot summary analysis for a Swiss Webster mouse inoculated with O111
bacterial antigens.
Swiss Webster mouse
PreInoculated

PostInoculated

LPS subtype
O111:B4
O157
O111
1x PBS/5% BSA

Whole LPS
+
-

O-ag
+
-

Lipid A
-

Whole LPS
+
-

O-ag
+
-

Lipid A
-

Sept. 02, 2015

O111:B4
O157
O111
1x PBS/5% BSA

+
-

+
+
-

NA
+

+
++
+
-

+
++
-

NA
NA
+

Dec. 01, 2015

O111:B4
O157
O111
1x PBS/5% BSA

+
+
-

+
-

NA
NA
+

++
++
+
-

+
++
-

NA
NA
+

Jan. 23, 2016

+
NA
+
NA
O111:B4
+
+
NA
+
+
NA
O157
+
+
+
+
O111
+++
++
1x PBS/5% BSA
No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. PBS control on January 23, 2016 became
contaminated during the blotting procedure. Blue highlighted regions indicate the targeted antigen

June 23, 2015
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Pre-inoculated

Post-Inoculated

June 23, 2015

Sept. 02, 2015

Dec. 01, 2015

Jan. 23, 2016

Figure A3.24. Images of longitudinal dot blots for a Swiss Webster mouse in the O111
serogroup. X’s indicate the absence of an antigen blot in that square. While subsequent blots are
not marked with X’s, control Lipid A groups for LPS O111:B4 and O157 were not available for
testing.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)
No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.25. ELISA graphs for a BALB/c mouse in O121 serogroup. Results of indirect ELISA of 2
serum screens performed over time on a BALB/c mouse that was repeatedly immunized with
serogroup O121 bacterial antigens.
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Table A3.13 Immunoblot summary analysis of a BALB/c mouse inoculated with O121 bacterial
antigens.
BALB/c mouse
PreInoculated

Dec. 01, 2015

Jan. 23, 2016

PostInoculated

LPS subtype
O111:B4
O157
O121
1x PBS/5% BSA

Whole LPS
+
-

O-ag
NA
-

Lipid A
NA
NA
NA

Whole LPS
+
+
+++
-

O-ag
+
NA
-

Lipid A
NA
NA
NA

O111:B4
O157
O121
1x PBS/5% BSA

+
-

+
NA
-

NA
NA
NA

+
+
+
-

++
NA
-

NA
NA
NA

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. Immunoblotting procedure was repeated for
January 23, 2016 serum screen due to mislabeling of membrane paper. Blue highlighted regions
indicate the targeted antigen

Pre-inoculated

Post-Inoculated

Dec. 01, 2015

Jan. 23, 2016

Figure A3.26 Images of longitudinal dot blots for a BALB/c mouse in the O121 serogroup.
Control O-ag and lipid A antigens were not available for LPS O121. Lipid A antigens were not
available for control groups O111:B4 and O157 on either of the test dates.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.27. ELISA results for a C57BL/6 mouse in the O121 serogroup. Results of two serum
screens performed over time on a C57BL/6 mouse that was repeatedly immunized with serogroup
O121 bacterial antigens.
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Table A3.14 Immunoblot summary analysis of a C57BL/6 mouse inoculated with O121
bacterial antigens.
C57BL/6 mouse
PreInoculated

Dec. 01, 2015

Jan. 23, 2016

PostInoculated

LPS subtype
O111:B4
O157
O121
1x PBS/5% BSA

Whole LPS
-

O-ag
NA
-

Lipid A
NA
NA
NA

Whole LPS
+
++
-

O-ag
NA
-

Lipid A
NA
NA
NA

O111:B4
O157
O121
1x PBS/5% BSA

++

NA
-

NA
NA
NA

++

NA
-

NA
NA
NA

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. PBS control on January 23, 2016 became
contaminated during the blotting procedure. Blue highlighted regions indicate the targeted antigen

Pre-inoculated

Post-Inoculated

Dec. 01, 2015

Jan. 23, 2016

Figure A3.28 Images of longitudinal dot blots for a C57BL/6 mouse in the O121 serogroup.
Control O-ag and lipid A antigens were not available for LPS O121. Lipid A antigens were not
available for control groups O111:B4 and O157.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.29. ELISA results for a Swiss Webster mouse in the O121 serogroup. Results of 2
serum screens performed over time on a Swiss Webster mouse that was repeatedly immunized with
serogroup O121 bacterial antigens.

241

Table A3.15 Immunoblot summary analysis of a Swiss Webster mouse inoculated with O121
bacterial antigens.
Swiss Webster mouse
PreInoculated

Dec. 01, 2015

Jan. 23, 2016

PostInoculated

LPS subtype
O111:B4
O157
O121
1x PBS/5% BSA

Whole LPS
-

O-ag
NA
-

Lipid A
NA
NA
NA

Whole LPS
+
+++
-

O-ag
++
NA
-

Lipid A
NA
NA
NA

O111:B4
O157
O121
1x PBS/5% BSA

++

NA
-

NA
NA
NA

++

NA
-

NA
NA
NA

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. PBS control on January 23, 2016 became
contaminated during the blotting procedure. Blue highlighted regions indicate the targeted antigen

Pre-inoculated

Post-Inoculated

Dec. 01, 2015

Jan. 23, 2016

Figure A3.30 Images of longitudinal dot blots for a Swiss Webster mouse in the O121
serogroup. Control O-ag and lipid A antigens were not available for LPS O121. Lipid A antigens
were not available for control groups O111:B4 and O157.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.31. ELISA results for a BALB/c mouse in the O145 serogroup. Results of serum
screens performed over time on a BALB/c mouse that was repeatedly immunized with serogroup
O145 bacterial antigens.
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Table A3.16 Immunoblot summary analysis of a BALB/c mouse inoculated with O145 bacterial
antigens.
BALB/c mouse
PreInoculated

Dec. 01, 2015

Jan. 23, 2016

PostInoculated

LPS subtype
O111:B4
O157
O145
1x PBS/5% BSA

Whole LPS
-

O-ag
-

Lipid A
NA
NA
-

Whole LPS
+
+
+
-

O-ag
++
+
-

Lipid A
NA
NA
-

O111:B4
O157
O145
1x PBS/5% BSA

+
++

-

NA
NA
NA

+
+
+
++

+
+
-

NA
NA
NA

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. PBS control on January 23, 2016 became
contaminated during the blotting procedure. Blue highlighted regions indicate the targeted antigen

Pre-inoculated

Post-Inoculated

Dec. 01, 2015

Jan. 23, 2016

Figure A3.32 Images of longitudinal dot blots for a BALB/c mouse in the O145 serogroup. Lipid
A antigens were not available for control groups O111:B4 and O157.
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Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)

No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.33. ELISA results for a C57BL/6 mouse in the O145 serogroup. Results serum
screens performed over time on a C57BL/6 mouse that was repeatedly immunized with serogroup
O145 bacterial antigens.
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Table A3.17 Immunoblot summary analysis of a C57BL/6 mouse inoculated with O145
bacterial antigens.
C57BL/6 mouse
PreInoculated

Dec. 01, 2015

Jan. 23, 2016

PostInoculated

LPS subtype
O111:B4
O157
O145
1x PBS/5% BSA

Whole LPS
-

O-ag
-

Lipid A
NA
NA
-

Whole LPS
+
-

O-ag
+
++
+
-

Lipid A
NA
NA
-

O111:B4
O157
O145
1x PBS/5% BSA

-

-

NA
NA
-

+
+
+++

++
+
-

NA
NA
-

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. Blue highlighted regions indicate the targeted
antigen

Pre-inoculated

Post-Inoculated

Dec. 01, 2015

Jan. 23, 2016

Figure A3.34. Images of longitudinal dot blots for a C57BL/6 mouse in the O145 serogroup.
Lipid A antigens were not available for control groups O111:B4 and O157.

246

Pre-inoculated serum
Post-inoculated serum
No capture Ab (Pre inoculated)
No Ag (Pre-inoculated)
No serum (Pre-inoculated)
No 2˚ Ab (Pre-inoculated)
No capture Ab (Post-inoculated)
No Ag (Post-inoculated)
No serum (Post-inoculated)
No 2˚ Ab (Post-inoculated)

Figure A3.35. ELISA results for a Swiss Webster mouse in the O145 serogroup. Results of
serum screens performed over time on a Swiss Webster mouse that was repeatedly immunized
with serogroup O145 bacterial antigens.
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Table A3.18 Immunoblot summary analysis of a Swiss Webster mouse inoculated with O145
bacterial antigens.
Swiss Webster
PreInoculated

Dec. 01, 2015

Jan. 23, 2016

PostInoculated

LPS subtype
O111:B4
O157
O145
1x PBS/5% BSA

Whole LPS
-

O-ag
-

Lipid A
NA
NA
-

Whole LPS
-

O-ag
+
-

Lipid A
NA
NA
-

O111:B4
O157
O145
1x PBS/5% BSA

-

-

NA
NA
NA

+
+
-

+
+
-

NA
NA
-

No response ‘ - ‘, Weak response ‘ + ’, Moderate response ‘ ++ ’, Intense response = ‘ +++ ’, NA =
control antigens were not available for testing. PBS control on January 23, 2016 became
contaminated during the blotting procedure. Blue highlighted regions indicate the targeted antigen

Pre-inoculated

Post-Inoculated

Dec. 01, 2015

Jan. 23, 2016

Figure A3.36. Images of longitudinal dot blots for a Swiss Webster mouse in the O145
serogroup. Lipid A antigens were not available for control groups O111:B4 and O157.
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Section A4.2 Serum lipoprotein capture ELISAs for LPS
LPS O104 ELISA
1.2

50% Mouse Serum
No Antigen
No 2° Antibody

Absorbance

1

No Mouse Serum
No 1° Antibody

0.8
0.6
0.4
0.2
0
50% Mouse
Serum

A

No Mouse Serum

No Antigen

No 1° Antibody

No 2° Antibody

LPS O45 ELISA
1.2
50% Donkey Serum
No Antigen
No 2° Antibody

Absorbance

1

No Donkey Serum
No 1° Antibody

0.8
0.6
0.4
0.2
0

B

50% Donkey
Serum

No Donkey Serum

No Antigen

No 1° Antibody

No 2° Antibody

Figure A3.37. ELISA results for serum functionalized plates. A. Plate was functionalized with
mouse serum and assay tested with LPS O104. B. Results for LPS O45 on a plate functionalized
with donkey serum (red bars are specific signal). Results confirm the direct association between
LPS and the lipoproteins present in serum. Functionalizing the plates with serum is less labor
intensive, more cost effective and provides a physiological presentation of LPS to primary
antibodies.
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LPS O26 ELISA
1.2

1

50% Donkey Serum

No Donkey Serum

No Antigen

No 1° Antibody

No 2° Antibody

Absorbance

0.8

0.6

0.4

0.2

0
50% Donkey Serum No Donkey Serum

No Antigen

No 1° Antibody

No 2° Antibody

Figure A3.38. ELISA results for LPS O26 on a serum functionalized plate. A. Plate was
functionalized with donkey serum. (red bars are specific signal) Results demonstrate the low
specificity of mAb O26 to its O-ag.
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Appendix 4
Section A4.1 Supporting images for Chapter 5

Figure A4.1. Size of surface-associated lipid vesicles. (A) Representative LSCM image of
surface associated vesicles. See Movie S1 for mobility data. (B) Representative dynamic light
scattering size distribution (by intensity). (C) Schematic showing proposed surface associated
vesicles.
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Figure A4.2. Elongation of lipid tubules. (A) LSCM fluorescence images acquired of the radial
pattern formed by lipid tubules at the edges of the buffer droplet (images 1-8, position labeled on
the schematic sample set-up and on the images). A DOPC sLBA (0.5% BODIPY lipids) in PBS
was treated with 100 µg/ mL LPS and then images of tubules extending above the sLBA were
acquired after approximately 30 min. The tubules were most evident by focusing approximately 2
µm above the surface. (B) Cartoon of possible convection currents causing flow within the buffer
droplets. (i) A droplet of water is expected to cause flow in the direction toward the edges of the
droplet, driven by evaporation, similar to the “coffee-ring effect”. (ii) Our open droplet set-up, with
an imaging spacer which creates boundary walls to the droplet. Complex buffer flows and
counter-flows may exist. (iii) These currents serve to stretch out the lipid tubules formed by LPS.
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Figure A4.3. Fluorescence time-course showing that holes are stable. Time lapse LSCM
fluorescence images over the course of 80 min showing the size and shape of holes within the
lipid bilayer after LPS treatment. There are no significant changes in the holes.

Figure A4.4. Dual channel LSCM fluorescence images tracking FITC-LPS its hole
formation. Upper panels: signal from the FITC-LPS (505-525 nm range); lower panels: signal
from the DOPC bilayer doped with 0.5% Texas Red fluorescent lipids (655-755 nm range).
Images are shown, (A) before LPS addition, (B) after addition of 100 μg/ mL FITC-LPS in PBS,
(C) after 500 μg/ mL FITC-LPS treatment and washing the surface with ten changes of PBS. (D)
A higher magnification image from (C), and (E) intensity profiles revealed voids in the Texas Red
lipid fluorescence but very low FITC signal with no observable signal difference on or off the holes
observed in the matched Texas Red channel.
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Figure A4.5. FRAP studies on LPS (Ca2+) planar lamellar sheets. (A) FRAP of a normal
DOPC sLBA in Ca2+ buffer. (B) FRAP of a planar lamellar sheet after LPS (Ca2+) treatment. (C)
FRAP of the sLBA (nearby planar sheets visible) after LPS (Ca2+) treatment. (D) FRAP after
bleaching an entire single-layer lamellar sheet. (E) FRAP after bleaching an entire multi-layer
lamellar sheet. The corrected intensity vs. time plots show the fluorescence recovery over time in
the bleached region. The first measurement post-bleach intensity in the ROI was normalized to
zero, correction for any unintended photobleaching over the image series was made* and the
data set was normalized to the pre-bleach intensity (intensity = 1 at t= 0). *by multiplication of
each intensity measurement in the bleach ROI by Fpre/Fpost in a region of the image that was
not bleached, where Fpre= prebleach intensity (t= 0) and = Fpost postbleach intensity at each
time point. The recovery half-time (t(1/2)) was measured from the plots. Diffusions coefficients
were then calculated using the formula “D = 0.22.r2 / t(1/2)” (r = radius of bleached area). The
diffusion coefficients for the sLBA are similar with a possible slight reduction after LPS(Ca2+)
treatment. The diffusion coefficient for the planar sheet is significantly lower than that for the
sLBA. The diffusion coefficients for bleaching an entire single or multi-lamellar planar sheet are
intermediate values.
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Figure A4.6. LPS concentration dependence of planar sheet formation. LSCM fluorescence
images of an sLBA before and after addition of 5 μg/ mL LPS in Ca2+ buffer. Sequential images
are shown after 2 min and 22 min after addition of the LPS.
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Figure A4.7. Cation concentration effects on LPS membrane disruption. (A) Representative
LSCM images from showing the effects of LPS in a series of buffers with increasing NaCl
concentration. All buffers contained 20 mM TRIS (pH 7.5). sLBAs were treated with 100 µg/ mL
LPS and imaged after approximately 15 min after LPS addition (column 1) and after rinsing the
surface with fresh buffer (column 2). (B) As in (A), except using a buffer series with CaCl2 instead
of NaCl. (C) The largest multilamellar lipid patch observed.
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Figure A4.8. (A) Reduction in lipid tubules and similar hole formation by multiple cycles of
LPS treatment. DOPC sLBAs were incubated with 100 µg/ mL LPS in PBS for 20 min, LSCM
images acquired of lipid tubules and then washed with PBS and imaged again. This was repeated
until 4 cycles of LPS treatment had been performed. After each LPS treatment lipid tubules were
formed and then removed during the buffer wash. Fewer tubules were observed with each LPS
treatment, due to the expected depletion of surface-associated vesicles. Note that holes were
formed after the first buffer wash and then ‘filled-in’ by the 2nd LPS treatment, probably due to
packing of LPS into the holes, joining up with the lipid bilayer, allowing lateral lipid diffusion and
‘healing’ of the holes. However, following the each buffer wash, holes of a similar size and
distribution were formed once again, suggesting that hole formation does not depend on surfaceassociated vesicles, but on the solid-supported lipid bilayer and interaction with LPS. (B)
Reduction in planar sheet formation by multiple cycles of LPS treatment. DOPC sLBAs were
incubated with 100 µg/ mL LPS in Ca2+ buffer for 20 min, LSCM images acquired of planar
sheets and then washed with Ca2+ buffer and imaged again. This was repeated until 4 cycles of
LPS treatment had been performed. Not all sheets are removed by each buffer wash, but there is
a trend to form smaller and fewer planar lamellar sheets with each subsequent LPS treatment.
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Section 4.2. Information for supporting video files
Movies are available for download at http://dx.doi.org/10.1016/j.bpj.2014.04.016
Movie A4.1. Mobility of surface-associated lipid vesicles. Time-lapse LSCM series of
images showing the motion of surface-associated vesicles on a DOPC sLBA. Total
image represents 39.4 x 39.4 µm, interval between images is 1.0 s. Movie is available
for download at the following address:
http://www.cell.com/cms/attachment/2014949947/2036222547/mmc2.mp4
Movie A4.2. Lipid tubule formation. Time-lapse LSCM series of images showing
treatment of a DOPC sLBA with 100 µg/ mL LPS in PBS. Total image represents 105.3 x
105.3 µm. Series 1 was acquired with continuous image acquisition (1.1 s/ image, no
interval) and the droplet of LPS is added to the sample at ~10 s (Series 1). Series 2 was
then acquired on the same field, with an interval of 15 s, to allow slower processes to be
observed. Elapsed time for each series is shown as “T #seconds # milliseconds”. Each
image series was contrast-adjusted independently for clarity. Disordered lipid tubules are
formed immediately after LPS addition and they extended and stretch out over the
course of Series 1 and 2. Note, the overall fluorescence signal is reduced between
images “9 s 981 ms” and “12 s 199 ms” (Series 1) because of slight defocusing of the
sample due to the physical effect of adding the droplet of LPS at ~10 s. Refocusing on
the sLBA after imaging reveals a similar sLBA fluorescence before and after LPS
addition. Movie is available for download at the following address:
http://www.cell.com/cms/attachment/2014949947/2036222546/mmc3.mp4
Movie A4.3. Lipid tubule mobility. Epifluorescence ‘movie’ imaging of a DOPC sLBA
after ~20 min treatment with 100 µg/ mL LPS in PBS. Total image represents 132 x 132
µm. High lateral mobility of lipid tubules is apparent. Movie is available for download at
the following
address:http://www.cell.com/cms/attachment/2014949947/2036222544/mmc4.mp4
Movie A4.4. Lipid sheet formation and growth. Time-lapse LSCM series of images
showing treatment of a DOPC sLBA with 100 µg/ mL LPS in Ca2+ buffer. Total image
width represents 317.3 x 317.3 µm. Series 1 was acquired with continuous image
acquisition (3.3 s/ image, no interval) and the droplet of LPS is added to the sample at
~9 s (Series 1). Series 2 was then acquired on the same field, after refocusing (3.3 s/
image, no interval). Series 3 was then acquired with an interval of 30 s, to allow slower
processes to be observed. Elapsed time for each series is shown as “T #seconds #
milliseconds”. Each image series was contrast-adjusted independently for clarity.
Patches of fluorescence, expected to represent planar lipid/LPS lamellae, are formed
immediately after LPS addition and expand in size over the course of the video. Note,
the overall fluorescence signal is reduced between images “6 s 652 ms” and “13 s 304
ms” (Series 1) because of slight defocusing of the sample due to the physical effect of
adding the droplet of LPS at ~9 s. Refocusing on the sLBA after imaging reveals a
similar sLBA fluorescence before and after LPS addition. Movie is available for download
at the following address:
http://www.cell.com/cms/attachment/2014949947/2036222545/mmc5.mp4
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Appendix 5
Section A5.1 Supporting information for Chapter 6
A5.1.1 Statistical results
Variability assessment determined that deviations of the logarithm of specific
signal remained larger, while those for the background and non-specific binding
were commensurate with one another. The ANOVA results (S2 Table) showed that
only the type of measurement impacts the variability. It was found that wg# and
power also affected variability. AIC modeling determined that all of the variables
were significant, but the residuals for the uncertainty of the specific binding were
significantly larger, even after LPSc, wg#, and power were accounted for.
Regression analysis (Table A5.3) showed no significance for any of the analyzed
variables (LPSc, wg#, and power), but showed that the uncertainty of the specific
binding was greater than four times that of the uncertainty in other types of
measurements with a p-value = 8.77e-16. This indicates that the uncertainty in
specific binding is significant, but not dependent upon any of the analyzed variables
except the inherent variability of LPS itself.

Table A5.1. ANOVA of variable significance (5%) in relation to
logarithm of integrated intensity.
Sum
Sq

DF

Mean
Sq

F Value

Pr(>F)
< 2.2E-16

measurement type

2

62.804

31.402

278.865

LPSc

1

1.266

1.266

11.239

0.00109#

wg#

3

1.306

0.435

3.865

0.0113#

power

1

0.52

0.520

4.616

0.0338#

112

12.612

0.113

Residuals

# indicates numbers with significant p-values for the corresponding coefficient
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Table A5.2. ANOVA of absolute values of residuals.
DF

Sum Sq

Mean
Sq

F Value

Pr(>F)

measurement type

2

2.691

1.346

45.687

3.10E-15#

LPSc

1

0.028

0.028

0.954

0.331

wg#

3

0.113

0.038

1.279

0.285

power

1

0.053

0.053

1.795

0.183

112

3.299

0.029

Residuals

# indicates numbers with significant p-values for the corresponding coefficient

Table A5.3. Regression analysis of residuals for LPS concentration
detection.
Coefficients

Estimate

Std. Error

t – value

Pr ( > | t | )

Intercept

-0.06009

0.15355

-0.391

0.6963

LPSc

0.00013

0.00026

0.521

0.6037

wg1*

0.02712

0.05411

0.501

0.6172

wg2*

0.01488

0.08470

0.307

0.7595

wg3*

0.10956

0.05350

2.048

0.0429#

power

0.00070

0.00052

1.34

0.183

mNSB

0.00378

0.04291

0.088

0.93

mSP

0.40259

0.04291

9.383

8.77E-16#

Residual standard error:

0.17160

Multiple R-squared:

0.4666

Adjusted R-squared:

0.4332

F-statistic:
p-value:

13.99

on 112 degrees of freedom

on 7 and 112 DF

6.21E-13

*wg# is a unique identifying number for an individual waveguide
# indicates numbers with significant p-values for the corresponding coefficient
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Figure A5.1. Integrated intensities of O-ag targeted detection of LPS. Spectra from Figure 6.4
were integrated and plotted to demonstrate the difference in values when using specific antibodies
for detection. Error bars indicate standard error of the mean for the average of three replicates.

Figure A5.2. High concentration of LPS O157 in a flow cell. 100 µg/mL LPS O157 was incubated
in the flow cell and rinsed. No hole formation was observed.
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Figure A5.3. Lateral fluidity of bilayers after incubation with 100 µg/mL LPS O157 inside a flow
cell. (A) Time lapse series of DOPC-BODIPY bilayers that were photobleached and showed lateral
fluidity during recovery. (B) Intensity profile graph of the overall average intensity and the recovery of
the photobleached region. Incubating with LPS O157 does not cause hole formation or effect fluidity
of the bilayers.

262

Figure A5.4. Specific and non-specific binding of pAb O157-af647 inside a flow cell. (A)
Composite 2 channel image of DOPC-BODIPY lipids and pAb O157-af647. White arrows indicate
points of fluorescence intensity, and the white dotted line is the region of analysis graphed in D. Arrow
1 is a DOPC-BODIPY surface associated vesicle, and arrow 2 is specific binding of the reporter
antibody. (B) Green channel of image A. (C) Red channel of image A. White arrows indicate points of
non-specific binding. (D) Line intensity profile of dotted line in image A showing low non-specific
binding and saturated intensity of the specific binding. Low NSB and high specific binding events
allow for increased signal to noise ratios allowing sensitive detection of LPS membrane insertion.
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Figure A5.5. Effects of multiple serogroups of LPS on lipid bilayers. (A-I) 50 µg/mL LPS
O111:B4, O26, O45, O103, O104, O111, O113, O121, and O145 respectively.
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Section A5.2 Data processing methods
A5.2.1 Data processing algorithm
The following is a simple algorithm designed to take individual columns of
spectral data and take the area under the curve as a function of the change in
wavelength. This takes advantage of a built-in Igor Pro 6.3 function called ‘areaXY’.
Raw and processed data sets are available for download from the publishers
website.
Integration algorithm for spectral data processing.
Function BIR5(W, B1, B2, B3, B4, B5, NSB, SP, index) //input function – designed to intergrate input
waves B1, B2, B3, B4, B5, NSB, SP where
ΔX is determined by the ΔW – usually about 0.3 nm
//The number of input background variables should be altered if using a data set that has more or less
responses recorded.
//Variables
Wave NSB, SP //non-specific binding and specific binding spectra
Wave B1, B2, B3, B4, B5 //background spectra
Wave W //wavelength range scanned
Variable index
Make /O/N = 100 NSB_int, SP_int, B1_int, B2_int, B3_int, B4_int, B5_int, ratio //generates the empty
waves to allocate the resulting values into
//if processing larger data sets (greater than 100 values expected), the size of these waves should be
changed accordingly

NSB_int[index] = areaXY(W, NSB) //calculates the area under the curve of NSB and using the
wavelength as the limits of integration...trapezoidal method
//index is using an assigned value to direct results to a specific location in the wave NSB_int –
following commands are engineered in an identical fashion, thus assigning values from one
experiment to the same row in each wave
SP_int[index] = areaXY(W, SP) //calculates the area under the curve of SP and using the wavelength
as the limits of integration...trapezoidal method
B1_int[index] = areaXY (W,B1)
B2_int[index] = areaXY (W,B2)
B3_int[index] = areaXY (W,B3)
B4_int[index] = areaXY (W,B4)
B5_int[index] = areaXY (W,B5)

ratio[index] = SP_int[index]/NSB_int[index]
End
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A5.2.2 Integrated spectral values and data processing method
Data set is available for download as an excel spreadsheet which contains all the integrated values of
the spectral curves and how those values were processed to obtain limits of detection and signal to
noise ratios. Data was integrated using IgorPro 7 and algorithm from section A5.2.1.

A5.2.3 Raw data of spectral curves
Data set is available for download as an Excel spreadsheet that contains the spectra
collected from a waveguide-based optical biosensor fitted with a USB 2000 Ocean Optics
spectrometer. File contains 11 different tabs, and the replicates for each concentration or assay are
contained within a single tab. Concentrations are clearly marked, and the waveguide number is
written after each replicate number. E.g. N=1/wg#.
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Appendix 6
Section 6.1 LPS interactions with complex supported lipid bilayers

Figure A6.1. DOPC sLBA controls. Controls were run simultaneously at room temperature with
every experiment. A. DOPC bilayer was imaged throughout the duration of the experiment and
rinsed equally as that of the LPS experimental controls. No hole formation or bilayer deformation
is noted. FRAP was performed on all sLBAs to ensure bilayer fluidity. B. DOPC lipid bilayer
incubated with 50 µg/mL of LPS for 20 min at R/T. C. DOPC lipid bilayer incubated with 25 µg/mL
LPS for 20 min at R/T.

Figure A6.2. DOPC lipid bilayers with 50% cholesterol. Bilayers (A-D) were incubated with
200, 100, 50, and 25 µg/mL LPS O111:B4 (respectively) for 20 min at R/T and then rinsed and
imaged.
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Figure A6.3. Lipid bilayers labeled with TR enriched with 50% NBD-cholesterol. To ensure
incorporation of cholesterol, NBD-labeled cholesterol was used for imaging with TR lipids. Bilayer
was incubated with 200 µg/mL LPS for 20 min. A. Red channel shows red lipids and hole
formation. Bright red spots occur due to the overlap of excitations of Texas Red and NBD. B.
Green channel with white arrows. Arrows show some of the localized cholesterol. C. Composite
channel with the red background subtracted out. Arrows again indicate the presence of
cholesterol in the lipids.

Figure A6.4 DOPC lipid bilayers with 5% Sphingomyelin. Bilayers (A-D) were incubated with
200, 100, 50, and 25 µg/mL (respectively) LPS O111:B4 for 20 min at R/T and then rinsed and
imaged.

Figure A6.5. Zoomed out image of lipid bilayers with 5% sphingomyelin and 50%
cholesterol. Bilayers (A-D) were incubated with 200, 100, 50, and 25 µg/mL (respectively) LPS
O111:B4 for 20 min at R/T and then rinsed and imaged. C-D. Both 50 and 25 µg/mL LPS bilayers
show the presence of very small, infrequent holes, which may be an artifact of washing.
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When we combined 5% sphingomyelin with 25% cholesterol in our sLBA
mixtures (Figure A6.6), LPS-induced hole formation was highly asymmetric both in
the pattern and size of the holes formed (Figure A6.6 A-B), as compared to all other
holes formations that we noted in the bilayers. It is evident that there are divided
regions between holes of larger size and less frequency, as compared to other
regions where holes are much smaller, but more frequent. We also witnessed
unusual patterns in the hole formation, and highly localized regions of fluorescence
intensity when incubating with 50 µg/mL LPS (Figure A6.6 E-F). In our previous
studies, these regions of intensity have demonstrated to be lipid vesicles, which
recover after photobleaching. However, FRAP of these isolated regions did not
result in fluorescence recovery after 5 minutes, indicating little to no lateral mobility
between the lipid architectures. The incorporation of a fluorescently labeled
sphingomyelin is a logical next step to analyze the distribution of the molecule within
the bilayer, and determine the interaction that LPS has with the molecule. This
particular ratio of lipids (5% sphingomyelin/25% cholesterol) is more physiologically
relevant in comparison to the higher levels of cholesterol, however investigating a
ratio of 15% sphingomyelin/25% cholesterol would probably be the most
representative of a cell membrane exposed to LPS. As yet, this system indicates
that cholesterol is capable of inhibiting hole formation at lower concentrations of
LPS, while sphingomyelin is not. Even optimizing the ratio of the two to conditions
that are more biomimetic may not completely inhibit this mechanism, as data with
sphingomyelin shows no inhibition. This is compelling evidence that hole formation
in cell membranes may be possible. Thus, investigating this system fully could lead
to interesting insights into LPS signaling in the presence of lipid rafts and membrane
architectures.
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200 µg/mL

100 µg/mL

50 µg/mL

25 µg/mL

Figure A6.6. Bilayers enriched with 5% sphingomyelin and 25% cholesterol. Incubated
decreasing (left to right) concentrations of LPS for 20 min at room temperature. Top row: images
using 1x magnification. Bottom row: Images taken at 5x magnification of some of defects seen.

Figure A6.7. Lipid bilayers controls for elevated temperature studies. A. Bilayer imaged at
37 ˚C and then imaged again under 5x magnification (B). No defects were observed.
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Section A6.2 Effect of murine serum on LPS-induced cytokine expression
LPS-induced Cytokine Expression

4.5
4

Absorbance @ 450 nm

3.5
3
2.5

No LPS
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12 Hours
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20 Hours

2
1.5

24 Hours
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1
0.5
0

A

IC-21 Cytokines

LPS-induced Cytokine Expression
(8 hours)

Absorbance @ 450 nm

4.5
4

No LPS

3.5

8 Hours

3

Positive Control

2.5
2
1.5
1
0.5
0

B

IC-21 Cytokines

Figure A6.8. LPS-induced cytokine expression in IC-21 cells. A. A time point study in a 12plex kit was used with 100 ng/mL LPS to determine the optimum time necessary to look at
cytokine expression. B. The 8 hour time point was selected from the time point study and regraphed for clarity. Results are plotted as the mean absorbance of three replicates with standard
deviation error bars.
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LPS spiked into serum and allowed to incubate overnight previous to dosing
cells, was determined to have a minimally measurable cytokine effect on the IC-21
(TLR4 positive) cell line as compared to the LPS negative control. While it was
evident that inflammatory cytokines were being expressed at levels above the
negative control in some cases (IL-1, IL-1b, IL-17a, G-CSF), the general trend was
that we could not determine the difference between the serum control and the
experimental group of serum spiked with LPS. This dictated methods for the
following experiment and determined that LPS should be added to the serum
immediately prior to dosing the cells.
LPS-induced Cytokine Expression
(LPS in serum)

0.8

0.7

100 ng/mL LPS

Absorbance @ 450nm

No LPS
0.6

Negative Control

0.5

0.4

0.3

0.2

0.1

0

IC-21 Cytokines

Figure A6.9. Cytokine expression of IC-21 cells when LPS is presented to cells in serum. LPS
was spiked into mouse serum and allowed to incubated overnight prior to introduction to cells. After
an 8 hour incubation period, no cytokine expression above the negative (no cytokine) control could
be detected. Results are plotted as the mean absorbance of three replicates with standard deviation
error bars.

Mean fluorescence intensity (MFI) of cytokine standards was processed using
a 5 parameter logistic equation (Equation A6.1). Equations were generated for each
set of cytokine standards (each microplate had its own set of standards) using an
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online tool (myassays.com). The 5 parameter logistic fit (5PL) is suitable for
quantitative analysis of asymmetric data results, which is often the case in biological
data. The samples are first corrected by subtracting the mean of the blank
measurements (in this case 0 pg/mL was used as the blank). The data points are
then plotted as concentration versus the corrected MFI (Figure A6.10), and then the
5PL is made through the data points. The concentrations of the expressed cytokines
can then be determined by using the 5PL fit. One of the limitations of the 5PL
method is that data points outside of the range of the upper and lower asymptotes
cannot be directly calculated. This is the reason some blank spaces appear in
Tables A6.3, A6.4, and A6.6. The 5PL fit equation is as follows:

f(x) = D +

A−D
x
[1 + (C)b ]m
Equation 1

Where A is the minimum MFI value (lower asymptote), b is the Hill slope, C is the
inflection point on the curve, D is the maximum MFI value (upper asymptote), and m,
is the asymmetry factor. This equation can then be solved for x, which is the
concentration of cytokine. However, to get x is a rather laborious calculation, and
therefore by using software to determine these values, we minimize the chances for
errors in the calculations. Values for each variable in the equation for the five
primary inflammatory cytokines are shown in Table A6.1 and Table A6.2, along with
the calculated R2 value for each fit. Different values were obtained as each kit came
with a set of standards to run in duplicate on individual plates.
Table A6.1 Values for the variables in the cytokine standards
determined from the 5 parameter logistic fit using the controls
on the 23ScCr plate.
Variable

IL-1

TNF

IL-6

IL-12

IFN

A

11.07

16.66

64.14

11.19

42.30

B

1.16

1.15

1.051

1.14

1.22

C

2337

142368

9405

12391

3397

D

9977

2090

35679

29674

39261

M

1.01

715.98

1.002

1.00

1.01

R²

0.998

0.970

0.998

0.999

0.999
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Table A6.2 Values for the variables in the cytokine standards
determined from the 5 parameter logistic fit using the controls
on the IC-21 plate.
Variable

IL-1

TNF

IL-6

IL-12

IFN

A

-17.8215

-8.19711

-3.79875

5.34817

42.2976

b

1.00079

1.03838

0.929849

1.03272

1.21926

C

4387.19

750.53

24188.2

25083.8

3396.78

D

14344.2

3564.72

64856.6

50619.4

39260.9

m

1

1.02497

0.998988

1.00075

1.00965

R²

0.973

0.919

0.982

0.995

0.999

Figure A6.10. Standard curves for murine cytokines using the Milliplex XMap 25-plex kit. Results
for duplicates of the standards were processed using a 5 parameter logistic and plotted on a semi-log
scale against the corrected mean fluorescence intensity (MFI).
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Table A6.3. Calculated cytokine expression in pg/mL using serum variants
IC-21 - TLR4 (+) cells

23ScCr - TLR4 (-) cells

Test Group

IL-1

TNF

IL-6

IL-12

IFN

IL-1

TNF

IL-6

IL-12

IFN

serum

9.738

2.604

7.483

-

6.484

4.346

-

81.978

-

0.670

serum + LPS

12.615

3.260

13.71

-

9.318

2.975

-

86.497

-

-

‘no serum’

9.841

2.522

0.459

-

0.956

7.632

-

-

-

-

‘no serum’ + LPS

90.964

26.814

52.63

1.452

2.701

6.534

-

-

-

-

d.serum

37.106

149.86

505.6

5.953

11.780

14.782

16.688

41.197

-

6.836

79.586

226.02
0

1204

8.668

16.881

10.252

9.360

9.167

-

4.146

d.serum + LPS

Table A6.4 Values for the variables in chemokine standards determined from the 5
parameter logistic fit using the controls on the IC-21 plate.
Variable

RANTES

MIP-2

MIP-1b

MIP-1a

KC

MCP-1

IP-10

IL-9

G-CSF

GM-CSF

A

41.99

-5.572

-4.204

9.305

-69.68

-12.54

138.34

3.589

6.535

4.465

b

1.213

1.543

1.494

1.287

0.929

1.375

1.382

1.266

0.922

2.002

C

93.20

2761

936.8

7151

2118

2713

1473

19399

13096

4241

D

8480

18815

14541

41700

21980

17399

32202

12337

28327

28388

m

0.654

1

1

1

0.993

0.993

1.012

1

0.999

1.005

R²

.903

0.914

0.930

0.935

0.956

0.999

0.990

0.999

0.918

0.970
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Figure A6.11. Standard curves for other murine cytokines/chemokines. Obtained using the
Milliplex XMap 25-plex kit. Results for duplicates of the standards from the IC-21 plate were
processed using a 5 parameter logistic and plotted on a semi-log scale against the corrected mean
fluorescence intensity (MFI).

Section A6.3 The effect of FBS on cytokine expression
The addition of 50% FBS to cells in an attempt to detach the cells from the
tissue culture treated surfaces produced an unexpected response. We also
examined FBS as a control presentation method of LPS in our cytokine panels.
Firstly, we did not observe any de-adherence of IC-21 cells from the culture surface
as was observed when using mouse serum. This negated the possibly of using this
as a new method to remove cells. However, the presentation of LPS in FBS
produced a dramatic response both in TLR4(+) and TLR4(–) cell lines (Figure A6.11
C,D), especially in comparison to the experiments performed in mouse serum
(Figure A6.11 A,B) Significant levels of IL-1, TNF, and IL-6 were produced in the
FBS + LPS group. Calculated concentrations can be found in Table A6.4. The FBS
+ LPS test group is very interesting in that it produces elevated levels as compared
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to the mouse serum. These results pose some interesting questions about the
lipoprotein composition of FBS, and whether it would offer a similar protective effect
in bovine cells as mouse serum does to murine cells. This is another important point
for the design of in vitro studies as FBS is a commonly used supplement and usually
the serum of choice for many cell lines. Studies that use FBS in experiments for
different animal cell lines should be particularly aware of the potential for altered
effects due to serum choice.

Table A6.5. Calculated cytokine expression in pg/mL using FBS and normal
murine serum
IC-21 - TLR4 (+) cells

23ScCr - TLR4 (-) cells

Test Group

IL-1

TNF

IL-6

IL-12

IFN

IL-1

TNF

IL-6

IL-12

IFN

‘no serum’

9.841

2.522

0.459

-

0.956

7.632

-

-

-

-

serum

9.738

2.604

7.483

-

6.484

4.346

-

81.978

-

0.670

serum + LPS

12.615

3.260

3.329

-

9.318

2.975

-

86.497

-

-

50% FBS

6.403

2.357

0.214

-

0.253

7.02

-

-

-

-

50% FBS + LPS

318.1

87.52

1736

14.33

7.695

12.99

5.793

603.2

6.92

-
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Figure A6.12 The effect of 50% FBS on cytokine expression. Proinflammatory cytokines were
measured using the 25-plex kit to determine if FBS had a detrimental effect on cells. A-B 50%
mouse serum and 50 % mouse serum with LPS. C-D 50% FBS with and without LPS. E. No serum,
buffer control. We spiked serum with LPS and discovered that FBS spiked with LPS results in a
much higher inflammatory response than mouse serum spiked with LPS.
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